var title_f36_34_37408="Ampullary cancer ENDO";
var content_f36_34_37408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ampullary cancer endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of an ampullary carcinoma. Note the nodular appearance of the tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Carr-Locke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37408=[""].join("\n");
var outline_f36_34_37408=null;
var title_f36_34_37409="Heart PI";
var content_f36_34_37409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 644px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKEAgoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK5/xT4v0fwzAX1K5USEZWFOXb6D+teJ+MfjDqmqboNFU6dbd3BBkYfXt+H51jUxEKe+5rTozntse+aprWnaVGX1C9gt1H/PRwD+Vcjf8Axa8JWYOb6WYjtHC39cV8wX1/e307PcTySO3VnYsTVcWxblsk+9cksZN7I6VhY9WfQl78etDiJFrpt9PjpuKoD/Ose6/aB6i18OnPrJdf0CV4sLdR6VLFaBuik1m8VUfUtYeHY9bT9oC9yN/h+Ajvi5Yf+y1u6V8e9ImYLqWl3dr6tG4lH9K8O/s3PaoZrAL1xQsVUXUbw8H0PrDQ/iJ4W1natpq9ukrdI5z5bf8Aj1dWrBlDKQQehB618MS2oXkGt7wx458S+GGxpmoSeR3gl/eRn8D0/DFbwxn8yMZYX+Vn2VRXifhT462dwUh8S2TWjnj7Rb5dPxXqP1r1/R9VsNZsku9Lu4rq3bo8bZH0PofauqFWM/hZzTpyhui7RRRWhAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUEgDJOBQAZryn4o/E5NDkl0rRCsuor8sspGVhOOg9W/QfpVb4nfFJLBpNL8OyJJccrNdA5CH0T1Pv2/l4LKzzSO5JJY5LE5JrgxGKt7kPvOyhh7+9MbeXU13O81zK8srnLO5ySfc1EiFzwKMAnk8CpPMwMJwK887iVIlQds07Zk9M1AsnPqfWpEck85ouBMqFeirmn75h6CoWuESo/t6ehovcLEr3Tp94iomuVk+8ajkuElHFQMVA6CgCaSRMYzmoCkbfdbB96jLgnuKTK/WmkK4skWOv5irvh3XdT8M6ml9o91JBKD8wB+WQejL0IqopwMhvwNQTsMnIqk2iWkz7R8F+JrHxZoEGp6c+Vf5ZIz96Nx1U/St2virQNR1DSoTFaX11ah23MIZGTJ98V6n4G+KuoabIltrkj39lkDzG/1sY+v8Q+tdsMdG9p6eZxzwkt4n0FRVbT7231Cyiu7KVZreVdyOpyCKs13p31OQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxv41+PPsqy+H9LkIlYYu5VPKg/wD3Pf2r0Hx94mh8K+Hbi/kw02NkCH+OQ9B9O5r5NuZZbqaS4uXMk8zmR2PUknJrixdblXIt2deGpcz5mJbxNcyEt90U+8kWNPLj/E1agxFZFscnpVKO1uLtz5MMsnOMIpNedax3lIAs3t709V9Mmu40H4falcRPcX0PlgKTHCzYZzjgH0Fbmh/Dm5uG87VtsC/wwQ4z+Jo1ewtDzGKFj/DnHYUkgY8ZwK9Kufh9rl3dNDBDBb2YchMuMBQeCQMkk10Om/CiwiRTf3E1xJ3AO1f8f1pKMmDkkeH+WvfJNKFHZOK+hv+Fe6MsTJFahCf4xyw+hOazZ/hugJ+y6jPGOyyRpIP5Cq5JC50eEyKoH3CKruR7iveYfhbBI+68vpZB3CRqgP5Vrf8Kv8ADr23lPbuG/vhzupxhLqTKaPm1sD+Lio+Ac8mvoOb4N6GTlLi7Uem8f4VPYfCnQLSQPIk1wR2kbj8qrlaFzJngGm6df6tOIdPtZZn9hwPqa9P8N/DZLW2M+rt5t2RkIPup/ia9ftNJtbKIR2kEcSAcBRiormHg+tKw0z5iDC01S4gkH3JCvP1rTeOOSPzIuG9q2/it4aks746tapm3kx5uP4W9a4uzu2UYU/hWcolpnrnwX8Yvpeqro99IfsF02E3dIpD0/A9K+ghwcV8WJNtlVwcE+nY19Z+BNaGveFNPvi26YoEl/314P8Aj+Nehgql1yPocWKp686OhooorvOMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPA/2iNVNxrOnaShPl28ZnkHbc3A/QfrXkch4XHc11nxXvftvj/WZAcqsoiH0RQv8wa5RMeYGboK8StLnqNnrUo8tNI2bOylv7i2s4Bl3OPp6mvbvD+k2+lafFbW6DCjk45Y+przn4TCO51K8mZdzIoVT6Zr1yFelJFMljjBI4q7HGAOlRwrVpBWiRnJiqoFLilFOxV2M7jcCjbTgKXFOwrjNtJipMUhFFguRnIppNPNMIqWUhjc1VmTg1bNRSDIqGWjnNZsory1lgnQPG4wQa+c/EmltoOvTWhyY/vRk91PSvp66TINePfGzSgLey1KNeY2MTn2PI/r+dSyzzbzemD0Ne//ALO+sB7XUdJkb51YXEY9jw3/ALL+dfO0bYcZ6V6l8Ertrbx9p65ws6vE3vlCR+oFXRly1IsirHmptH04vSlpAMZpa9g8sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZPIIYJJW+6ilj+Ap9VtTQy6ddRqMs8TqB6kg0mCPjnXrt7nVLu6k+/PK0uf94k1lSO2zjvVvVQRdbGBBVQCD2IGKfFa+a8KHgO6r+Zrwkeyz2L4X6Wtj4et5NuJJx5jH69K7yEcis7TrdLa1ihjGERAoH4Vq246VaJLsQwKlFRr0p4NaJmTJRThUQNODVSZLRIKWo91Luqrk2HGmmjdTSaTY0hDTDTiaYallIQ01+lOprdKgpFC4HWuS8cacup+HL+2I+Yxll9iORXXXHQ1z+vBjpd7s+95TY/KpZoj5jdTG5U9VODXefD2Y2/i3Q5k6/aox+bAf1rgSzNI285Ymuw8DOx17THAyIbiKRvoHX/ABpdUw6NH2HRRRXuHkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQeooooA+VfjBpiaX4/v1QARTFZlA7bhk/rmud0g/avEFhbquVaVRivRf2hoFPiyzcdWtFz+DNXCfDiJZ/G1gX6B2b8QDivFqq1SSR6tN3gmfQEHAA9OKv23aqajFXrbAGaSGy2KXNRFwKYZaq5NixmlzVTzqPPFHMHKXN1LuqssoNSBqdxWJd1JmmbqaXAouKxITSZqIyD1pPMFK47Euaa54qMyU0yA0rjsQTjg1kaigaCVT0ZSK2HIOazrxAwx2NIs+Wr2LytSuIz/DKw/Wus+Gcn2fxrpIdFkhluFidGGQVY4/Tg/UVn+P7D+z/ABZdoBhXYSD8RWj8P4zL4u0QpyftcWf++hQnZoGrpn17RRRXtnkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVLW9Tt9G0q51C8YrBAm5sdT6Ae5OBQ3YEr6Hkv7QWjyy/YNTjUmNY2gcjsc7l/9mrzv4Q6ZJc+IWvekVsDk+pIIr0rUfGOualpz3Go+HoJdCn/AOWYYmVV7NnP9MVgfCJFittQRR/y0B6deK8ivyufNHqenSUow5ZdD0IdabqOrWWk24kvp1iB6A8k/QVIn3hSrpFjLcNczW8cs7fxON2B7Z6VmWcdqnxFsY90dghmlH9/gfpWb/wsW4VT51pEh9wwr0qS0sVcO9vDvXodgyKzNZ1bSLJQ16bZW7CTGT9B1NHKwujy3UPiDqRmylxCsf8AdjXGPxIp9v8AEXUigCm2lOf4l5/St668QeEZ7gvNZW0r5+99lz/SrFtbeFdYJNtZ2nmd/KXYw/DijlY7lvwl4sl1eZIriBUZsj5exAz+Irs0kNcfp+l2Ok3Akto2HOQWYnFdRFIJEDqeDRsG5aaXiomlP4UzJrP1W5FvbsfWgSRwHjDxjqcV/JBZOYIV43hefzrCtfHGp2YJ+3NJns3z/wA67q0s7e+V2uYVKsaryXHhbR5iPJtPOHBG0yEfzxRytjvYwLb4jarhQ628v4YY/gK1YviBeMFMunxAEZPzkVp2HiXw+Jt1v9iikPcxbP1IroI720uVVzHDIp6MoDA/jQ0wTMfSvGdheDE5EDZAGWBFbryLNGrxsGRuQR3qGaw06VSxtIDnrhBUFtbW9puFsnlq3VQTj8u1Sh2PMPjDo7veW1/GPlYeW5x0I6Vp/s+6LLe67LfSJ/otpglj/fOdo/rW/wDEHyz4dKSdZZVQH07/AMhT/CXi6DwrpIt9M0K7n0pH3TXhbazMeC23GPTqa2opc6ctkZ1ebktHc9rFFVNK1C21TToL2ykElvOu5G/ofQ+1W69fc8sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK87+N8rL4asYM4Se9RX9wFY/zAr0SuI+MemNqPgm4eMZks3W5A9QMhv0Yn8Kzqq8HY0pO01cwB4mWBSsVnJNYJ8nnJjoOMhe4rP0FbSLxTqI08ILaaGOZdn3TnqRVrw15U3h6zKAGMxAfiOD+tY+ixQ6f47uLW3fckkG7bn7h6kf1/GvJuenY7ccEVdhbKYziqNWoeKEBl6hYXd5fiCW9+x2LD78I/eyHuNx4X8s1i+KfD2n+H303ULaxMtrHIwvGZi7MDjBYnnsefeuzfLIVYBlPUEZFQ/MilVZgp/hJyP1qrq1ibdj51Gnf8Xi1PX9Jt4rHSJ0KRWsLbjKWQKcqOmWy31r3a18O2jeHLGO8jjtr+KJSLhAA6OB69/QjvUsVjaW0xlhghikPVkjVT+gp6qDIXbc7e5odRyd5CVNRVkZzQyPAyvtLocFl6H3FXNEO6JkPUVf2ZTDDGarabF5V469jU7lbFooQK5nxO/zJGO9djIo2muJ8UfLfQ+lJjjqT2mmteW8dubj7NC3+tcfeK+i+hPrUvibTrDRhpV/a6VBJZWkpM8aIBkFcAk45AP8AOrenrut1K9QKsCRgCu4gHqO1VzaE8tzwDTbC7/4WNrOsR2kNrp127mK0ikEisW6AL+vTvXtWl+DLaLRbeYyS6fqGzMjxvwSecMp4NaFnYWcFx58NvBHL13rEoP54rRb5jubLkdN3NPn5nzSBR5VZGJY2l7HCwumiYhsK8eQHHrg9KsCPB5q1cSnvVdHy1ZvVl6nMeO/KNxodtcECF5y8mTgbRjP863LbxDYXbJp8VpIkEy+XGzIAj8dMdRxXLfEEwy+I9HguTiBY9z/i3/1q3PFcSWWlR39soP2V45lx3wwNWtBbmv8ABCR10jV7QsTFbXrKgJ6AgZ/lXpFcD8FbF7fwebqUfvL24ebn0+6P5E/jXfV6tJWgrnmVnebCiiitDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqK7t47u1mt5l3RTI0bj1BGDUtFAHhugXLaRouq2E/M2lTyIR6jJx+oNZPhbf/wmdnJKcyTwyOx9TtJ/pW14ytWX4g+IbdFx9rs0lVR/EQq/4NWLo0q/8JPoEw4DB4j9SpH/ALNXkzjyyaPWjLmimelLVyEZqpjDVctuRWSGy0FGKY0AaplHFSBc1oo3M72KBs1J5qRIEToKtMKY1JxsHM2VJxUFuv8ApJOKty1FaDLMfepK6Fl1yprjPGEW0wyehxXcYBQ1zfim1NxpsyoPnA3L9RRJBB6kPh5t1uK2Vt1fqK5Twxc8KCetdnbjIpLUb0I1tVXoKV4sCrm3ioZRwapxsSpXMS9G2qcT4eruoHisxD81SarY5PxkBceMIYzyFtB/NqL6/nuvBMVgCTPNeraJ7rwR/QVFrUg/4TO7dz8sduq/+Og/1q7ZWTDUvCFqRiSa++1OvoMqR+grSKu0iG7K57fpdlFp2m2tlAMRW8axr9AMVaoor1zyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8r+JEP2T4gaBfHhLmJrZvqDx/6GPyrj/EFjJo+r2F3Gp+yrdLJkdEORkV6T8YtNku/Cy31uP8ASNOmW4Ujrt6N/Q/hXKeK5Y9S8GzXMXKNGkq+3Iz+XNebiY8tS/c9HDyvA6xx83FWbXis/TJ/tel2VznPmwo5PuQK0IOK5lubMvJUy9KgjNTg8VtEwkDioHqZzUD0pDiZ+rXcdjYT3UudkaFsDqfb8aZoKyx6ZE12R9okzI4H8JY5x+GcfhVPxZFLNpuIY2l8uRJWjUZLqrAkAd+nT2rCu/FCLCoslkvbgnAgiU7h7sMZFZmtro70NxVK9CvGwFclD4llEeLyOezl7xyxsT+BA5qnceIdTMxFlpVzPbjrIw2FvoDzTvcSjYksk+y61LEOEb94v9f1rvbTGwVxGnR3N5qKXc1tLbwom1RKMOxJySR2HFdnbNhRSjoxz1LpqtO2BT2fiqly/BqpMiKMu+bJIqii/NVi4bJpkQGcnoOTWaNnoji4tOl1rxnqYUf6LG6LM2ewAG38dprptIQ3/wAW7GNR+70+2aVh2BKkD/0NapfDtxLa6pfOQDcXLOSfTr/Wtj4QJ9v1vxJrRGUllEET+wySPy2V0UVzVEY1naDPUaKKK9Q8wKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGyIssbJIoZGBVlIyCD2rynX/hveWenaiNG1eVdO8t5RZupJOBnaDn2x0/OvWKCMjB6VE6cZ7lwqSg9Dyj4eXH2rwhZ85aEtEfwOR+hFdLHwa5Lw1B/wj/inXPD8hIj3i5ts90P/wBYj/vk11SuN1eTJcrsz007q6L0Z4qUNVeNuKkzTTIaHk1G7ADNOpjLu60mwSIoRuctUxRT1AprMka5ZgqjuTis+fWbZWKwsZn9E6fnQkUouWxHqa7X+TirFlGu0FgMkVnS6gZTlrds+xBoj1goPmtsKO+7/wCtSSZp7OTRqXMQ25ApkbYFR2+qWlx8u/Y3o/H61M6DqpBHqKTRNmtGP8ziqty/Bp5yKrzcik2NIpScmq2rTCy0O+uCcFIWwfcjA/Uire3L1geP2klsLDSrb/X6hcLGB7Aj+pWnFXYSZV8LeBPEGpaBaNFqkFrpt2vmMmCXCk/TuOevevYvD+j2mhaTBp9gpWGIdT1Ynqx9zVnT7VLGxtrSEYjgjWJfoBgfyqxXrU6UYbbnmVKsp77BRRRWpkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5v8XLGazbTvEtimZrF/Lnx/FGx4z7ZJH/AqfbXUdzDDcwNuhlUOp9jXf3ltFeWk1tcoJIJkKOp6EEYIrx7R0k8O67deGL9ztDGSxlb+NDzj/PcGuDFU9edHdhql1yvodtA+QKtKaxoJSjbWrUhkDAc1yI3aJqydVm1SMsLKCN17Etz+WDWrQelME7M4O4t9UvZf+JnfGJe0cSY/Vv8ACrMHhyxYZLzs/wDe89/6GuquQGUq6hl9CKyJraJWzEzRn2PFPmN1VurbFL/hHlThNRvUQ/wiQH9SCf1pp8OaWMtcqZ3/AL8zlz+p4q0ysRgysafBaIzZfc/1NLmQOXdmU2g2DsRYpcB/+mUrAfzxWppmhT2xDSXk2B/AGzn6mtq32xqFVQAOwqV2+Wi5DqvZFaXCjFUZ3AJqW6kx3qgSXao3EkSx8tms3wzB/b/xLedvmtNFiwPTzW4/x/75pfEGqRaJpclxI6+cQVhQ9Wbt+A6muk+E+hvo/hdJrpSL2+b7RLu6gH7oP4c/UmurDQ5pehhXnyxfmdpRRRXpHnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXG/E/w7HrOhPeQkx6jp6tPBInU4GSv44/A12VNkRZI2RxlWBBB7g1MoqSsyoycXdHjvhnxJDrlsEl2x6gg+dOz/7S/wCHauhtrkqcE15Vp2msIp1hcw39ncOiyrwePX9a6XRPELSSiz1YCC86K54WT6e9eO1qetY9FhmDAc1OCDXOx3Dp61ftr4HgmkmS4mhKm4cVnz6d5pzuIq/HMrd6tRFTVpXIbsc+ujMT/rWq9Bp/kr1JrW+Qc8VG8q4quRIXO2VREAKjmOFNPkmUZ5rOvbr5SBWbZaRUu3yxGazNT1SDSrYzTnPoo6sfSodY1WDTbdp7huTwqjqx9BXKxRzanci91Lp1ig7KPekkaD9KtrjxJ440dNX/ANXcyFhD2WNQWx+OK+iAABgcCvEfCPPxO0YHtBJj/viSvbq9HCr3LnBin7yQUUUV1HKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHhUcQj8W+JYQOBes2PqWNM1XS47qMpKmR2PcH2qzAfM8beKXHT7Tj8if8K1TEJBXjVNJM9iHwo5XT9Uv9CxBeo13p68LIPvxj+o/zmuntL+3vIhNZTLLH6qeR9R1H41Tu7MjPHFc9caS8Fx9o06Vracf3fut+FTuOx3UV2yd6uRalgda4CPxFc2uE1SzY4/5aw8g/h/9etC21zTrgAx3kaH+7Idh/WlqgOzbU+OTVaXU89DXOvqNmq5e+twP+ugrPn8RafGdsLS3L/3YkJ/nS95isjq1u2c9axNc8QQ2bmCD/SL48LCnOD7ntWLJf6rqKlIU/s63PBY8yH6elTabp8Fov7lMuertyx/Gq23BIpwWk89ybzU2825P3U/hjHoK2LaAk5arEcAPJFTEBRxSuUVNCYW3xH0CVjhXMkWfcowH6mvcK8A12ZrC507Ul/5dLmOU/QHmvfUdZEV0OVYZB9RXo4R+60cGLXvJjqKKK6zkCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqGu6lDo+j3eoXJxHbxlyPU9h+JwPxobtqCV9Dxnw+/wBo1TX7vqJr5yD+JP8AWultV3Gub8H20kGjo0v+snYyn8f/ANVdZYx968STuz2ErIke1DDkVn3OmA5wK6OJMipTACOlCQnI4WbTSD92s240S2diZLZCfXGK9He0VuoFV305CfuinYOY84XRLVDlbWMn3Gf51ZjtDGMRxqg9FGK7k6Yn92mNpyDotJjTOQjtHY8irsNmVHIro1sVUdKjkjVTgCkO5kiDaOlV5lwa2JI6qTQ5HSkNM5/W7b7Xpc8XUlePr1Fel/DDVv7X8GWEjNmaBfs8nqCnA/TB/GuGkiPINS/C6+GjeLL/AEic7YdQAmt89N4zkfiM/wDfIrqws+Wdu5z4mHNC/Y9eooor0zzQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikZgqlmIVQMknoKAFryj4nao2ua3B4ZsmPkQMJr2QfmF/DP5kelafijx480rab4RUXd6ch7kcxxe4PQ/Xp9ayNB0X+z4XMr+deTNvnmOSXb/AA5rixNdW5YnZh6LT5pFu2t+gUYUDAA7Cte3h2rS21uBjiryIAK4EjrchsQwKmqIjaacpqiGPpM0VWllMbn0oAsN0qNxUQu171DNeDHy0DSY6Z9oqg7Zans7ScmosYNSWS7cimGLNPXJqUCgDMuLbviuc8R6fOyQ39gSl7ZuJYyOuRz/AErtnQMvSqjxgHpSTs7j3Or8HeIIfEmhQX0WFlPyTRZyY3HUf1Hsa3K8ak0e9069k1HwxfNZXb8vCeY5fqOn5/pXUeFviFDeXK6b4gg/szU+g38RyH2J6f55r1KOJjNWe559XDuOq2O9ooorpOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKrajfWum2cl1fTpBbxjLO5wBXm2peNNW8SSSWvhWJrOzB2vfzDk/7o7fqfpWdSrGmtTSnSlU2Ox8T+MNI8Ogpez77ojK20XzOfTjt+Nee6i+v+MZAdWY6dpGcraRn5nHbd/9f8quaH4atdPkNxKWvL9jua5m5bPqM9P510CQ56159XESqaLRHdToRp69TO03TrexgWC0hWKMdh1PuT3rVhg46VJFEBVgDFYJGjkNVQKeOtFFUQEi5FQA7TirI5FQTLih9xp9BVbmmzIGFMjbmpgaQzPeE56Uw2+Tk1qYGOlQyY7UrFKRTdAq4FQrHluasP1pyJnFIYkcfoKmEVSRpUoWnYhsqNHxVaaOtJlzUMkeaGhpmQwINU9U0601S1MF7EJE7Hoyn1B7VsSw+1VmiIqNjS9zA0bWdY8EN5dx5mqaB2P/AC0tx/h+n0r1PQ9ZsdcsVu9MuFmhPBxwVPoR1BriGQ85Fc9JpN5pV+2p+F7j7LddXtz/AKuX2x0/D+VddHFOOktjnq4dT1jue0UVyHg7xxaa8/2O6jNjqqcNbSH7xH90n+XX6119ejGSkro8+UXF2YUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWVrfiHStDiL6nexQnsmdzt9FHJpNpasaTeiNWuU8Y+NtP8ADn+jgG71NvuWsRycnpuPb+dcpqvi/W/EpNv4bt30/Tz8r3s/DsP9kdvwyfcU7w/oFno6l0BmvH+/cScs2euPSuSriktIHVTwzesykml6r4iuFvvF1wWQcxWMZ2on1x/+v1PaukggSKNY4UVI1GFVRgAVMvJqxEgrgbcndnZpFWQ2OPjpU6pTgtOp2JbEApaKKZIUUUUAKpxSTKHSkJxSg5ouHmZc0hifnpU8M25QaW/t/MQletZkMphfa3ap2NN0bBk4qF2qHzgRwajaT3pisPb71XIE4qhaq00+R90VrqAq0JX1BuwYxRTS3NKDTJFprCnUGgRXkSq7JVx6gcVLLTKrR5qCWHHIq6BSlMipsVc5jWdGttTAeTdDeJ/qrmPh0I6fUVY0Lxxf6DcJp/jAGW3Y7YdQjXIP+9jr/P69a1pYRVS4t454mhuI1kicYZWGQa0p1ZU3oKdONRWZ6Ha3EN3bxz20qSwyDcjochh6g1LXjVvYax4ZuHufCtxutmO6SxmOUP0z/wDWP1rpNK+KWlS4j1i3utMuBwwdC6Z9iBn9K9GniYTWuhwVMPKO2p6DRWPY+JtDvwDa6tZOT0XzQG/I81rqwZQVIIPcVumnsYNNbi0UUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV594w8cSLdNo3hdRdak3yvOuCkPrz0J/QfpUTmoK7KhBzdka/izxvpvh6T7NhrzUTjFtCeRn+8e38/aubl1XxjrPzxvbaJbN0UL5kmPfP/wBak8NeHLbTD583+kajId0lw+SST1xn/wDWa6eNFPWuGVeU9tDtjSjDdXORm0fxDPGVl8V3jA9lQp+oasiLw7Bpdx513G93LnPmS/MK9KEKHpTZLZGBDKCPespKT3ZpGSWxycN/EwAzt9quRzqe9XLvRLSbP7vY3qtZFxoN5CSbSfcP7rVi4mqkmaaSg96sRzgVy7PqFqf9It2wO4Galh1RTw5Kn3os0PRnVpODUocHvXORXyn7rg1YS8PrTuyeQ3NwNGRWUl371It0D3o5hcpo5FLmqK3Ge9SrKPWncXKWDzTelNEo9aRpR2oFYl6is3UbTP7yPrV+Nwe9PIyMGjdAnZnMhyCR0NTWySTybV6dzWtJYQu24rz7Uiy2lrIYd6I4GSCe1JRNLuWyLFvCsEYUUsj7RmlDBlDKQQehFVJ3OeapszSJEbc2TU6kYrOMuKabo1NyuW5p7x60hkX1rJadjTGnZetFw5TWaVaiZ1rJe8A6saiOoqB1NFx2NcuKQyCsU6iW+4jH6CgS3sv+qt3+pGKNR2Rrs471WmmjTliKrx6dqUxG9kiHuc1dt9BjJzcyPKfToKOUXMkZzXzSNst0LsemBSjQTfHdqKow/uFQa6SC0it12wxqg9hUoGKpRJczkbvwPodwPmstjesbsv8AXFUI/DeraExl8Ma1cQ7eRbTndG3t6fp+Nd4cVBOoI4p3cdUxXvoyp4N8cjVb86TrVr/Z+sL0Qn5JcDJ2+nrjnjoTXb15f4i0OPVolZWMF9D80FwhIZCOeo7Vb8I+Np4LoaP4u2298vEV0eEmHbJ6A+/Q+xrtoYnm92e5zVsPb3oHotFA56UV1nIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVl6/r+m6BbedqdysQP3UHLv9B1Ncp4m8est6+leGIBfX/3WmzmKI/1x+X16Vh6b4Z3Xh1DXbltR1BuSZOUU+w7/wAvauWriVDSOrOmlh3LWWiF1LVdc8aHy7dX0rQz1JP7yYe/t7dPc1s6NpFrpVqILKIKv8TH7zH1Jq9EtWEWuCU5Td5HYkoq0RIo8HNTYpAKdQiWKCR0pwkx1pmKKd2IkyDQUBHFR0oYinfuFhDHVeeygmH72FG+oqzuozS0HdmO+g2LHKxFD/skim/2JEv3ZHH1rZxRilYfMzJi0sIf9YSKk+wAdK0aKVh8zM8WZHSnC1b1q9RRYOZlP7M3rVDV7xNNjTfy8hwtbdZ2vacNT054RgSj542PZh/j0/GnFK+ppRcfaL2mx53rN/fw36TidwAQyYPFeiaDqceradHcR4D9JF/ut6V57ORc2rQTKVmiJGD1HqKqaDq8+h3xZBviPEkZOAw/xrqlDmjpue3iMIq1O0VZrY9dZgqlmOABkmvMNZvjLFcXOSHuZCR7L2H5Yre1zxbYz6PNHZvIbiZdm0oRtB65PTpnpXDz3BnSNTwEHFTSg1qzPLsLKCcpqzO08PX8umeH4GmYyzXDkxIx+6gPJP610Wm6laaorCFgXX7y15xcaoJIvlBUpGsSL6KBj9Tk/jXY+BNHFnZC9myZ7hcqP7q/4mlOKs29zPG4eEIOpLSTZ0RtlPak+yJ6VZornsePdlYWqjtTvsqEYIFT5ozRZBdlY2EB6xqaetlAvSJB+FTZozT0DUFhRRwoH0FPCgUzdRvPrTuhWZJwKC3pUeaKdxWHFqTNFGKQxDTGGafQaQyq8dZ2r6Xa6ramC+iDp/CehU+oPatllqJ0qbFJnIabqGu+Cz5YVtV0Jei5/eQj2/zj6V6L4f8AEWma/AZNMuVkZR88bfK6fUf16VhMuK5rU/DKm6W/0WdtO1FDuV4+FY+47f54NdFLEyho9UZVKEZ6rRnrNFee+HPHkkV4ml+LYVs7zolyOI5fr2H16fSvQgQQCDkGvQhOM1eJwzhKDtIKKKKsgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBrssaM7sFRRkknAAryzxF4jvfFd9Lpfh+VrfSoztubsdZfZfb+f0p3jTW5fE+qNoGkSFdOhP+m3C9GIP3R7ZH4n2FX7C0gsraO3tUCRIMADv7n3rgxGI+xE7qFC3vSG6NpVppNsILKMKP4mPLOfUmtNVzTYlq2i4rjSOlsbGmKlFL0pO1UiBaWkFOpiCiiigQYpKWigBpopSKTFKwwooooAKKKKAEZgilmOFAyTVNtTtQceYD9KbrrbdIuiOMpj8+K5OyHynPpXZhsPGpFykc9as4OyOr/tizzgyhT71dilSVd0bBh7V5tqR5rc8M3S2djd3U5PlxRg/z4rWvg4whzxZNGvKpNQtuYvjlUg19zbnDSRq0gH97n+gFc8kLSHOM+9XnaXUb2W5n5eRtx/wq0wSFcdKwT5VY+6p/uqcYPVpGYLXaOaidQp4qe5uRyFNVPMBPWqVzojf7QjLnpXe+BNe+0Rrpt0f30a/um/vKO31H8q4QHNEU0lrcxXELbZI2DKfcUSjzKxzYzDRr07HtuaOKpaVex6jp8F1F92Rckeh7j86t1x2sfJSi4uzHUU2igQUhNLTSKQwzRmjFIBTAcDTgaaKUUyWOBpQabmjNMBxpKAaDTsAZo60lLU2AidKgZMVd61G61LRSZi6vplpqlsYL2IOv8J6Mp9Qe1Zeg+Ib3wdeRabrLvc6I52wXOPmh9j7e35eldHMlUby3hu7eS3uUEkTjDKaIVJU3dDlBTVmegxusiK8bBkYZDKcgj1p1eU+D9XuPCerpouqSl9JuW/0Wdj/q2P8ACfQH9Dz0Jr1avWpVFUjdHm1KbpuzCiiitDMKKKKACiiigAooooAKKKKACiiigAooooAK5D4k+In0TR1t7LJ1K9JigC9V9W/DIA9zXX15CJh4j8b3+qsS9lYn7Pa+mR1I/HJ/EVhiKnJDTc3w9Pnlrsi7oGlx6PpyW6YMh+aR/wC83+Fa0Iyah6tVu3WvJWp6TLMK8CpwKbGOKlUZrRIxbG4oxUwTikZeKvlJ5iEdacaQ9aXNIYUvegUtABRRSigQ3FGKdmkNAXG008U+mtSKEooopAZviM40a4/4CP8Ax4VzFrwhrpPEzAaS6/32Ufrn+lc7bJ+7J9q9TB/wvmcOJ+P5GVqAzVe7umFmtjHwJCryH1Azgfrn8qsX5+bHvWfajzr1ie5wK3xUrU7dz0cjoqdd1ZbRX4/1c0LaDyrbeR1rH1K5yxC9K6XV0FvZRAdSM1xd026Q158Vdn1NCfMnUYwZc+1Wktg0eVbMnZdvH50y2i3MqjvXQ2cCRKMqM120qKkuaR5OaZrLDz9lS36syYtOuXHyqv5n/CnSaVdFSNqH6NXRpMFGABTjeIPvAVfsI9EeZ/b2L2bX3E/gS4axtri1v3SJQweMuwwc9f5D867KN0kXdG6svqpzXCi6gb7wFPj8ktuhkaN/VGwa56mCUndOxyTx8qs3OSWvY7nFLiub0i8vTeLFLP50J/vAZH410tcNWk6TszWnUVRXQ3FBFOpMVkaDSKTFSYoxTEMxRinGkNMBtFGKSi4xwNOBpgpRTTE0PApSKVakC07E3sRYpCKnKcVGwqWrDTuVpV4qhMMGtNxxVK4XrWckaRZi65pser6bLavgMeY2x91h0P8An1rb+GOvTanpcun6hkajpxEUhY8uvIVvrxg/TPeqXRqwL66/4Rvxdp2tR5W2uD9nvAOhBxyf5/8AAa0w9Tkn5E16fPGx7BRSAhgCDkHkEUteueWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc38Q9X/sbwnezo22eRfJi9dzcZ/AZP4Vx/hiy/s/QbSBhhyu9/q3P/wBb8KsfFST+0PEPh/RlOULNczL7DgfoH/Orp615mLnedux6OGjaF+46JMnNXYVxUEK9KuxiuaKNpMkXtVhFqKNasqMCt4RMJMDwKiapHNQsaqTJiiM9aWkPWisjQWgUlGaBik0A02ii4WH5pKbRRcLDs0lJRSAKKKKAMLxW+LaBP7zk/kP/AK9ZVtxauaveLGzPap6KxP6f4VRRgtmR616+GVqSPPra1GYt794fWqOhjddD61evBzn3rO0Z/LvXB7GnjFeKZ7WQv3aq9P1NzxO3CL6LXFScyV13iBt6qwPauRk++a5IHv4dWpJGppkeZAa6GKLK5rD0sf6ojvmupto8x816CdoI+OzBuWKqX7v8zPmG1Tis6aZIYfMkBclsBR3Na92m3NYt3H5tsyrjKuCMnHt/Wrbag2jDCwhOtGNTZvUu+HrZNbuJYo18lo13ZY5zzitWbwreR8wuj+wbn9aqfD1DbapcecyL5ke1fmHJz0r0GvOnjKsJWPQxeDoQqWp7HL+G9MvLa7ZrtSqqOMnOa6iiiuWtVdWXMzOnTUFZBRRRWRYUUUUXASkNLSGgY2mmlNJQMUGnCmCnii4mSoalWoV61Ipq0yJInHIqN1p6mlYZFaNXRmtGU3FVpVzmrki1A4rCSN4szZUwc1l+ILEalo11bYy5Xcn+8ORW1MvWq3Q1nszVGt8M9TOp+DrJpG3T24NvJ6grwM/8B211NeY/Da5/s/xjr2jE4jlAu4h2HTIH/fQ/KvTq9ihLmgmeXWjyzaCiiitTIKKKKACiiigAooooAKKKKACiimyOscbO5wqgkn2oA8meX+1PiZrl0eUsY1tU9j3/AFDVugc1yvw+LXNvqmov968u2fJ9Ov8A7Ma61RzXi1HzSbPXguWKRYhFW4xVaEVajFESZFiIVMTgVEhxSs1bp2Rg1diM1RsaUmonPNQ2WkBPNGaSjNQULRRmigAooooAKKKKACiiigAooooA4/xVLjWUGeFiHH4ms9p8xgA1Qv7prvUrmbOd8hC/QdP0qQA/dHpkmvSi2oqL6GioJajnAc8gkVisDbagck4POTW3EpYe1RX+n/aItyHDqflzQ3zKzO3CzjQne2+5FdSGWAD0Fc5cja5rWczWv7u4RlI45FZl5hiWFZxXKz3YWlC8dUauh5eBT6SY/QV2VimUzWNoemNBp8SyKRIfnYehP+RXUWUG2LkVuqqskfHY2PPXlNbNmLqS/e4rAxuYoOrED9a67U7YlTtFYdtZsLt2K52IWx+lb+1jyM5KdKSqJ+ZXayZAHjJDDuK7LwzqLXlqYp2zcRcEn+Ietc9K+YwoHOeTVWK5eznE9ufnU5+tefOPOrHsNc6seiUVXsLuO9tI7iL7rjp6HuKsVxtWObYKKKTFAgopaKBjaSn0mKAGYpMVJigigLkeKctKRxTSeaQ9yQHmpFNVt1SxtVJktE6mpgciq4NSK3FaxZlJCSiqrirTnNVpKiZcCnMKqMOauyiqrDmsGbxOZu5TpXxE8PagOEuCbWQ+ueP/AGYflXsNeMfEeNl0SC7j/wBZa3CSAjt/k4r2SGRZYkkQgq6hgfY16ODl7rRxYtapj6KKK7DkCiiigAooooAKKKKACiiigArH8Y3P2Pwnq84OClrJj67SB+tbFcl8V5fK8Aas3qqJ+cij+tTN2i2VBXkkcl4Fg8jwtYjHLhnP4sa6JRWZoEXk6Hp8fpAn8hWoleJ1PWJ46spVeOrC1aIZKGxRnNMFLV3IsKxwKhJ5pXbmo881LZSQ8ng00GhjxQKQx6mnUwGnimIKKKKBBRRRQAUUUUAFFFLigDyWAY2n0PNaMa5GT0aqVqNwOe9XwcRqByTXpPc6ydB8wHQVZiC9/SqwI3bs8YpswuJFTyYmJfhMdWPt/n+tJtLcSi5OyEu1h8pzLtJPAyen4VvaDpNrBpUTtZRidwWZnXLDk469OMVJo1lHYRA6hAgus/6xuQf90mrE94nn7Iyzk8kIN2B746V51eq637uH3h793GL0/AiMO2QKCD9KuxkImKijXPzDP4jFOYNjjFawulqTJX0ZDOc9QaoXunG8tZTa/LdoMxsDjPqp+tXJMg85FS2DgTYPGRUVJyjG6LtZXRyNtFNIpillhjkUZVXO3ee6knoR6VXuQ8Urwyp5cqnBTOcVtR2kN94huTdZMcaO5UMQCS5A6ewqpq+kPvDWV4rp/Ckx5X2B9PbirhX960jpnGHNZOz/AA+82vAzN/Z86H7qy8flzXSVzHgq3ms0uYrqVGZyGWNDkD1OfXpXT1E2pSbRwVo8s2goooqTIKTFLRQAlOAoxSgUAGKQ07FIaYEbVG3WpG61G3WpZSGk4FPjaomNIr4NJMdi8pzSg4qCNs1KK0TM2hxaonpxprUmxorSVXYVZkqu9Zs0RheMYPtHhnUE9I9/5EH+ldz4JuTeeENHnJyWtUB+oGD/ACrldSj87TruM/xxOv5g1p/CKbzvAOnf7BkT8nauvBP3mjnxa91M7KiiivROAKKKKACiiigAooooAKKKKACuI+Mr7fAd2v8AfliX/wAfB/pXb1598Zpt+hWGnJzLe3iKv0HU/mRWdV2gzSkrzQtqmy0t0/uxqP0qwlNC7VVfQYqSMV4x6hPHVhahSplq0QxwoNKKRqokgc81C7YqWQ4FU5n4NQy0iZXz3qZTWPpN8t7arMo25JBU9iDgj9K1YzkUIGianKaYKctMkfRRRTEFFFFABQBRS0AFLigUopoR5Vbja2OwNWgQuSxxjpUUieVc3CHgo5H5GrWlWk2pXQjTAQDczEcKP6n0H+Fd85qK5md0Y39B1gBLdDEBnlP+rjPQn1PPPT2Hv2rr9Os/s6eZcMsl6eXdu3+yPQDpxVZrK0tHgkt4yJoskk/ekGOQT3Pp/hUa3cckmY5AwPY9RXnTm6700QStKNqasuv9djQlZZco6goex5BoWPaoEagKOgAxUaOGHPIqxGQOnStYxUVZGD00IwMHuKVhxUkjDHSot/WrEm2Qyg9uarxsI5lbHQ1PNIB2qszqTyKzkr6M3irmdck6d4iSWRcWl2rIWPTLHI/8e4+hqG6yHII6HvV7xDAl1pEAZjtMqRsf7gZgCf5VWKvIWs7j/j/hHJP/AC2UdGHv6/nWMJaXe50JqUVJ77P5dRljcmC4R1PQ12UTiSNXU8MMiuCjJDZ9K6zQZvMtmjP8B4+hrSRz14XjzdjToxQKWkcYYpaKUU7CDFKBRRmmAGmmgmkY8UhjGqJqexqCR8CoZSI5ZAKqS3IQjnk02eXJNc3ql28utWVpCT1Mj4/uj/69SaJHa2z7lBHeri1n2QxGo9q0Fq4mcgNNanmmNTZKIJOhqs9WnqtIKhmiISMqw9QRTPgi+7wWU/553Ui/yP8AWplGTVD4Ky+RY6zpb8S2t4WPuGGP/ZDXThHaZjiVeB6RRRRXpnnBRRRQAUUUUAFFFFABRRRQAV5d4ym/tL4m6ZZj5otPgMrD0Zhn/wCIr1GvIfDEn9p+INd1k8rPOY4j/sg8foFrlxcrQt3OnCxvK/Y6fGTUiCmKeanUV5p3MetSLUa1ItUSx9IelFIaZJDLVCccGr8lUpu9QzSJyujSm31HVLTOAk/mqPZhn+ddXZzb1rh9TmFj41gZjiO7i2E+46f0/OumtZSjUti2ro3g1PU1RSUHvVmN6pMzaLANLUYaiSVYo2kkOEUZJqiSSiqS36yDManHvSG+CthlxSuh8rL1LUEVxHJjBwT2NT00SxRSikFOFUhHnXia2a31udcEJKRID2wev65rQ8Kzi3M0MuY5SFBDDB7np/wLP410HiaBprGN1jMghmWR0AyWTo36HP4Vz+phJHeWPiaAbtwP3h1xVVZc8VBnfRkpU+R9f0L0lyZ5mJOSOKaywzcTIre/f8+tZiTHIY9TVpJgRz1qV7uiL5eXYntftFu7RqwkXOVDjqvs3r9a0w47HBqhDLjoamMoNUmZzXM7lkyHuaVSGqkX5pA7A8Gi5PIW5Fz0NVZEYHinebkc0xiD0OKTZcU0TInn6bdxFVzsbB98cVBcmLUYreV1EbsN0cgPzRsDyPzFLFI0YmbG4CJjj6CqaIYrC1hYEOqbmz6sdxH61zOPvFxjrdf1p/wxVuoGjkZiAHzh1HTPt7GtPw7KRdBc8OpH9ay7jLCIhv4jG349P1/nVvRm23kX+8BW/Qco3i0dbS0lFI80WlzTap/bkZiIucd6L2C1y/mkJrM/tEc4YEDrxUqX8ZAJYYPcUcw+Vl0mmMaTeCoIPB6VE70mwSFdqz7uXHANSzzADrWdK+5iahs1iiG5mEcTOxwAM5rmPCbNqOr3d+/3SRHH7KP8io/HOqrFamzib97J1x2FavhGD7Np0CYwdoJ+p5o2RR2dr0FXB0qna9BVwVaMZC01qWmmmSRtULipmpjCpZaK5GDWD4Yc6X8VJoRxFqduWA/2gN2f/HW/Ot9zzXNeKnOn6nomsLwLS5CyH/YPX9M/nV0pcs0xTXNFo9bopFIZQRyCMilr2DygooooAKKKKACiiigAooooAy/E99/Zvh7UbsfeigYr/vYwP1xXAeDrb7J4dtFxhnHmH8f/AK2K3Pi9cmLwl9nQ/NdTpFj1Gd3/ALKKrwoIYY4lGAihR+FedjJe8kd+Fj7rZZQVZQcVXj5q4i8Vyo3bEUU8CgDmn4q0iGxtIaeRTDSYEEtUpetW5jzVKY81DNInA/EtChsLhOGRiMj8/wClbeiX66hp8Nwp+YjDexHWqfj5Q1nauwBC3CZz6VlWxbw5qxhkJ/s66PyN2Q0botHcQy9K0IZcisSOTgEHIPerUU+KlMGjaD5FNuEE9u8THG4dapxTg96tJICOtUmQ0Yd1JLbxtG3yP2PY1VuNRnuPKURCMg/M27PFdQypIu2RVYehGaalpaqciCMH/dFNJBcyY/PvGjW3QgKRmTsK6QVGrKoAAAHtShxTWhL1JAaXNR7qN4p3JsS5rn9asNkv2mFcqfvrW2XqKSQEYp8xcJODujkntQsYEbYA6ZqsJCD8wINb97ZK2WgbYf7vY/4ViXFqYznJTvtbkH6VHNbc76c1LdjkuMdDzUoux3PNZlw5jOfLcD1X5h/jUKXQfrz9Kad9jbkurm2lyGNTCX0rFiOOVarCykcGnclwNPzfWgyA1RWX0NSpJ64NFxWsX7fJjuMZ/wBUw/Sq7zmeGCWQDMkStx2OOf1zVzS3G2U84xzjmsiF8WUCE52ggfTcayWsmKOsmIAXZowRgkNn0wc1a0tCt+inqHH86o52NnNaekqDeR4OQDwfYD/61ailszqKKaXpN4oPNsOIyCD0Nc5Kk1jI6MjNGejgV0W8U1nGKTGtDjUuL2OEwp5Loc4Yg5q3p9pcNGqc7f4nYYFdAzJnO1c/SoZJwO9JsrckLBEVR0AxVaacAcGoJrjPSqrPnqalspRJJJCxrO1O+SztpJHOAozTru6SFCzHArnZrabVLgPd5W2U5WH19zSRZzF0k2oajbzz5BuZMKp7KK9J0tQAAOgrj5lEnim2jA+WGMnA7V2ViNuKJPYEtDpLT7oq3VGzb5RV4VcTCW4vakIp4FLirsTcgYUxxxU5HNMdeKlopMpOKxfFlv8AavDt6mMlU3j8DmtuXiqsqiWKSNhlXUqfxqS0dJ4Jvv7R8KaXcE5YwhGP+0vyn9RW3XB/B6cnQLuyc/NaXToB6A8/zzXeV7NKXNBM8qpHlm0FFFFWQFFFFABRRRQAUUUUAec/FJ/tGt+HbAHrK0zD2GP/AK9WBy1Z3ix/tPxMto+otbPP0JJ/xFaMXLc15OJd6jPUoK1NFuBauJVeAcVZUc1mkORIo5pwFCinVqkZNkbDmoXqZ+tRSVEi4lSU1Rn61ck6mqc/es2axOY8cLv0GZh1Qq36ipYFh1DTIxOiyRSxgkH6U/xHH52k3cfqhql4TfzdAtWPJUFT+BqehaFtLG501hHbyefZ9kc/Mn0PcVpq/wCFTAZFNZM0rlCrNjvU8d1t71TMbA03kUBY11u/eni9HrWKCRTgzU7i5UbYvF9aX7UPWsUOfenCU0XJ5Ea/2setIbwetZXmE0biaLj5UahvKja7z3rOyaUBj60XDlRaefPeoHlz3zTRGxqVLck0DKr26SHhcH1HFRS6K8vzxMof3GM1tQ2vIyKvRxYApopV5Q2ZxkltNbcXELp743D8xQBkfIc13QRWGGAI9DVW40qCYfJ+7b25H5VaZqsUn8SscWxIpd7KucHHrit6fSp7Zi8Shx6gZ/Ss2dJWzyyn/Z/wNPc1jU5th1ldmKJ1bIZ+FPrULEZ2qflX5R9BUYjw6vuLSrzyc47dPz/KnojE9OtChrcezBTuYe9bmixYkLHog/U/5NZltbMZFAGWPAArprS3+zwberHljTkzGtLljbuOZ8VEZwO9OkQk9arPBnPNZs40iU3K+tRtdD1qrJA46VAYXzSuWki3JdA96qyTZ70wxHuaiaI9s1I0K8wHeq7zFjgU5oiPvU0KF6CgoiaHeQzdadsCA1KKhuX2xOx6AZpAc5oo+0eINQn6hSIx/n8K663GCK5XwWha2lmPWWQtmuuhHNOW4LY2LM/KK0Y+1ZtqOBWlH0FaRMJky07FIlPxWyRiyNhUb1MwqJxUyRSZSnWqh4ar0/SqE3BrJm0Sv8NT9m8UeJLQn75jmUe3Of8A0IV6NXmXht/s3xKxnAurIj6kEH+lem16mFd6aPPxKtUCiiiug5wooooAKKKKACiiigDyy8HnfEnXH/55xRIP++FrXiHzVi6e3m+L/Esx5/0jZn6cf0rbjPNeNV1mz14aQRdhFWkqtB0FWkoiRIl7UvajtQela9DIifrUT9KlbrUTng1DLiU5e9ULk1emNZlw+WNYyN4mdfr5lvIv95SK5/wHKW064hP/ACylP610k/3TXL+EP3Oraxbn++GH5n/GktmWzqh1qXAYcdaipyHFICcQhl96a0PYipoWB4PBqbZmnYm5SFsCelP+x1eSPmrCxU0gcjLFnThZ+orWEVO8qnyk85kfZB6UotR6VreSKPJFHKHOZQtR6VItsPStLyh6UojFHKLnKC2w9KnSADtVoIKULTsLmIljApWGKlxUcnQ0CuRBsGpkbIqt3qeHpQDJcVWurG3ulxMh+qsVP5irVFNAm4u6MkaHBGu2BigPPI3Z/GlTR1B+eXP0XFatFM09vU7leC0hg5jT5vU8mpitOooM3JvVkTRg1G0QqzTWpWBMqNGKiaNatsBVeSpaKTKzoo7VWlwOgqaZqquc1LLRWl5NQsOasSjAqAqSM1JaGk1na9J5OkXT5xhCB+NXz1rE8YybdJWJfvTSKoprcHsT+E4vK0uAY6rn8+a6KHrWfpkQjt0QdgBWjHwaN2Poatp0FaUfQVl2Z6VqRmtYnPPclSpe1RLUo6VrExkJ2qJ6l9aieiQRKsw4qjKOavTdDVKQ1jI3iYob7P4/8Oy/3/MiP4qf8a9UryTXn8rxD4amBxi8Vc+gJWvW678G/caOPFr3kwooorsOQKKKKACiiigAoooJwM0AeReGm82+1+4zxJfSY/M/410MVc14HGdJupD1e6cn9K6WAV4b1kezsi/BVpKrQ9Ksp0rSJlIl9KVqQUN0rQyI3qCTpUz1BIeKzZpEo3LYBrKlbLGtC8bisxzzWMjoiiC4PyGuW0xhb+M7hD0niyPr1/oa6if7hrj9VkFt4p0yfpkhW+mcf1oiNnbrTinGRTKljbPFIBUOAKuwNkVEIgVHFOhG1sU0S9S/GKsIRVZDUqNVozZYGKWmKafVEhRRRQIKKKKQBRRRQAVFL0qWoZTxQNFYnmrEHIqqx+arVueKSKZYxSU8DikxV2IuNopxptIAooooADTWFOpDQMheq0verb9KrOuTUspFJ0JNRGKr7KBUMmB1qbFplJ04qvJgA1ZnkHaqMjE1LKRETlq53xE3n61plqOgYyH8P/1V0Lda5xc3PjR+4giA/T/69OI2dPbDCgVbSq6DBqZetSimadnWpH0rJszWrGeK1jsYTLCVKtQpUo6VsjCQetRP0qU1E/Q0McStNWfLWhNVCYVjI2ict40by4tLuP8AnldKf6/0r2QcgGvGviApPh5XHVJlP6GvYbdt1vEw7qD+lduCejRy4xbElFFFdxxBRRRQAUUUUAFMmJELkdQpp9R3Bxbyn/ZP8qAPJvBI26AM9Wmc10kA6VzvhLjw9Aw/idj+uP6V0dt0FeF1PZexdiFWF6VDH0FSitUYskFBNJmkzVXJsNc1Wlbg1NIapztwahsuKKF2c5qi1W5zk1WcVizoRVn/ANWa4jxBBLe31y0AJ+xW4lYjt8w/xFdvdcRGo/hvpi6wnimSQfLcJ9lQn3Bz/wCy1rQhzysRWnyRuO0q5F3YW8458xAT9e9XUXnIrm/B8jLZSWkoxJbSMhHpz/8Arrp4fmGKzas7FdLk0UnODVlQG6VSYFTU9q3PNCE0XUGKlUU1RkVKgq0ZsVRUgpoFOFMli0UUUxBRRRQAUUhpRSAQmq0rVO1Vpe9DKRWZvmq5a81nufmq/Z9KS3KexfX7tIRTk+7Qa1MOow0w1I1RmpZSCiiikMKRqWkNAyNulQv1qZqgkNIaIJWwDVGaTJ4qe5Ymqm0k1DNIohfJqFqtOuKrSDFSy0VXYAknoK5LwzdiTxLdsx/127H5g10OrzeRYzyDsprCfSG0nS/D+tLuzdM4cemG4/NauEW4sUpJNHaLUydahQcVOlZosuWpwa1Im4FZEJwa0YG6VpFmU0X4zUoqCM1LmtUzBocaY1OzTDTYkQyiqM4HNX36GqFz0NZSNYnM+OF3+Gph3Dqa9W04ltOtSepiU/oK8s8WDd4duif4dp/X/wCvXqOlHdpdmfWFD/46K68F1OfGbItUUUV6BwhRRRQAUUUUAFVdWkEWl3khOAkLt+SmrVYnjWbyPCWryf8ATs4/MY/rUydk2OKu0jz3wkCPDViD1IY/+PGulthwKw/D8fl6LYJ0/dKfz5roIF4FeItz2JbFuPpUgqNKfWhkx+aQmkprHincViKZqpTNxVmY81TlNZtmkUVZOTUD1NJUD9ahmqM3W5hb2Esn91Sa6/4UWX2TwbbSMuHuXaZvfJwP0Arz3xazyxwWUQzLcSKij15/xxXtem2qWOn21rH9yGNYx+AxXdgo6uRx4yWiieRapANL+I2p2oG2K6AnQfUZP67q2YThqi+LsH2TW9C1ZRhSxt5D+o/m1OQ81hiY8tRm1CXNTRfCBxSIhRqLc1aC5HNZWLbsSwmrC9KrRjBqwh4qkQx4pRSUopki0UUUxBRRRQAYoxSilxRYCNulVJupq4/Sqc3U0mVEpP8Aeq/ZdKoN96r9n0qVuVI0EPFKabH0pxrYw6iNUZ61I1RmlIpCUUUVIwpDS0UDImqCQcVZbFQSUhopyJk81GVCipZTVSVjioZoiGVuTVWY8GpGzk1XmNQzRGB4qkI01Yk+9NIFA/X/AAr0DxroSn4bC1RcyafCki/VB836bq4+zs/7U8Z6NZ4ykTGeQew5/p+tezTxJPBJFIAUkUqw9QRg16GEp3g79ThxVS01boeSaPcfatMt5s5LoM/UcH9RWglc/wCGFeze+0uc/vrOdkx7Z/xB/OugTrXBJWdjuTurk8fBFXoW6VRSrcR4pohmhC1WAapQmrSnitUzGSJM00mikouKwx+hqjcj5TV9xVOdcg1LLic14nUt4dv1/wBjP5EGvRvDEgl8OaW4Od1rGf8Ax0Vwerx+Zpl7HjO6Jh+ldb8PJvP8FaQ3pDs/75JX+ldWCerRjjF7qZ0VFFFeieeFFFFABRRRQAVx3xWufI8G3MYOGuJEhHPXLAn9Aa7GvM/idcf2h4i0bRomJEZNzMB29P0DfnWNeXLBs1oR5polsYvLt4E/uoo/StiEfKKzohlxWpCOK8mJ6cyVaWiirMwprninUyTpQCKkp5NVZTVmWqchyazZrEgeoWqY81Wu5VhheRzhUBYn2FSzRGX4btjrHxHgBG6CwBlb6jp/48R+Vey1wPwg04xaLcapOv7++lLBj12A4/nmu+r18NDkpo8nEz5p+hxXxfsjd+CLqRR+8tXSdfwOD+hNc3YTi4s7ecHiSNW/MV6ZrVmuoaRe2bDInheP8wRXjvgucz+G7cH70JaI/gcj9CK5sdHVSOnBy0aOrtjWhCDWVDMkMReU4UY7Z9u1aWnXCXMTNH91WK/lXHE6JFkCnqKdRVkCinUgpaBBRRRTEFA60UL1oAeBS0ClxxVWEROOKpz9avP0qlP1NTIqJRYfNV+0GBVM/eq5bdKhFy2L0fSnGmx9Kca2Wxi9xGqM1IajakxoSiiipGIaQmlpDSGNaonqUimNQMpTjrVGXrWhMKoyjBqGaRKkgqs4y1XGFZ2pzi2srif+4hI+vapsXc0/hfALvxBrGpEZWILbxn9T/IfnXplcl8LtPNh4RtncYmuibh/x6foBXW17NCPLBI8ivLmm2eSeMbQ6V8REuAMQalF17bgMH9QPzq6vY1rfFywM/htb+Ifv7CVZVPfBIB/ofwrD0+dbm2ilQ/K6hh+NedioctT1PRw0+an6FtKtxGqo4qaNsGsEasvRHkVcQ8VSiq3H0q0ZSJKKKKogRqrzL8pqxUcw+WkykY1wm5ZF/vKRWj8KJ9/hGOA/etp5Yj/31u/9mqnNw9UPh5ef2b4u1XSJCRHdf6RDn1xkj8j/AOO1rhZctSxOJjzU/Q9OooFFeqeYFFFFABRRRQAyeVIIJJpWCxxqWZj2AGSa8c0GWTVNY1LW5wc3MhEWeyDp/ID8K7f4o35tPC0tvET596626AdcE5P6DH41z2k2gtLOKFeiKFrz8bPVQR34OGjkzTthk5rUi+7VC2XitBBgVyRR0TY6iikJxVECmopGFNaSoXfipbGkRznrVFzzU08lU2bNQ2bRQ4muc8VyySQQ2NuMz3kgiUevI/8ArVvO2Fql4PszrPj57hxm20xMj0Lnp+ufyqqUeeaiFSXJFyPUtMtI9P0+2tIRiOCNY1/AYqzRRXuLQ8TcK8S0OH+z/EXiPSyMCK6MkY/2ST/QrXtteSeLIfsPxTDqPl1C0DH6qCP/AGQVyYyN4XOrCStOxbmdorK4dPvLGWHGegrT0JFW2ZkVwJG3ZbZzwBxs4xxVa24aq/h+ZzqbRsbfDRsWMI2hyCMEj8Tg9/fGa8yJ3yOloopwFaGQCloopiCiiigApVpKUUAPFPxxTFp9aIlkT1Tn6mrknSqk3WokXEpsOat21Vm61ZtqzRb2LsfSnmmJ0pxrZGL3EJphp1IaTGNoooqRhSGlooAZTWHFPxSEUhlSVetUp1xWlIvFUbleOKllxZmynArB8Rq09tbWUf8ArLudIgPqa6CVcmsyCMT/ABC8O2h5VN9wfwViP1WinHmkkVOXLFs9ctoUt7aKCMYSNAij2AxUlFFe4eMV9QtY76xuLWYZjmjaNh7EYrxrwx5tm13plzxNZTFD9Mn+oNe215R48tf7H8b218mBBqSbH/31wP6r+tceMhzQ5l0OvBztLl7l4GpEPIqtG2Vp6tg15aZ6TRqQngVbjbisuCSrqPxWiZlJF0GioEkqYHIqjNoWmSfdp+KRxkGmBlXI5zXJ+JhLY3tjrNqP3tnIGbHdc9P6fjXZXKcVlahaLc28kTjKupU/jWesXdGys1Zno9tNHcW8c8LBopFDqw7gjINSVx3wuvnn8O/Ypz+/sXMJz/d6j+o/Cuxr24S5opnjzjyyaCiiiqJCiig8DNAHnPi8nVPF8MPWDT49xH+23P8A8T+VWYounFS6faGSa6unHzzylvw/ya0Ut8HpXmVYOc2z0qc1GKRBDHgVZAqVIcU7yzUcjBzuQYqKTpVopxUUsZKnHWk4gmUmBqtMxFPlaZCcrkVWkmJ6rWTNkQSkmogOasbd3IFNdNqmoaNUzM1e6FpZTTk/6tSR9e3611Xwr037D4UhuJAftF6xuJGPU5Py/oAfxrz/AMUpJdyWOnxZ33U4Tj6gf1r2y3iSC3jhjACRqEUDsAMCu7Aw3kcWNnooklFFFeieeFeZ/FaPyfEnha8HBMskBPsdv+Jr0yvPPjMNunaJN3j1GP8AUH/CscQr02bUHaohkPDVBocYuL/z0hW3MLOCu9g205wNh4XOA2R6fWq2txebZlBa/aGz8uOqHBwRwe//ANfirGnbV1CzyzrICUaJjlo2KE4zzlDgnqRlRjvjx1uepLY6cClpBS1qYBRRRQAUUUUAFKKQU4U0DHrTqatPq0SyKSqc3U1ckqpL1qJFRKjdas29QOOasW4qEaMtp0p2aYKdmtEzJiGkNBpKTGFFFFIAooooAKQ0tFAETjNUrhavsOKqTipZaMxx81Z2gL5vxbt88+TYsR7ZBH/s1aUn+srO8Ony/i2h/wCelgR/n8qvD/xEFb4Ger0UUV7B5IVyfxN0n+1PClwyD/SLT/SIyOvy9R+Wa6ykdVdGVgCpGCD3FTKPMmmVGXK00eR6FdfbNPgmb7zr831HB/UVolaxdCtmsL3UtNcH/Rrhguf7pPH8v1rpEiLLXhuDTaPaU00mRRZq7CSRUQhKjkVLGSOi1SiyJSRZQGrEYOKhiErkYXArQihIUZrWMGzGUkRhaXZVlYvapBFWipmbmZssOe1VGtuvFbxh9qabf2qvY3Eq1jnvD1udO8TMyDEV4hDD/aHOf8+tdvWLNbYMcgHzRsGFbQORkV2UVyxsc1V80rhRRRWpkFRXRIt5MddpqWo7gZiI9aAMu3twkSjHapRDVsIKULWPIa85W8qjyqtbaNtL2Yc5SaKomirRKVGY6h0i1UMqSHPUZqrLbKf4RW08Q9Kgkh4rJ0jSNQw3hC9BVSeM7TxW9Jb57VVltcjpWMqRvGqctpFn9q8e6aGGVto2mP15x/SvU65DwxZ7fEl7OR92EIPxx/hXX13YaHLA48RPmmFFFFbmAV598ah/xTdge4v48fk1eg1wXxfTzdM0iEcl79OPwP8AjWdb4Ga0fjRUmuYreXEpYZychCQB7kDj8aWwgt59VS8Wc3DEMYtjKUjXABHXJyf8jnJPFOs6T2yq5AKvGTjePY+o/qasaXbsdRluhaNah4wr79u6Rs8H5Seg/PPtXjJHpt6GyKKcBRitLGVxtFOxRiiwXEpMU/bRinYVxgpwpcUAUJBcUU+minVaEyN+lVZB1q24qJlzUtDTKRXmrEC4FIY+anjXAqbFti0U7bRtp2IuNpMU/bRtosFxlFP20m2iwXGUtOC0u2jlC43FGKkCUuynyhcgYVWmQ4NXylMeLIo5AUjBlT95WbYxmL4oaLL2ktpE/EB//rV0clv83SqE1t5finQbkDlXdM/UY/rVUoWmmOpO8Wj0CiiivVPMCiiigDz7V7Ax+NbqUDC3ESt+IAH9K04LfArU1i1D6nbTY52lf8/nUsduB2rjnRvNs7IVbRSKCWwbqKsx2ij+EVdSHHapVjqo0kQ6rKqQAdBUyxVOFpwWtFTRm5shEeKcEqXbS4qlAnmItgpNlS4oxT5RXIXTKkVPF/q1+lJilThcVSQmx1FFFMQUyTsKfUch+cCgApcUClpDDFGKWigBCKTFOooAjK0wpmp6QilYdyqYhTHgyOlXMUYqeVDUijpkAiublsfex/WtGo4lwzH1qSrSsiW7sKKKKYgrkvG9sbu/0aPGQkxkP4Y/+vXW1m6hAJb63Yj7gNRUV42Lpu0rmMlqQ3SrkUGB0q+IBmpFiGK5VROh1Sj5R9KTyq0PLpPKp+xF7QoeVR5dXvLpDHU+yD2hR8uk2VcMdNMdL2ZSmVdho2VZ2UbKXIHOV9tG2rGyjZRyBzlcpTfLq3so2U+QOcpGLmnrHVnaM04KKPZg5lby6PLq1spQlP2Yucq+XSiKrQSlCU1TFzlXyqPKq3so2U/Zi5yp5VL5VWtlG2n7MOcreXS+XVjbTttHsxc5V8ukMXFWttG2nyBzlBocnpVa8ts3Fi+OUmBrW2c0y4jyqH0YGqjCwnM0aKKK6DAKKKKAK90m54z6GnBKkcZIoxSaGmNC04ClxRRYAopcUUAJRS0UwuJRRRSATFKveigdaAFooopiCq0r/wCkY9BVmq72xadpN+MjGMUmNDlang00Q4/i/SnBMd/0pajdhRS0gX3p2KYhKMUtFMQYoxRRQAYpKWigBB3paKKACiiigAqGRczKfapqQjJzQAzbS4p2KXFKw7jMUmKkxRiiwXI9tIVqXFJilyhchK0wpVnbSbPepcCuYrbKNlWNnvRs96XIHMVtlG2rPl+9Hl+9HIPnKhGKjkOKvGIHvTGtlY8mlyMfOjN3OTwtTRN68VaFrjo/6UotgOrZ/CjkYc6IxTgKmEQA6/pS+X70+Ri5iICjFS+X70uz3p8ouYixRipdnvRs96fKK5FijFSbPel2e9HKFyLFGKk8v3pdnvRyjuRYpMVLs96PL96OUVyPFNkGVH1qby/ekMecc9DTsFySiiiqJCiiigBG7UUpoxQAlApcUUAFFFFABRRRQAGkpaMUDEoFLijFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows where the heart is located in the chest. In atrial fibrillation, the electrical signals that control the heartbeat become abnormal. As a result, the top two chambers of the heart (shown in purple) stop pumping effectively, and blood that should move out of these chambers gets left behind.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37409=[""].join("\n");
var outline_f36_34_37409=null;
var title_f36_34_37410="Patient information: Cardiac resynchronization therapy (The Basics)";
var content_f36_34_37410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16656\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/48/3845\">",
"          Biventricular pacemaker",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/60/38850\">",
"         Patient information: Implantable cardioverter-defibrillators (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/41/36499\">",
"         Patient information: Medicines for heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/49/6931\">",
"         Patient information: Pacemakers (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/20/11589\">",
"         Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/16/20741\">",
"         Patient information: Pacemakers (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cardiac resynchronization therapy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cardiac-resynchronization-therapy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6756828\">",
"      <span class=\"h1\">",
"       What is cardiac resynchronization therapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT) is a treatment for some types of heart failure. Heart failure is a condition in which the heart does not pump as well as it should.",
"     </p>",
"     <p>",
"      When the heart pumps, the walls of the left lower chamber of the heart (called the left ventricle) should pump at the same time (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"mobipreview.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). But in some people with heart failure, the walls of the left ventricle do not pump at the same time. This can make heart failure worse.",
"     </p>",
"     <p>",
"      CRT uses a special device called a biventricular pacemaker, also called a BiV pacemaker or BiV pacer. This device is put in the chest near the heart. It sends electrical signals to the heart to make the walls of the left ventricle pump at the same time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6756843\">",
"      <span class=\"h1\">",
"       What are the benefits of CRT?",
"      </span>",
"      &nbsp;&mdash;&nbsp;CRT can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Improve symptoms of heart failure",
"       </li>",
"       <li>",
"        Keep people from needing to go to the hospital for their heart failure",
"       </li>",
"       <li>",
"        Help people with heart failure live longer",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6756858\">",
"      <span class=\"h1\">",
"       What does a BiV pacemaker look like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A BiV pacemaker has 2 parts:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A pulse generator &ndash; This is a thin metal case with a battery and small computer in it. The pulse generator creates and sends electrical signals. The doctor sets the computer to tell the pulse generator when to send electrical signals.",
"       </li>",
"       <li>",
"        Wires, also called &ldquo;leads&rdquo; &ndash; The wires connect the pulse generator to the heart. Electrical signals travel from the pulse generator through the wires to the heart. A BiV pacemaker usually has 3 wires (",
"        <a class=\"graphic graphic_figure graphicRef68651 \" href=\"mobipreview.htm?3/48/3845\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A BiV pacemaker is similar to other pacemakers that can help treat abnormal heart rates, but a BiV pacemaker has an extra wire.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6756873\">",
"      <span class=\"h1\">",
"       How is CRT done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will do a procedure to put the BiV pacemaker in your chest. He or she will make a small cut in your upper chest. He or she will put the wires in a blood vessel near the cut and thread them to your heart. Each of the 3 wires will sit in a different part of your heart (",
"      <a class=\"graphic graphic_figure graphicRef68651 \" href=\"mobipreview.htm?3/48/3845\">",
"       figure 2",
"      </a>",
"      ). Your doctor will then connect the wires to the pulse generator. He or she will program the pulse generator and put it under the skin in your chest.",
"     </p>",
"     <p>",
"      Depending on your heart condition, your doctor might use a &ldquo;combined&rdquo; device. A combined device has a BiV pacemaker plus an implantable cardioverter-defibrillator (ICD). An ICD can sense and treat abnormal heartbeats that could cause sudden death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6756888\">",
"      <span class=\"h1\">",
"       What problems can happen with CRT?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can happen with CRT, either during the procedure or afterward:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A wire can make a hole in a blood vessel, the heart, or the lungs.",
"       </li>",
"       <li>",
"        An infection can start around the pulse generator or wires.",
"       </li>",
"       <li>",
"        The wires might be put in the wrong place during the procedure or move out of place later on.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other downsides of CRT include the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You will need more surgery after 8 to 10 years to replace the battery.",
"       </li>",
"       <li>",
"        There is a small chance that CRT will not work and that the BiV pacemaker will not improve your heart failure. If your heart failure does not improve with CRT, your doctor might change the settings of your BiV pacemaker. He or she will also talk with you about other possible treatments.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6756903\">",
"      <span class=\"h1\">",
"       Do I still need to take my heart failure medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. After CRT, you will still need to take your heart failure medicines. You will also need to follow your doctor&rsquo;s instructions about diet and exercise.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6756918\">",
"      <span class=\"h1\">",
"       What else will I need to do if I have a BiV pacemaker?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a BiV pacemaker, you will need to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Follow up with your doctor on a regular basis. He or she will make sure that your device is working the right way.",
"       </li>",
"       <li>",
"        Avoid certain electric or magnetic sources or equipment. Your doctor will tell you which electric or magnetic sources or equipment you can be near, and which ones you should avoid. For example, you can be near televisions and radios. But you should probably not use a welder or a chainsaw.",
"       </li>",
"       <li>",
"        Let all of your doctors and nurses know that you have a BiV pacemaker. You should carry a card telling people you have a BiV pacemaker. The card should say which type of BiV pacemaker you have and which company made it. Some procedures and tests are safe for people with a BiV pacemaker, but others are not. For example, you might not be able to have an imaging test called an MRI scan.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6756933\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"       Patient information: Medicines for heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/49/6931?source=see_link\">",
"       Patient information: Pacemakers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"       Patient information: Pacemakers (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/34/37410?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16656 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37410=[""].join("\n");
var outline_f36_34_37410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756828\">",
"      What is cardiac resynchronization therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756843\">",
"      What are the benefits of CRT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756858\">",
"      What does a BiV pacemaker look like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756873\">",
"      How is CRT done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756888\">",
"      What problems can happen with CRT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756903\">",
"      Do I still need to take my heart failure medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756918\">",
"      What else will I need to do if I have a BiV pacemaker?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756933\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16656\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/48/3845\">",
"       Biventricular pacemaker",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_34_37411="Recording vis evoked potentials";
var content_f36_34_37411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Recording of visual evoked potentials",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A schematic diagram presents the steps in recording of visual evoked potentials. Each alternation of the checkerboard pattern is followed by amplification of the electrical activity and conversion of the analog signal to digital form (A-D conversion). Signals of repeated visual stimuli are averaged to reduce the effect of random electrical noise.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37411=[""].join("\n");
var outline_f36_34_37411=null;
var title_f36_34_37412="Lindane: Drug information";
var content_f36_34_37412=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lindane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/37/37461?source=see_link\">",
"    see \"Lindane: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/21/40275?source=see_link\">",
"    see \"Lindane: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hexit&trade;;",
"     </li>",
"     <li>",
"      PMS-Lindane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiparasitic Agent, Topical;",
"     </li>",
"     <li>",
"      Pediculocide;",
"     </li>",
"     <li>",
"      Scabicidal Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Scabies:",
"     </b>",
"     Topical: Apply a thin layer of lotion and massage it on skin from the neck to the toes; after 8-12 hours, bathe and remove the drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head lice, crab lice:",
"     </b>",
"     Topical: Apply shampoo to dry hair and massage into hair for 4 minutes; add small quantities of water to hair until lather forms, then rinse hair thoroughly and comb with a fine tooth comb to remove nits. Amount of shampoo needed is based on length and density of hair; most patients will require 30 mL (maximum: 60 mL).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F188901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/21/40275?source=see_link\">",
"      see \"Lindane: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 1% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Lindane lotion:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133687.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133687.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lindane shampoo:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133688.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133688.pdf",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F188867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only; never administer orally. Caregivers should apply with gloves (avoid natural latex, may be permeable to lindane). Rinse off with warm (not hot) water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion: Apply to dry, cool skin; do not apply to face or eyes. Wait at least 1 hour after bathing or showering (wet or warm skin increases absorption). Skin should be clean and free of any other lotions, creams, or oil prior to lindane application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Apply to clean, dry hair. Wait at least 1 hour after washing hair before applying lindane shampoo. Hair should be washed with a shampoo not containing a conditioner; hair and skin of head and neck should be free of any lotions, oils, or creams prior to lindane application.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     (scabies),",
"     <i>",
"      Pediculus capitis",
"     </i>",
"     (head lice), and",
"     <i>",
"      Phthirus pubis",
"     </i>",
"     (crab lice); FDA recommends reserving lindane as a second-line agent or with inadequate response to other therapies",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F188915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined (includes postmarketing and/or case reports).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, headache, restlessness, seizure, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, contact dermatitis, skin and adipose tissue may act as repositories, eczematous eruptions, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aplastic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning and stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F188870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lindane or any component of the formulation; uncontrolled seizure disorders; crusted (Norwegian) scabies, acutely-inflamed skin or raw, weeping surfaces or other skin conditions which may increase systemic absorption",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F188854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May be associated with severe neurologic toxicities (contraindicated in premature infants and uncontrolled seizure disorders).",
"     </b>",
"     Seizures and death have been reported with use; use with caution in infants, small children, patients &lt;50 kg, or patients with a history of seizures; use caution with conditions which may increase risk of seizures or medications which decrease seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Not considered a drug of first choice; use only in patients who have failed first-line treatments, or in patients who cannot tolerate these agents.",
"     </b>",
"     Because of the potential for systemic absorption and CNS side effects, lindane should be used with caution; consider permethrin or crotamiton agent first. Oil-based hair dressing may increase toxic potential. For external use only; avoid contact with face, eyes, mucous membranes, and urethral meatus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medication guide:",
"     <b>",
"      [U.S. Boxed Warning]: A lindane medication use guide must be given to all patients along with instructions for proper use.",
"     </b>",
"     Patients should be informed that itching may occur following successful killing of lice and re-treatment may not be indicated. Should be used as a part of an overall lice management program.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F188873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nursing mothers should interrupt breast-feeding, express and discard milk for at least 24 hours following use.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Lindane External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (60 mL): $132.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Lindane External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (60 mL): $132.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F188874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agalin (PL);",
"     </li>",
"     <li>",
"      Aphtiria (FR);",
"     </li>",
"     <li>",
"      Aprurol (UY);",
"     </li>",
"     <li>",
"      Benhex Cream (NZ);",
"     </li>",
"     <li>",
"      Bicide (IL);",
"     </li>",
"     <li>",
"      Davesol (EC);",
"     </li>",
"     <li>",
"      Delice (TW);",
"     </li>",
"     <li>",
"      Delitex (DE);",
"     </li>",
"     <li>",
"      Demar (VE);",
"     </li>",
"     <li>",
"      Desintan (FI, GB);",
"     </li>",
"     <li>",
"      Elentol (FR);",
"     </li>",
"     <li>",
"      GAB (IN);",
"     </li>",
"     <li>",
"      Gama Acaderm (CN);",
"     </li>",
"     <li>",
"      Gambex (ZA);",
"     </li>",
"     <li>",
"      Gatox (HR);",
"     </li>",
"     <li>",
"      Herklin (MX);",
"     </li>",
"     <li>",
"      Hexa-Defital (AR);",
"     </li>",
"     <li>",
"      Jacutin (AT, CH, CZ, DE, HN, LU, PL);",
"     </li>",
"     <li>",
"      Kwellada (GR);",
"     </li>",
"     <li>",
"      Lencid (BE, LU);",
"     </li>",
"     <li>",
"      Lendianon (BR);",
"     </li>",
"     <li>",
"      Lindano (AR);",
"     </li>",
"     <li>",
"      Lindano-GBHG (PY);",
"     </li>",
"     <li>",
"      Linden Lotion (KP);",
"     </li>",
"     <li>",
"      Milinor (HR);",
"     </li>",
"     <li>",
"      Nedax (BR);",
"     </li>",
"     <li>",
"      Paracid (BE);",
"     </li>",
"     <li>",
"      Pruritrat (BR);",
"     </li>",
"     <li>",
"      Quellada (BE, IE, LU);",
"     </li>",
"     <li>",
"      Quellada Cream (AU);",
"     </li>",
"     <li>",
"      Quellada Creme Rinse (AU);",
"     </li>",
"     <li>",
"      Quellada Head Lice Treatment (AU);",
"     </li>",
"     <li>",
"      Quellada Lotion (AU);",
"     </li>",
"     <li>",
"      Sarcoderma (PT);",
"     </li>",
"     <li>",
"      Scabecid (FR);",
"     </li>",
"     <li>",
"      Scabene (PK);",
"     </li>",
"     <li>",
"      Scabi (TW);",
"     </li>",
"     <li>",
"      Scabix (BR);",
"     </li>",
"     <li>",
"      Scaboma (MY);",
"     </li>",
"     <li>",
"      Skabicid (CZ);",
"     </li>",
"     <li>",
"      Texa (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F188853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly absorbed by parasites and ova through the exoskeleton; stimulates the nervous system resulting in seizures and death of parasitic arthropods",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F188869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &le;13% systemically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Stored in body fat; accumulates in brain; skin and adipose tissue may act as repositories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children: 17-22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Children: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aks S, Krantz A, Hryhorczuk DO, et al, &ldquo;Acute Accidental Oral Lindane Ingestions in Toddlers,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:375.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies JE, Dedhia HV, Morgade C, et al, &ldquo;Lindane Poisonings,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1983, 119(2):142-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/6186202/pubmed\" id=\"6186202\" target=\"_blank\">",
"        6186202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eichenfield LF, Honig PJ, &ldquo;Blistering Disorders in Childhood,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):959-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/1651468/pubmed\" id=\"1651468\" target=\"_blank\">",
"        1651468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frankowski BL and Bocchini JA Jr, &ldquo;Head Lice,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(2):392-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/20660553/pubmed\" id=\"20660553\" target=\"_blank\">",
"        20660553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogan DJ, Schachner L, Tanglertsampan C, &ldquo;Diagnosis and Treatment of Childhood Scabies and Pediculosis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):941-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/1870912/pubmed\" id=\"1870912\" target=\"_blank\">",
"        1870912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurt TL, Bost R, Gilliland M, et al, &ldquo;Accidental Kwell&reg; (Lindane) Ingestions,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1986, 28(6):569-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/2431535/pubmed\" id=\"2431535\" target=\"_blank\">",
"        2431535",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/8602186/pubmed\" id=\"8602186\" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pramanik AK and Hansen RC, &ldquo;Transcutaneous Gamma Benzene Hexachloride Absorption and Toxicity in Infants and Children,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1979, 115(10):1224-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/92217/pubmed\" id=\"92217\" target=\"_blank\">",
"        92217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomon BA, Haut SR, Carr EM, et al, &ldquo;Neurotoxic Reaction to Lindane in an HIV-Sero Positive Patient, An Old Medication's New Problem,&rdquo;",
"      <i>",
"       J Fam Pract",
"      </i>",
"      , 1995, 40(3):291-5-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/34/37412/abstract-text/7533205/pubmed\" id=\"7533205\" target=\"_blank\">",
"        7533205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9562 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37412=[""].join("\n");
var outline_f36_34_37412=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709012\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188883\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188917\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188886\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188901\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188887\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188864\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188850\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874687\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188867\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188866\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188915\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188870\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188854\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299605\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188859\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188860\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188872\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188890\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188873\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323319\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188874\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188853\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188869\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/37/37461?source=related_link\">",
"      Lindane: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/21/40275?source=related_link\">",
"      Lindane: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_34_37413="Armpit stretch";
var content_f36_34_37413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76033%7ERHEUM%2F55131%7ERHEUM%2F67887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76033%7ERHEUM%2F55131%7ERHEUM%2F67887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Armpit stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use your good arm to lift the affected arm onto a shelf, a dresser, or any object about breast high. Gently bend at the knees, opening the arm pit. Try to push the arm up a little bit farther with each stretch. Perform sets of 10 to 20 stretches at each session.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Walk up wall stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Face a wall about three quarters of an arm length away from it. Using only your fingers (not your shoulder muscles), raise your arm up to shoulder level. Perform sets of 10 to 20 exercises at each session.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Towel stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Take a 3 foot long towel, grasp it with both hands, and hold it in the horizontal position. Use the upper, good arm, to pull the affected arm toward the lower back. This can be repeated with the towel at a 45&deg; angle. Perform sets of 10 to 20 stretches at each session.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37413=[""].join("\n");
var outline_f36_34_37413=null;
var title_f36_34_37414="Supracristal VSD short axis 2D and color";
var content_f36_34_37414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1181px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/54870/Supracrist_VSD_short_movie.mp4?title=Supracristal+VSD+short+axis+2D+and+color\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Supracristal VSD short axis 2D and color",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 394px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGKAiEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6A+Injaw8CaRaahqdrfXUdzdC0jjs1QvvKO+TvdRjEbd/SuDg/aC0GeaOGHw74meWRgiKsVsSxPAA/f0z9qj/AJEzQP8AsMr/AOktzXg/hu3luNXRorRr37Oj3DQiXyRhVOCz5G1c4yRzWtOmpK7Jbse9Xf7Qvh60vmtJ9B8RCdWKEKtq67h1G4TkfrWff/tOeENPmEV3o3iWORl3AeRbnjkdpvY186ahdtJoEbwz20NtaaiWa3QMXiOSC2e+ckAHJK8+1cj4+IOsRYxjyFxj/ealKKSugTdz6w/4ar8Ef9ArxJ/4Dwf/AB6j/hqvwR/0CvEn/gPB/wDHq+KqKzKPtX/hqvwR/wBArxJ/4Dwf/HqP+Gq/BH/QK8Sf+A8H/wAer4qooA+1f+Gq/BH/AECvEn/gPB/8eo/4ar8Ef9ArxJ/4Dwf/AB6viqigD7V/4ar8Ef8AQK8Sf+A8H/x6j/hqvwR/0CvEn/gPB/8AHq+KqXNAH2p/w1X4I/6BXiT/AMB4P/j1H/DVfgj/AKBXiT/wHg/+PV8V5pKAPtX/AIar8Ef9ArxJ/wCA8H/x6j/hqvwR/wBArxJ/4Dwf/Hq+K80ZoA+1P+Gq/BH/AECvEn/gPB/8eo/4ar8Ef9ArxJ/4Dwf/AB6viqloA+1P+Gq/BH/QK8Sf+A8H/wAeo/4ar8Ef9ArxJ/4Dwf8Ax6viukoA+1f+Gq/BH/QK8Sf+A8H/AMeo/wCGq/BH/QK8Sf8AgPB/8er4qooA+1f+Gq/BH/QK8Sf+A8H/AMeo/wCGq/BH/QK8Sf8AgPB/8er4rzRmgD7U/wCGq/BH/QK8Sf8AgPB/8eo/4ar8Ef8AQK8Sf+A8H/x6vivNJQB9q/8ADVfgj/oFeJP/AAHg/wDj1H/DVfgj/oFeJP8AwHg/+PV8V5ozQB9qf8NV+CP+gV4k/wDAeD/49R/w1X4I/wCgV4k/8B4P/j1fFVFAH2r/AMNV+CP+gV4k/wDAeD/49R/w1X4I/wCgV4k/8B4P/j1fFeaM0Afan/DVfgj/AKBXiT/wHg/+PUf8NV+CP+gV4k/8B4P/AI9XxXmkoA+1f+Gq/BH/AECvEn/gPB/8er0D4UfFXQ/ib/an9g2upW/9neV5v22NE3eZv27drt/cOc47V+dVfVX7DH/M7f8Abj/7cUAd34h/aV8H6Dr+p6Reab4ge50+6ltJWighKM8blSVJlBxkHGQKz/8AhqvwR/0CvEn/AIDwf/Hq+Vfix/yVPxl/2Gr3/wBHvXKUAfav/DVfgj/oFeJP/AeD/wCPUf8ADVfgj/oFeJP/AAHg/wDj1fFVFAH2r/w1X4I/6BXiT/wHg/8Aj1H/AA1X4I/6BXiT/wAB4P8A49XxVRQB9q/8NV+CP+gV4k/8B4P/AI9R/wANV+CP+gV4k/8AAeD/AOPV8VUUAfav/DVfgj/oFeJP/AeD/wCPUf8ADVfgj/oFeJP/AAHg/wDj1fFVFAH2r/w1X4I/6BXiT/wHg/8Aj1H/AA1X4I/6BXiT/wAB4P8A49XxVRQB9q/8NV+CP+gV4k/8B4P/AI9R/wANV+CP+gV4k/8AAeD/AOPV8VUUAfav/DVfgj/oFeJP/AeD/wCPUf8ADVfgj/oFeJP/AAHg/wDj1fFVFAH2r/w1X4I/6BXiT/wHg/8Aj1H/AA1X4I/6BXiT/wAB4P8A49XxVRQB9q/8NV+CP+gV4k/8B4P/AI9R/wANV+CP+gV4k/8AAeD/AOPV8VUUAfav/DVfgj/oFeJP/AeD/wCPUf8ADVfgj/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfav/DVfgf8A6BXiT/wHg/8Aj1d/8KPirofxN/tT+wbXUrf+zvK837bGibvM37du12z/AKs5zjtX5119VfsMf8zt/wBuP/txQB9VUUUUAeMftT8eDdA/7DS/+ktzXzdPuMb7JJItykFonKtj6j+VfRf7WUeoS+BdCTRrOa+vzrSeXbwxNKz/AOjXGcKvJwMn8K+Yjp/xBIx/whmrY9P7LuK2pzUVZkyTbLeo6Mth4m1LTpLu4ntrQw3CI5CgvJGGLEDgnJxmuN8cknVoSQB+4HT/AHmrrtYt/iHquvXeqzeC9UinuUVGSLSrkINowMZyc8eteearqMup3CzXCorqgQBAQMZJ7k+tEpRcbIEnco0UtJWJQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUtACUUUpxQAlfVX7DH/M7f9uP/txXyrX1V+wx/wAzt/24/wDtxQB4B8WP+Sp+Mv8AsNXv/o965Sur+LH/ACVPxl/2Gr3/ANHvXKUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVZsLK61C8htLC3mubqZtscMKF3c+gA5NLqFhd6dezWeoW01rdQttkhmQo6H0IPIoAq0VuHwl4iF3ZWp0PUxc30ZltYjauGnQDJZBj5gBzxVfW/D+saFJDHrWl3unvMC0a3MLRlwOpGRzQBl0VuXnhHxFZW1vcXehapDBcsqQySWrqJGb7oU45J7DvUOt+Hda0Fol1vSb7TzLny/tUDR78dcZHNAGTRS4NAUntQAlFOIIptABRRRQAV9VfsMf8zt/24/+3FfKtfVX7DH/ADO3/bj/AO3FAH1VRRRQBxnxD/5C/gj/ALDT/wDpvvK5/wAGa1eCw1+XxRqdo5sNTkt/tIjFtEiBYyBgscDLd2J561f+MV7c6f8A8IfdWNvBc3EesttinmMKNmxuwcuFYjgk/dPpx1rhdPmaygubew8A+DraG5CieOG9KLKFOV3AWmGwemelcWJzHDYWXJWmovc3p4arVjzQjdHZR3+qJ8TX06a7hfSZNMa5ht0g2sjiRFJZySWPLYwFABxgkZr896+4xcX761/bH/CD+Ezq/X7cdQbz/u7f9Z9k3fd469OK+HcVWFx2Hxl/YTUrb28zKUJR+JBRSUV1khS0lFAC0lFFAC0fhSUUALSUUtACqM8U/YPlyetJHncMDNeg+A2tJfC+uaTe6NZXEl/saG/c4mhKnnZ7fl75oA89cYOMYppxxXpkngC1ghmeaaaQgZTEi856D60yP4dxN9lDzun2hd4JYcgdR9aAPNuM0cV6uPhnbPBJJFJMXJISISKSAO5PvWxpPwn02cRmaO+fehcIsqBuB2oA8Qo4r6Ds/hFoM9vmW21OA/8APRp1I646YrD1P4UabbS/JfusXKZZwfmHX6/SgDxjv7UDrzXqlr8Mre4gSRLqRhuKsRjt1q1d/DTSbcRu93cLGwyx3L8n1oA8jK7evam17f4h8P6PL4HsdDsdOhS9tHaU6kg/eSFugc9wePYYGK8YvrSaxuJLe5QpMhwwNAFekpaSgAoopR1oAKSlooASilooASvqr9hj/mdv+3H/ANuK+Va+qv2GP+Z2/wC3H/24oA8A+LH/ACVPxl/2Gr3/ANHvXKV1fxY/5Kn4y/7DV7/6PeuUoAKKKKACiiigAooooAKKKVRk9D+FACqM0rAA4HJq5pemXWqX8VlYRmWeU4VR29ST2AHJPQV7Pqug+GtZ0bR7T+zkiudOt1ilvNNdYxcn+I4fJYZ/iPPJ7YoA8KoNewR+AfDU91JDENX3RoXJEsZBA68461LZ/DrwzcrERPqgWblWMkeFHvxTA8aor3C3+GHh2WfZ/wATnaV3K2+MKR/OtSP4S+G8w/6LrUiyJvDLKmCP8fagR890V9D3fwd8MIoxPqcTt8oVpEOD19Kwn+G3hb7TDDHe6m7y5AAZOCOuTj60gucX8KLu8i8UGy0+xe+fVLaSwkhhkWOYRsAWaJ24RwF6ntkd677xJc6M3xGt00+0Gq6T4as7K3uNRluA3kbLhWec7cedjcY8YIOOBjFaWhfBrw9fQSSz32rW8SOI1YbXYsenyqMge9T2Hwb8Ow3+mpNcahI8ksiSIzo0atEejlR91seo4NAXOf8AHi3lp4d1G3uLpUv9X8S/bdJb7QGL2rK6iRGBO1DuUdv04yvFJkuPEqeFrawbWIPDthPb5kuSmLjG6e53ZyQr9FyQQo45rofij8O9M1S21bxVoF/p9lHb2yTTabDAwjjYABl8zO0OcjCgc814/q2gavpFlY3mqadeWltepvtppoyqyr6qe/WgZ7zrGgeJdLki0bT7m9kfVbyyF94rvbzcBMG3L5CBsqgYj5j8xwRwK4r4x2+p6PoVhov9lX1toMN7NNDfahdLNc3kxUBnYBiEGBwoHuSTmuU8C+EovEtrrF9qGsf2TpelpE1xcfZ3uCpkfavyKc4z1btXNarALHU7m1juobyOGRkW4hYmOUA4DLnsaAPfdL8NeHm8HJNaaTodzp39kwzQ6nJOGupLszRiZGjJ6Lkr0+UY5O41eOleEb3XjZ/8Iro0Mc2ualo4ZJG+SCKHeHHzY3ljw3RRwK+ad55680B2ByCR+NACdqbTi5PXmlHIP9BQAyiuz1/wNNpmj+Gr2x1C31eXXDIsUNijPsdSo2ZI5b5sEAcH1rf1L4P6jpsqW11qEDX50efVXt7ePzSjRMFMGVPLc9R0II5oA8tr6q/YY/5nb/tx/wDbivE7n4XeI2h0xtI0+81OS7sY7yaOC3Ia2Lu6hGB7/JnPHWvc/wBia2lsrvx5bXMbRTwvZxyRsMMrA3AII9QaAPqOiiigDyz4/wA32fSfC0ucbdZ/9s7qvOtO1bzLtV3Gu1/afl8jwn4ek6bdZX/0lua8M0fVcX6ZavkeIcJ7asp/3f1Z9jkNOM8FO/d/kj3G3lyqHPavhE19n6dqO+FDkdBXxgaw4Ppum66f93/248DMI8rS9f0Eooor7U80KKKKACiiigAoopaAEpygk9KApJ/rW54b8PzazI+D5caqSCeN5HYUAJoejPfo9xL8trH1AHLn0Fd3ZRW0ttHHGVjumA2xr8qqB3/KqttoaQW0ieVKsix5GXIUgdqZpkMlpEm8qI5+FOCSg64B9aAOmNtbx2yW93bvEx5WONyDISOCDQYI7uwt7fyLu2MchLeWd4GOuRVS+DxwxXMrtNbIwWOUPkrjsfSpbfUpVXzIpHV87QI+pH+17UAbNy0VxqNvBp1lMzEAFCzKHPrg9BiuquLFEmQXNhf2eU+Vrd927jnAPSvOdX1y+imiV7kL5TACRGzx2Htk9q0b29127aG6vJ5CyBfL8uTg/wD16APTtCt7AxJC15Mj/wCsL3PD4JxyBxUmsW2iRo0s7xpMgyLmFfMGegPP8q87tbyYXVoZlZvKXEzAkpknk59a6K+1nQ4Fee2WT7UP3ZDkFST7Hr+FAFfVr2xawf7LLmSHA8qIcydgcHoaxrue0kSFpDL86kNFIMEk8ZHbis+41iRlmSNYkZidhjI3e49BVK31GVNNnS+hMspA2FzxtB7elAC3mFnkTdJ9hC5jxJkjHUKPc965fxU2m3+lxLDG73yctO2SwP8AdJ6YHvW+tzp0yvH9nbLkfvJHPy57g/0FYN69k87Q2g3WyAq4YYLH1NAHnrqR1GD6U2tfXLUxXOBEiAjKhemKymRupFADKWjoaSgBc0lFFAC0UlFABX1V+wx/zO3/AG4/+3FfKtfVX7DH/M7f9uP/ALcUAeAfFj/kqfjL/sNXv/o965Sur+LH/JU/GX/Yavf/AEe9cpQAUUUUAFFFFABRS0oUke3rQAgGTWhpWm3WrX0Vlp0JluZTgKOg9ST2AHJJpNK0+61W9isrGFpZ5DhQOAB3JPYDqSelelR6Emjad9gsSZ1mUfbLyJsNN/0zTuIwf++vpxQAzT4LPw/G+l2kuWlT/TdQUcyf7Ef+wP16+1aWmWiCU3EEHnWnDKQ2TGuetYN3pTrqEK2/yjbvVmYt8vQjBrY0tpblGFtKFuGGwRA7FIHb60AX7X7JFqEU0NvNMrE75hKQN3t6Va06G0srW9e5iupXm+ZFdSpT33DtWLb3SwSvboApDkOsn3R61ojWL2G2dop2eNfk/ethiD2A7j2oA6fwvZzz6bPOdJnnjblZBKQ+B/T2rX0+3so5opWl1JI41LMkmBFgdgRzXnmh61rc1vdW1ldFlP8ArVBwVGegHfirlhcXlv5qTtLJCqsEBfLBj6CgD142emfZt089vcRsMmJicjuCB3rm72fRLCdo4pgI8BSjxlDETzkEe9ZWh3+nRad5OtJLuLbRg4Y8dwf51na5rduZESwiiaKE7QZSuT9W70AdBoniC0024vrOe51G3UyrML+zQFpAoOYiP7pznNVZfFtuujeIo9OtfIu7t3e0WIjy4i42yE59V9fwqLwaLe/hvNQvFsinnRWqvqLslrtfJZU2fN5vHGeMVTaHS4dd8X3F5pkjxaFEbmKzuWwHO9UxKqn3zjPPFABpviTwv4e064xJqVxNd2yrJpN0gktHnBHz7u5GOOMgGuX+I/iJZPsfivwxqOszXJv3uLiC9ZZLfTpSgURrGwIOedrEY2gDtXe654c8FW+iXFzqqf2Wt3Jatb3iKZPsbSwmQrjunBx74qPUfDvh0aHPe6Amm6XFLbWDC51dm2zxSeYHSXGfmfavbtxigDzHwj8QBceIm1PxfrWqWl1DEkVvPptrDsdA+54poQFDqwPfofXiuA8WX9pqnibVL7TbQWdlc3MksFuP+WaMxIXj2r2fxf8ACfw/cap4q1HT/EEOj2OmSP5lqbRjHbsEBWPzC3JYkbfXNeCEE8gUANPvQKO9HQ0AFLgjnpSpxznFez+DPCeh3vgW0e7s7dr3UYLqYieR1v5TFuKGxUfIUyuG38khvQUAcvY+OP7H0DwO2jZ/tjQLq7uHE0eYsyMpTHPPAORxXVJ8WLD+zbNre2TS9Sg0W+tRJptt5Xl3MsmU2HdkJgZP+0Se9OufB+i3NreeHILGKC7stKs9TTVAWNxLLOYdyyDO0oPNOAACMDnk1Tuvg/BHcSwW/iyxuJRPd2MarbyAyXNupdk/3dmMv2Y4560AbOhfEjwy9xp+q6/qGsjxHZ6THZw33kCcRXG+QtMVLDzGCsAC3HtxXe/sZypPq/xDminmuUkmtHWecYklBa4O5h2Y9TXk4+EFn+78zxfZR7fsRuENq5eL7UgMa4H3nLE/Ln7o3ZHSvWv2N9Pk0jWviJptwVaazntbeQp90sjXKkj24oA+mqKKKAPD/wBrdzH4B0Rx1Gsp/wCk1xXzFp9+yXaHNfTH7YRx8OtGP/UZj/8ASe4r5Mhm2yA5rzsZTU5a9j6nJa3JhpR83+SPcdD1INapluwr5kNes6ZrBjhUbj0ryY49a48mw3sJVfO36nk5lrJfP9BtFLSV7p5gUUUUAFFFFABSijtTlXJGKAN1NOsJ0tnsprmVDApuFkjC4mycomCcqBjng+1dPp9vNaQiGWLyUADCTHzL9B3rnNCukgkEUwIhk6gD9a9W0lLJbJxqUp8hkwjE7tpPYe1AGXawb7CYid3jQYZInxjPfnv7CmLJGJLWIg3wQZVB8pXnOCMcmpNG1VNIjuYpbeN7UMTFLnksDxx/jVrxL4js737NNfraWkirndAm1jxwWx60Aa2pXenyWAtRDPZuwLSRSxjGO+3Hf0rd0LQ9Imjijj8ieS42qZVmJ2DuD3zXm82prqgiP2nLAAIshz+R61p2uqNZrAqSi2lBHmkId5HpgdM0Adp4v8J6LbTwxw28M9khzKI7j5gOxPesiaDTrO7MVsZgrp8sDDKqMcYbuaz7nVbhDKJIU2yNvSXGBt75B9apHX7jT7h2LRzDy/vsclF7ADscUAWJo5J7HZbJMscbZkhBwSM/eIPUVhWkcUEtxFITJJG5LE5yob9M1or4m0s4j1WGeZ+DHh9oC/xcjrU+peJ/C8Cx+VYNGV+4C+ScevrQBzJ1a0jnmMSSSSg/dKAFcdfrmizuU1W6lkdkt7VBwsp65HapbnxLb3MASCzgSMPv810G8D696y7rU7eQNPIfuNlQuBuHtQBtRRW6vBAygSjgtksSO2BWJ4x0tbG8BjuJWjkGQ2MZP0qS28Wm0tJBbQxeY4OHcfMoPoe1YX9oT3d7FNcsJBk4DE4HvQBTxcynkktjgNxU1vHp8zzLqUktqEgcxtAgcvKB8qsCRhSep7elbusTWKxwRDEsr43SIPu+wrmr6GNZ8K5PPU0AZbdelJViQITwDkVAevpQAlFFFABRRRQAV9VfsMf8zt/24/8AtxXyrX1V+wx/zO3/AG4/+3FAHgHxY/5Kn4y/7DV7/wCj3rlK6v4sf8lT8Zf9hq9/9HvXKUAFFFFABRRTkXceuKAEAJNa3hjTV1fXbGxk+0CCaQCVoEDuifxMASBwOeSKr6Xp9zqN/DaWMTSTyHAUHA9yT0AA6ntW9d6jb6RA+laA/nbgBe3yDDTkdUQ9owfxbGTxgUAb0EEWkQXOn+Hs3YVsXd/t2m4weEXPKx+vqfartiCZV3TLA7YATnEZPp61F4SmW8BeFykowJRnbn2rb8SGyju7S50tUluU+WSFhjn60AQ3KC0u5S9zJFIsew+YQ4kHoD2Nanhq6soIGkutNuFQfMJ48Pg9BkkVLB4tiCXEAtLIRsm6fzk3bG9Qf6VzUOu2sPmwWVyyeYpLbc4jye46GgDrdMtNK1TUpnuLiE7grBHby947KPVvXtXZJ4X0W60ye+ljt43yViV5iAB79q8l06VIZTLmKS2IzkjgHtk9vpWvb6xdTWn7uRbgxybthQjYo7DtQBpJomk2dvctJBLaXituklil8z6YGcc+tVppYPNtpIkckrgTDPyf7R9Ko3mqzSLM6FIOP9UXAJXsufrUMvitm2iZAiRp8yxAYCZ5GPWnYCnrlrJBMtxfNIAkuWdmJ3humDVXVbm0tYAkqtGueNqbgMdK37TxH4WKyyHTpSxO1WklLYXHcGse78XaOs0Y06yRtrEgSjcpPvnrSA0NM8Q69oujz3mn6BNPo8zJKJrqzMtorZwJQegIPepbPxFd2lxFcztYX0vlyJfGSMML0SNuxPn7+D09McV0WpeNLHQvB3hS4kivHv59Ln8iyjdRZMryOh81TySMkgCrl7oPhGw8G2dzAsraWot2XV47ckOzsokEs27ayjLDaFBUrQBy+ovrHjDwtqECrJcRSXKThLa1OFMcZCxqeiqqZ4HpXB6r401i90JdGZrZ7ER2sQKw/PiAt5fOep3nPrX0bewONJe1l0O003Tze3K2RtrjcL2FbORo5sqepwOeh/CuQt9A8PaZ4Fur+HQtPn0610y1urbU3uN8t3Kzr529AeNrEr04HHegDg734p+K7JdT0/XtK0iSK7uHnvLO8ssNvZQCCCcrgYx6Vy3i7wxaaZpA1Cz+3xztcbJ7G4h2tZIyBkDsTk7skqcYK45zXrvxdbSbSDxZrt94c0271B9Uht7OeRm2tFJa5Ex2t8+eo7ZAParkehWNhq2vz6NoFpr97/o9vf2V5e+WlrZm0jcy5Y/xNn5zkLjAAzQB8zRwvLIqRqXdjhVXkk9gPetLWfDWt6HFFLrWkahp8cxIja5t2jDkdQCwGa3rfSoE1rR9X0RmfSXvoQ6ucvaSbx+7f29G7j3r2Dxn4fOp/FdhruhajBpzTXkljDfamzW+rXgy0aLniJX4GB2wM0AfOkdnc/Yje+RN9j8zyfPCHZ5mM7d3TOOcV0ek+ONZ0vQjpdsbZkRXS2upIQ1xaK+fMWGTqgbJzj1PTNe2aTplh5Mei674UsbMX/iSCCXS0uzJFaPJZ/Oy7TkN6KSdh65xXO3XhLw3H8NLi5XTrcacunPdL4gN1mc6iHKi02f3eMbcZ/izQB54vxE1xNMtbHNpuhMQa68gfaJ442DRxSydWjUqMD2HpTl+JGuR3qXS/YjKl9eagv7njzblNkvGemOg7VxcnJyevem0AdpJ8RdbeaeRhZ75pLGVsQ8ZtF2w9/Tr619BfsY38uq6t8Q9Rudn2i7mtbiXYMLudrhjgdhk18k19U/sMf8AM7f9uP8A7cUAfVVFFFAHg/7ZB2/DXRz/ANRmP/0nnr4+83Hevrz9tBtvwv0lv+ozF/6Inr4zM496yqQ5nc9DC4hUoOLfU14rtlGM1zxq2LgAd6qUUoctzLFVVUtYSiiitTkCiiigAoqazglurqG3t0Mk0ziNEXqzE4AH41LeWs1ldzWt3G0VxA7Ryxt1VwcEfnQBBEAHXeDj09amlIY7lXafSk3llClfpTBtB4NAF20MiKJBIMA9DWtZ6s9kEkctKobI7gfhWHGmQCh49Ke05MXk5GOpoA6SS+SX/VYCyHcWzzmqlzK8xWSURkE7VY5PFUrOWGGJoigcno5OdtR3NyTshUkqowD60AbXkvN5XmMsbFt0Wz+L61swSJGXzKJZ5BlnJ6sOgrkop5BOuXJcrtUseF+taUc/kebH5Cyq3JYP0b/CgDRlurrzWaUKmRzzkEe1UvtpM8kaIxBbljzwKrz6ijQIJFLnBUkdAPSqsuqIE+RdrAYHrQBJqEHlwmc3SzSFggXOSo9x61Nb6fJcNFDsG4DOWGBzWE88j/M5ypOeT1q3JqQeMFvNZsYTngUAOuLWW3DwuNrKcBgeKpXG7ftmbBAwtJLeTSld/b1qGV2lOW6+tAEpcNKmAF29T61Zmut5AVAoAwcHqaz/AE9ulP3dT3oAcs5C4GQo6DPSkZt7ZP3qj70dDx1oAcj4YginTRoEVt2WPamBiDnG401uTkCgCNhg0lWo4GnnihgBeaRgiKO5JwBRqVlPp19cWd5E0N1byGOWNuqsDgg0AVaKKKACvqr9hj/mdv8Atx/9uK+Va+qv2GP+Z2/7cf8A24oA8A+LH/JU/GX/AGGr3/0e9cpXV/Fj/kqfjL/sNXv/AKPeuUoAKWkpy8mgBAKvaXp11qd7FaWEfmzydADwB3JPYAck9BVrQdA1LXppotHtHuDBH5sxGAI0yBvYnooyMntWjqmo22kWEmkaJKswk+W9vl/5eCP+WadxGD/311PGKAHalf22lWEuj6I3mGQbbzUE4M57xp6RA/8AfXU8YFc5EC02FbaemaYF3AkscDtUkYVmznJ7UAalnNLC6oJTlO47j0rVg1lLiIQFPniYlQe/1rnEZoSCfmIORSxuskpmc7mHJVTigDee5klUhCD5p+Zc8AVUtJJHldLYQbsksCDnpyahkvo8maMbF24CCssPKWIWRvn64PWqinJ2W4NHSRTRWcbiad5YZGDiEDl2B7+1Wb7Wrpow9qEaGXgg8FW9OP61zm0oxIwxVR1PP4VPaRrNHIWDiRedg7n3rtxuHpYSnacv3idmlsjTC0pYioox2NC4vb57YtIIj5ZGMDBwPaqk13c38ed7LknzAAACP8aoC8ZMqd6tghuc5/CtWOzuBoEd40bJbSyGJZQPlL+leU3OPzO+nTw1WWl0ktbvrfQy4ZZfPfy494UEYAzxU89nPHb2kwKfveig8/jXf6D4A1CyntX1BI4oyw82Xeuzaf8AazjPt1q3P4K0ywjubltRtJ5vJeSK3jYsQ4PBJHH4VrgMRHE4iNFQlJXSbim/vey+Zni8JSw1BVJ1YqTV7Nr8DmtH8EzXmlQ3mra/YaMl7uWwjvN+JyDgkkAiNM8bzxkGucm0XWItMnvGtLmTSoZvJe6RGaAOenzdMnt9a9u8BeIdI8zSk1SQw3OkwtbiFrRJ4ruAvv2fN918n72OldDqHivwufDZWCCOGRreaz8iS2Mm5GY5HDBF65yQTX1WKyLkm404y30fS2vlr066dT55ZhFNKR88XGleINJjgW90zUoBNIYIPNjdQ0gx8qep+YcD1pzeHPEiajPp8mj6mL22VfNtvs7h4w7ALuXsCSPqSK+h9H8T2GsahqV3btcajFDeQyQW84LBUWAxEqD93G4kAYz61z3ijxPFa22uW3h5p4pV0g2kE9ravAys06u6szOzfdDck98CvOnkmKV7Rba8jaGOpSly3szxRdD164hm8rTNRmjt5Ggl2xOyxSIpZkPYFQCSOwFSeM9Fn8L+IZ9Lmu1upEiidpoywDrJGrgc88BgPwr0vwh8SNGsvDdhBqV7rNleWVjeae1pbKGtrozK5E8nIO7cwU9TwpzgEVyHiC80Txh8UIJ5tQNnokyWqT3M6lCqxwIsgAAPJKMB7kV5Di4uzOwu+GvDF9p2mf2ut9ao82lzajLpMsbN59qjqgDY4+cliO4259DWZ498KzaRDYanZTST6Xe20V2sZk3SWXmAkRyeh44PerVp44jf4oR+IL2GSPRyTaNbRD5ksShi8pcngiM469elUNa8YS3XjjVNYsk32d0/ki2nA2yWygIkbgdfkVefUZpAcm80gO7zH3bt2dx6+v1qLzW24JOM7sZ4z9K6fUfDTXtjc6z4ZjkutHiTzbhCcyWPIG2T1GTw3f61y7Y6rQA0nPWg0GkoAK+qv2GP+Z2/7cf/AG4r5Vr6q/YY/wCZ2/7cf/bigD6qooooA8B/bUGfhbpQH/QZi/8ARE9fFuxvavtT9tDn4YaT/wBhmL/0RPXxptr0cJg1Xg5PuRKVmVth9qZV1Uz2qkaxxVBUWkhxlcSilpK5CgoopyrnrQAqZzkHBHQ08knljknqSetIMLx60tABjPf8qeqpu+YnPamnjGKQkkigCfY0fzMQQe9MHlkkvmnAx+UdrHeeuaiOc4JBFAFtZmKgeWrR+oHNSv8A6QwWFFXaM5NUCTgKDgdaDI23C5B7nNAFhdzocn5weT2NdD8P7WDVfGnhvTbxWks7zU7W3uEV2XejzIrLuBBGQSMgg1y4Z0GFPFdT8KXJ+J/g8HvrVl/6PSgD38eC/BraP4l1qH4bW0mi6De3VrcFfEt4Ll1t2w8ixFQnT5sGQdCPTPR+F/hl8LfEHiPUtKPg97c29ra31pK+qXTfaredCQ4XeNu1gykc8gc806x8EeJ7/wALeMltbm/iWbxHfXB0O7jSC31K3Mu4p5mwSqJF4Dh9p9MEmtbxjqGqQW/hzx14T8Nav9uhtZ9KudJNk6TqjoTGCmPuRzInzDIwxIoA80+JngTwLF8LfG2ueGvDf2GTR7+OwtL3+0bibzis8SStsZioGWdB97OCeOK+ZdxxX218ZdBHhn9lm/0ctvltoLQTPnO+VrqJpG/F2Y/jXxJQAUUUUAFFFFABRRRQAZoUZIGDRSjGPegB6xEHO8CmSDexJJJ7nOc0nqeacitjcFOPWgCFlK0lTOfMH3cEVDQAlfVX7DH/ADO3/bj/AO3FfKtfVX7DH/M7f9uP/txQB4B8WP8AkqfjL/sNXv8A6PeuUrq/ix/yVPxl/wBhm9/9HvXKgZoAUAn6Ve0nTrjU76KzsojJcSH5RnAAxySewHUk9BSaTYXGpX0VnZRebPJwB6DqST0AHc9hW1ql/a6VZT6PoUom8wYvL9eDcf7CekY/Nu/FABqWoW2lWEmj6FcGQyfLe3y5H2j/AKZp6Rg/99Hnpiub4HAxgdz3pADxwBinAZoAcFHGSce1PEYcfuuMdc1GCeRToQhkHmZA9R3oAcxP3WGMU6GVYhuiUM5HO6mSMScqeBTMfKcUAW0uUAfzYgH9MdKhMcscsedo3HK4NV8ksSwzmgsWOWJNVGTi046NDVup6f4w8MaePCmjavb20Vg04ERVJCxmbGS3J/8ArVHZeFY7TR7G4WVnubpyrIeoUY5rL03xhqN7Lo9szwhrMJBCoiBBXPGR3PJ5r2e90lW1KXW7QwrbxRFhHniGTbwCp9+a5cyy7GUcPSxPtOf2knfrZt6J+Wu57WXZrg44mcKtNQtFuOu6W616/wDBMPWPAvhy3sbeJrTzdWnUBUVju3ep7fhXT6ZoWmx+CP7B1A+bJIgRdgBELE5GD6561wU2v3NtrPh+e6ZZbqSY+dI/CsGOP0ru/EUcejaI9vF5ckvlNJGCx2uUOSODz+dd2eYXG5FhcNgMLK7qSvKb/mvtdr3Y9utvmeFgZYbOMRVxONdkk3GC7K+u+rVvxPKb6fUL22s9HtUuXNjdMTg/KcnHT14rC12SfSdZkVZNpPzMAeCT1rah1m7m1ufUFdYXdvMJj4AOOwrgdduJJ76RpHLcnBP1r9KxuMqZdhFWnH3nbRd3vr2ueLhqPPVcF8K/U2pLyCSSORJQsnsangvjNujccfzrn4NE1drIX6aXfmxCmQ3It38vaDgtuxjGe9XbdZ7eOC4khkWGbPluykLIAcHB74PpWeUZ4sfeM4qL9Tqq4RRWmp6z4HgWz0eW6sW/0nB+Q8VZ0HWBqElzaZihvp/kYMuQxrB0/VHttPtpPKaO2lGxJMEKSOvPfFb3gXTX0/xfDeTW73PmZceSu5sY5I9PrXdilyxnUau7O3y6HzUqalOTqdTJ+Mvg5bGwsL2KOBZEhEUzRAKrMM4P1rxXGG6dK+iPipff27pUmm+QbmVpQ1k0Z+YHupUferyPUvAOu6dZx3V1bqkEnKndX5fhsozZx9pjIpzm76NddbLW+m3y00PtZ5jgatKnGg7cqtro3Z6P8v11OTL+5NPiTeD2HvT7iyubeKOWaCVIZCypIyEK5XqAehxkZqW30+/ntzPBZ3UtuN2ZI4mZflALcgY4BBPpmuecHCTjJWaK3LOh6pPot6Zbd0kjkUxz275Mc0Z6ow75/TrVvW9HtxZrrGis8ukyNtdG+/auf4H9v7rdD9azDpt+lt9rayuVtgofzjE2zaTgHdjGCQQD7Ve0y+vvDmoyCS2ZSVCXFncoQssbDO1lPYjBB/EVIGKwLcgdfSmV1HiTQRaQrqWmxzrp8m0vDMpEtozDIV8/wkcq/RhXMsMkkUAMr6q/YY/5nb/tx/8AbivlWvqr9hj/AJnb/tx/9uKAPqqiiigDwX9swZ+GWkD/AKjUX/oievjuOLc4FfY37Y4z8NtHH/UZj/8ASe4r5J06AyXca4719pw7hlVwc59pP8kcmIny6+RbtNJLoDtNchxivc9K0lTbLle1eGV4mcRtNfP9DiyrF/WZVF2t+o2nKM8DrSAVraZcXdvp99bxFEtr1FSXdErFgrbhtJGV5A5GK8Y9gy9op/fkVYEJxg847iopV2MN3A9aAGsAD1pCDjI6UEDJ5zSruz8oz7UACkd6k8lmQugzjqKjJycbSDTt7xqQpPPWgBg6ZxQTk5o5cnatJ0HI5oAWiiigAycYFS2lzPaXUN1azSQXMLrLFNE5R43U5DKw5BBAIIqKigDqf+Fi+Nv+hy8Sf+DSf/4uj/hYvjb/AKHHxJ/4NJ//AIquWooA3tU8Z+KNWsZbLVfEut31lLjzLe5v5ZY3wQRlWYg4IB+orBoooAKKKKACiiigAooooAKUDPem9aeI2KggcUATxeUoUyEewFPYpLksSsY7dKasXlDIx+VMVWcgcsM5xQArBSAowq+ppr26sMoflHepxDFvHmH5jz9KjupNwCwghaAKbKAT7V9T/sMf8zt/24/+3FfNs11dXWk2VjJtaC1LmECJQwLkFssBlug69O1fS37D0TwyeN0kUhh9h/8AbigD59+K4z8U/GXb/ic3v/o96wtLsLjUb+K0sYzJNIcADge5J7ADqe1dT8QtOutU+MHi2zsYjLPJrd6AB2Hnvkk9gO57Uuv621vo9t4e0uaGWO0RoJr6OII86lizRhgMmMNnryfpgUAZ2qajbaTZS6RobCUONt7fDgzkdUT0jB/766njArngAVwMAHqBUkkBO4gkf7JGKiQYHJ5oAcv3TjrTe+O9HQ+4pxB25IoAWMB22gcnvSSxtE+GHNA3AAg4NDyM+C/WgBueCKOecUrAgdKa3SgA6deaZkdhTgOOaacZ4oAktppLeeOaFyskZDKw6gjvXv8A4E1/WfFXha6iukWQgpDuSMKZW/vMfYDrXz7Gu6RVxnJxX038K9Dl0axO+UiG4iU8ngd68vNcfHAxhWkruMk0r2vbU9TAYB4ylWjdLS12r2b7fK5xF1Zi3uWS+iE5tpcFeuwj0rqrTxB4avxY22v2EtxfRs3k5yVXI9M9TW7Jpy2uvG7tTHPa3FwEnTyzkZ/z2qZrazTUr2e5060gsocsl4uNyEcfjX3eP4py7E4ehz80lV2cG01JWut0+uyTufFwybGKVZuKUqKvaTS0ae26PAtaka3VrdYnguUdy4YY4J+XH4Vx9wXMp3nJr034jXNs99PeRGOUyfKuTzx3rzJiZpRuOM138SVFOlSpXfM+nTtqdmVzdSl7Rxtc9N0jUdSk+A2oWy6jdrbjXIbfyxM23y2hkJjxn7pPJHTNdrd6Nf8AjjwR4Sn1G6ln1C3tbqK3BCjzCJgqqegGFHHrivNvC/hi6m8J6nr6X9p/Z1hJGJLQzbpXZmCg+WOg5+8foK9F8LXVxfWst1aMmk2Vk8cayGQgeY5wFU/wk8n0ABzXwONxOJy/EL2K95fP+tND7DAZdRxmFl7R2v17djH8eedps1t4cS2MWmaXGEgcnPmyMAZZM+7cD0ArtfAAGoeEbiHR9Qd9bV4t0cBKyrGrchfUetafjfRIJfBDWdneW9yY5Csc6fMVkwW2Z77sHkV4Zol3c6ZqgZC8ZPBYEgj8a++4fzFZ9l7hbkqQeq3T6p+j1vrdNWPjsyy+WErNN3Wtntfvvs1/wT6B8UX2kaS2o67H5AmhuvLs7hRuAuSoyMDggDJz61xHirXJfEUUMBZkjKhnjA4Y465rZstDsdRsrZNVuJU04qZoiT+73nqRWh4wt9OtfD9wmnxpLPYwiTIGDt9z+NcOJxuW5bjKFLExc6kpWjJpuMel7vRa7pO6vexwYalicXRqSw2iim5K6V9b7bv56aHl3xQfUda8GeCLVjLdXX2u8tIFwMkBo1VRiprLV7XR/G+l+CoJd2iW9vNo15JGwHnXFwu2aQMenz7V3c4VOMiq/gS0stbuGn/4qW48RxXRk0+00aREeNVUM8pZgQmCRg9+lXpvBvgaK+IlsPG/2aK0W+vblxGj2iM5Tc8RXccMOSOMc9K8vOVBYyood+1j3cMnGlFS3NmIW+r+J774YyzqLODToLGKQyqq/aLd/NkJk7rlpscf3eBivP8AxdrLarq2veK7KxvWuIdTiW01MECK3RFKxo64IMhVFOc/wnjmvUfEvwa8KaPaWd3p48T65cXkyxwQadLEzNvG7eW24Vcdzwc1ir4C8Ej4f6nr7f8ACUxRWF59jutNa4i3idXCYzjacbhz9RXlm5znxY1m+tfiKt67rcyXelWJuoZhlLkNAhYMB27+3auH8Q6NCloNW0TfJpMjbXRjl7V/+eb+391u4969T1jwb4T0SCzvfFml+MdKt7m4S0S6uLqCXA2k7vlByFC4I9/wqxoml/DzTvGJs9CvNd1OH7Xb2Ms3nRfZZzKxGGBXLIpXOe/bpQB4EVHP8q+qP2GP+Z2/7cf/AG4qvqPwu8Aa1qmv6hqXiG9tJba/e3uneaCGMScE7RtwF5GK679mPRLDw544+JelaRO9zp9u+n+RM7BjIhSZgcjg9eooA+g6KKKAPDf2u08z4faIvrrUf/pPcV8yaFY7tSiGK+pv2povP8HeH4x31pf/AElua8I8PaWV1SM4r73hmajl9S/8z/JHz+cYj2TaXb/M7HTNPxboMdq+Wa+zLK32xouO3pXxnXz+dNNwt5/oeVwhOU5V3L+7/wC3Gpo+nfazvlIWFT+LV1strDLbKkfJAwMDgVjaHbBtNhZh/rHZVOcYNai2jRgxPNIkmeD0YV4R9qYFxaT2dwSAF79cipLjypdvmxAhujJ2roRpsO5RdsZA3RhUOq6OltCHtwyjqrN0NAHMXFsm7COSOxxVeMorHemGHH1rWt/PJZCse0etRSmAsVZAHHUUAZvDPnHB60hGM7WBFXZ7dgA8SHYePpVXcwO0qFUcZFAEYEkZJXHIzigK7guBmpZVZSoGCrdDT2UKgVScsM8dqAKpGeCMGm4xz2q6YlAHzbzUDsmwqqc5oAgINFO2nJCjA9KCp4Hr0oAbRTtpxxTaACijBH409YmZsKuSaAGUVOlnOzECNsDvRHZzyHCRMTnAwaAOi+GPhP8A4Tnxzpvh43v2AXnm/wCk+T5uzZE8n3dy5zsx1716VpPwW8K6oljJa/ES5S2vnEdrc3Phm5t4JnJwFWWRlQkngDOSaxv2bbKaD40eG5ZB8p+1LyMYP2Sb/Cvcvhj4d13xl8E/CmiXEemWXh7Mc8t0ly8t1Ksc5kCrGYlWMllxu3tgdjmgDh9A/Zl0/X7SW60nx8J4YZ5LaTOjMhSWNirqVaUEEEelecfEH4XxeHbbQrrw5rreIrfVTdBZBYtbBPIdEYjcx3As5GRgccZBr6Q8ZatceBPEvjDStOys3iqCO60dATj7dIy20oA9ctFKcdgah+JOhWugXfgLRbSTy7ax0m9gRivLbWsxn6nrQB8nQ+ErwMUuEdX9cYA+pq3Jon2GVUm2OuOMdB717xHb2ttbXImZ7pWOQchgT6ADr/KvOPE2JJJPOMiseF8xcBfagDziRI2STy2bCHBJHWoYVeNGMa7mx6V2MGky3aORFFHbqPmnbp+VY2rCC1KxW7b1xyx6k0AYCxuc5QljyatQ2xdzuRvZRVy1jfC7jtU9Q1aBuILJOxJ6Hbk/hQBTJ8kKphJPoO9fSP7HYkF74y81VVjFYYC+mbmvm+SYsDIQwkY/KDyRX0V+xjv+1eNPNzu2WPX63FAHl/i66t7fxn4wtrZPJmudYvjdzk/PIPtMgCL6JgAkdz7YrhtV0xsGSFcL7nmum8d2pb4heK59xCLrN8GPb/j5krJWyMgJWclOvlk8fhQCMC1LhGilRGHo/X86gkggdd6Axv8A3G5z+NdbHo1pOjNEjNKvUHtXPX0MlrLsjwyDlQe1AGRLEIz8wJFDurKFRcVrT/Kqtcxpgj+HtVcQxSqyxIcnkUAZ3ljHUAikZC2M9RU8glj4aP5unNIo3IzK2H9KAISXkIU4x2prq6/wj6+lWIRuYmQDI5pDsk3bpCo75oArbDgksPeogMtgDrVpvKUqwyQO3eoQ+Jd6gLznFA1vqb3hfSbi41KFVVclhjJ96+n5dBuJNN06PzmXCjeV9e4rwvwFoM3iO1uH027SG/g2uEkB2sn8XI719Apby/2NZWcV9ILiRPlcfKHx69xXy2b0ZYmcJzmoQUuVyabUW1fVLWzXXY+oWLhgKSpYZc1S3Ny9ZLXVPbTsZ/iZDp+2SK7eExLtQKRhW7nHrWd4Ru2vbG90vUbn7Wrxs+/aOD149atjRPN0eWPX/maZ2EMgY7MgdC3qDXPeDtE1PTNctfuxldxO/wCZWTH68V+gYL+y8RgZ4CjUi61COk7LdK/NF63Se9j85xEMbSrfW8RGShVlflu9dfhfn5Hnvifw1awWWo3B+1SwpbieG4MDFdxfaUJH8685sCsc6yeXHIUYHa65U49R3r6317SLzUfDtxpksscP2osjPEMoqE8HHrivl3WNOj0jV7qyjmMyQSFBJjG7HfFZ8O5pUz/EuNdxk6Ss5LVSv1vZfd5XR7+Iw0MLBShdc7bUXukrKz1Z2/wv1fSZV8T6ZqKJFc6vBHHawwxbUeZX3AZ6KOnWuhurqx0+HTfC0sqtbQusupyRH/WyOQW2nr8ifL065rlLaw8P+HNF0S81zS7nUbnWInuVmguzAbWJZCgMYxzJlGOWyvTjrXRpomj39hZWltZ3MWty6FJrX9pNdM5ldC5KSIcjBROq459qxzjJWk6tJaXa020+d/XuejlWaewnyVn7u/o9j0zUfEmgalos1j4ZmiuprFA9vYtbtEmVOQ+TyWAH415PoVkninxBFFfymJppCzGNB1Jz0+tXfhraXEWlv4g/smfUbn7XFZWtr54hDs6li7sf4QAMe59K6TVtG1DVfEbNZ2eneFVtXityLm6UtcXDYYopUY4Ug/iB3rp4Xxv1Wc6U6ai5Kymt15PfS+qPJ4hwcOZTwtRyT1actm+q/J6Gvr9hNZaVFDZBriyjB27eSPXjtWMdY1iDwTc3emQwG5iYwu8ke4umO4PBx716bbaU7wxzwXEdsQh805YqzBiCfzHSvOfGc2r20j6dJd2+nW0s3lG4SIukbH+IhQSc+wzzXzGPz3FYrCvLMfSjKopK076Np3va3VdVv2O7KMioRxaxmGn+7s24ve1tvPXv5GH+z9peuRT6r4q0ezi1S7WV7C5spJxAWRwrh0YjGQRyD26V6Jr3h7xtqWtatM+kae0muaOmlXFzHd4htAHYk4PzMdpxxxu9q8+1mwsdJ0y0h0C6kMUqBrme1SWPzZBwc78HJ5+gqbwFa2eqeYt3pd7fotyBe6hPqTwQ2UBHGMHl854Oc8V6Cb67mNXl55cux3vjHwz4itrNrHwbo1yodLO0vdRhvUhuNQtYoyNi54iKkAZA5zU7aNq83giTQrX4c2NpaOjytZXWoh43dHUqGZTuZn5IbPBUZrgNO0rw5Np+qwGC8kubK1uJjdHU5DcOw3FDFCDhlwF3ZGQMmvFob++uZMpfXe8DnFw+P50zI+kdH8Aa4mqaNcf2LHpWhx6xHcnQjci4W0jELJJIWJw3mEj5R6VN4m+GlxdeLoxpuiW//CNgafE0SuEXy4mkMoxnPG4e5zXz7b3VwF3y392Svb7Q/wDjTZtZuZ28uK8u9o+8wndV/nQB7xe+CPEumtqWm6B4Ysp/D91qkszxNMgeS02qFiVnztDEHPcYFdt8DdPt9N+IvxChtoltgYdML2S8izYJOvk7v4sBRyOua+RJ77UHcrDd3pjAwB9ocD+dfRn7Gfmm58Zm4d5HKWXzOxZvvXPUmgD6ZooooA8n/aIQyaH4YQQ3ExOsj93bwPM5/wBEuuiICx/AdOa8u0u3EF4skmk6+qjv/Yl4f/aVe7fEP/kL+CP+w0//AKb7yuf8Ga1eCw1+XxRqdo5sNTkt/tIjFtEiBYyBgscDLd2J5616OFzSthaTo00rPX+tfI87GZZSxcuao2tLaW/yOSi1K2UrnTtfxn/oBXv/AMZr4txX6DR3+qJ8TX06a7hfSZNMa5ht0g2sjiRFJZySWPLYwFABxgkZr8+Qc8Vy18ROtbm6Bl+WUcBzeyb9617+XyXc7Tw0Hm0WCKI873BDDI61buILuD5LpWIB6tzgex9K7j4MW+nXfhWNJo0F4ksmdx++M8ZrovFWn2R0x5LbGwcOCM7D/hWB6J5zo8JndIJYFmiyDgEjI+vY10utaVNa2yhrRpdO/wCeg+baD3rB0q8m0G/zPGGtycjjKn3B7V6TpuvWRK3MbW/2eUbZbeRsj8u4oA8X8RaBdWGbpV3Wu0yBo+hHWuzuvgd8QZcFPCcu7HJN/aDn/v7XX+Jo/Ddz4L11rZNm2ynaPynJCSCMkAqexOOa9b/aH8NaFN4A1fV5tF0yTVjLZr9ta0jM+PtMS48zG7G0levTigD5yb4HfEfYuzwvKGHrf2pH/o2qus/CDx7pmlXeo6n4XMNjZQPcTyC8tm2oilmbAlJOACcAZr6Y+IPh7R/A8vh7xd4e0mw0uLSb9U1AWVskKvaT4ikLBQN20lG56bTWb47H/CQTfE/V2w9loPh660i1OMjz3gMtwwPqB5SfgfxAPj8xQxqq/IXY/WnyhpbfAijyn3ivUCtr+z9PnkAtYmW5XnaT96l+y+U6yylos/KU/vfWgDkSgxuXeD1AYdaVbOa4IMaYz1PpW3qNs4uIUVfMQnkgYKj0xV610iSOZQJWCv0whNAGBHp0ySoJjjsGAyDWjFpQuXMMdsksxB3EkLj3rsdM0SCKVjdkeWTguoJA/CtDxRpOnW1ij2cvCfwqAdx9zQB5beaU0MTKY2GDhvm6VBHpr3Cr5SbBj+PjNbDoC7kyb23Y2HqxPT8a9o0j4Aa1c+CX1a5kMPiBwJYdMYjaY8fdZj92Q9h0HQ+0ymo7geEWGhpJI0bS5IB6DnNW7fw4kEW+5uFRyeFHGKmlszb3/lO8ttdxSGOaGRCrRODyrehrpNI0U3SxzyK88kpwQWOMfTpVAYc2lDT5IpZLrzBjLCMbsD3zT2uLSBvNjjw5AO9h0ruX8GW9zbOyzy2bxtgmVOD+PpWZJ4ViZm33kUwQ7vkGdo/rQBW8P+Kr3Q/Eml6vp32M3dkztGLiAuj743jO4Kyk8SE9Rziu50v46eNLAQaXpOieE7S0j+WKKGxlijQZzwomwK5ddDsWjWWKXc7NhmXKlQPrUUeiSSytBEiiDJfeH3M9AHpJ+KPiPV57O7v7LwjNfWbk2rTaRJI8LnGTGxuMr0HIx0rR1Z9W8c6tp114ivtJe3sYJowllbSQf61oidxaV92PKXGMdTXmukWLWN9brcMrbmym2MyH6GvUJbSxsdOe8CMdRZdywScA/wDAewoAYNPj061mSyg5bIDK/b3Y/wAhXD3uj2VmZZ71TLI+WIdsIPx9a6+C4vbiaKS5tFnuGXEUKtwT/ujjArPv9PkttTefWzFdmRcCKPnafQKKAPLtXS81nCQSCKxj+UR26cfT3PvXPajaCydIjBhwOQ3JHua9B1jUtQS5MUEMcdupwscSgFfwHWsDVbTNwFL+dqMnzeUv8PuaAOUtbWS4lLSMI16exFSLaruaR0LKhwMnrWpdQS28fksUkmPLBf4ahW2WOPzZSsjL0J4A/CgDM8tHkO4iJSeWb+lfRP7G3lfbPGghfeoSxG715ua+dNSiR0Mk5VF7Enk19C/sVkmbxmSCBsscZGOM3FAHlHje1u28deK54Axi/tm+B29v9Jl6jvWDZmVZiQoLqclDx+I9a9yksrGXUtda42pLJrOpAPnv9smwCK8x8V2EsWou9ugM0RyU6HHqPWgFsaeh6S09rJPbW226HICt98H2NYer6HPf+cqW6w30PMsTcE+6+tdP4V8SW1zai1ulWCdekp42t7110WoaNfGBdSW2a7jG1ZkfBYehYdqAPAYbCSASQXkb5I+XcOtVYbcCXBQqvQc96+otN0Dw1qEoj8tbiNzh7eVhvib1Vv8AINcd4p+F8739++g2zTRRjLwupDoPXHce4oA8PaOS3kEciqxflS3WnGyWNlknVIx3z3rsp9FurdHtLxI1dBuiZ1xj2zWOIrVwV1OBmZONyt+ooAxIHQHdGkTRucYIrO1SE+dseNwcbhtHautXTFSPbbofIk6SZ/rUF7b7rQhJQ8kYK7nXg+xNJjRxARmD7AzAc5x2rc8Pi1huraW6tY7qNHDPExxvAPIp+maS95C8sx2Opye4x+FStbpdOFsPmkXkykbVx3A9ayrpOGrsehlrarLlhzHungbxFoF1qCvpWifYHzh2VVAA9BjrXeWdtZ32vIbzUVttPsLdrq5mY4OzcBgehOQP/r15n8L9Og/slpJC6zKwUlV3HJ6celS+L7KL7Y8Oo63HFBEwM6KGDMByAB0bmvkaGCxGIxM4UISnT6pJyvy7bK+nN+J9BiXl+GqRVSryTitG27rm339HY9u1PxR4an8FWEuo2Zh8P3ty1mjYwYQN22XHUdM+oz35ryTxF4luPBvittAZra9toVVoLkdXikUMD9cHnHFXtY1e1j+Bfhy4gszLaPqTxhbhstgeZzkd+DXnwPhy8kN7L9tha3GBbFt4cDoqsegFfTz4XzDEUnL2N7Xjo1dNaNNX2v6r5Hk4XOMroTcKs3yt31Taet4vunY9K1rXLvUPDUjaIn+mcLsz8rA8fnXzj4gsbyPxBeW+qGKC8Vtz72wM+3r+Fe83cjSaPaWn2T7Fb3QWWIhtztjvmuN+N2nLHpemyTrvugn7yR/vn0B/wr18kp1uGst9nW5U5yaVkpS8k3dLR3v8Vr6HhVMRRzbM5rCJ8qje7utt7Kz30tscZ4d8V3OnaYtrc6Zp9+bTdJZG9gMr27EgkrzgrkZ2tlc84rX/AOFgO+lxafY6TZRXyWf2A3SRNJcSQkljH6KMsfujpx0qxF4QtI7GCS11eKW3nRXTzEO7ae2KgPg6yg8xUu2tbgqWjlXcNpx/s9qmti62I+OX6L8C4QjGXvbGhoGl6tofh7U7nVYrS8sbp4XudGvUYo4wWjZXVgUI74x6H0qPTvH+t2d7LNc2mnXKPNHPDDNACls6AKGjHY7AF59M9a5C9Ouaf5Q1eaWW3XAGJ9+7PTAzk1u3OnXNnp1tf38SwwzLujDSKWI9wDx+Nfb5HhMFGhac4zcnppZ+S31fnueTjq9RSWllZff1+/t0PYvBPiW81yx2p9nhuGJXauchS5ckE8E5OMelYfxp1PXdGeHUNCvmsikiu/kqAd+ODk9uorG+HPi+K2We00nSZtQ1IjMe0YjA7lnPCgcHNbOoabqmv6jE/iKWK+hhBdLWPCQoT2Yj/WY9elfA8R4GrPOX7K0acOV6pXbt9lpXsr/aej2PWyWtGhh3KvFty5lv06Npv7ml6i6pPc+NtM0vUdRkuEhaBXz3z/FgdQM5xVdvFEOhaTHo1po+n3tv5xmEd07klyAOQp68fhXQXem317o+yyEdnZL1lc4MuOyk9AKwdWnWys0bTLSFblV2tMyA5PsTSHJ3bsYEXiK80vTnY6FpRv47ea2j1IxsskUUm7KdcOdrFQSM4rzMo7RiKGLYv05xXf3D3N/bynUZRDbx8sx6H6VhmxkINwpEdmvKs/DOaCTHksdiRjd5hYdF4xTJoUiTykTJHLEVf8l55yXxGmflA4LVHdxKo8mJF2jrg/qTQBnOsKIHaYGQ/djXnFfRP7F+/wC0eMzIckrZf+hXNfNEsarestuQ0mPmK/w19MfsZKEufGQDbhssjn/gVzQHQ+mqKKKAPJv2jPFX/CFaD4Z8QfY/tv2PWh+483y9++0uk+9g4xuz07V4HZfHvw7YW9zBY/DDSbaC5CieOGeNFlCnK7gIMNg8jPSvVv21f+SWaV/2Gov/AERPXxXQB9CH9oXRTrX9sH4b6cdX/wCf43Sef93b/rPI3fd469OK+fEJByKSlXrQB6v4Nu4o/A1qqKY7tJZdsinG5Sehp9t4luopWiY+YDw2PSua8NB20aMBioMjY/PtW8toEKP8pLcZXof8DQAlxdG8nAaNlh9hwKdY3Hlu8aTDy+oGM4qYXQsDsjYOzH/USrg/QGpLEKZ3uIIEZjyYM9fpQAzVkZtBuRbI0jzxsnTjJBHUdPxr3rxh8XvC3izw3LpOo6D4titLp43LwLaK+Y5FkHLTEDlBnI6ZrxOeZ4nbyrd49/PTCt7H3qwga7gjbyFLx9WjbJx7jvQB7vqnxe8PeKNMvdDuPDHiSa3v4Xt5FUWY+VlIOCZ8A88e9ULm8j0P4Ra54Z0nwt4pYXlldxi81C4sXeSadX+eVlnyeWHIXoOhryfR9SghdxbLDbbSPOJz09RXqehto2qwG2vNSninmXajpzGw9xnigDw57ZLeAoVlTYdyzKu4Z9Kl+yXV/axyXZaS17ukRGPc+1eqeJfDR0WMGb7LLbrwXhmzke1cleXVrZSxrYyySxEcwucYoA4a70tILgG3nFyV5Vsc4q/p2+O6Cyu8WeWycqR6rWhO4kvzItoyhf44hyv4VsRWNxb2nnm3kaFl3IpjBBPuP8KAMXX9Za3s/Ltbh5FBwAwAOK5WSRpXjEjlEPXJ4NWtbvpLqZkMEa+WD/Dj8xXOw3wuF8poXYoeDjGPegDsvB2s6f4Y8YWmsz2Md/8AYopXihIGGmKERk56YJznqO1eh2PjDW9S+CXirxJdanPDrK65C6XCkgQ4Me1UXoEA429+c5ya8ct0Z4gyqGUHhuuPrXdDxPYQfCDV/DLmWXUL29juI2KDy1VShIbnOflPaolG9mBneOvGMHi3WNP1d9NgttR+yCK+ZV2pPKpOJR3OVx15GMc1l2utlVLQblk6qwOCTXPohWI/uZCh/jU8frT4wylWRTsX/ZxmqSsrIDfW5lvpgZ7yViThtr8fQiteC3UxyTJGCV6vvwc+wrnrGATWbsA4AYEeWOc/WtvSopvtcZV0UZ3BJFJOPamBe0na8z+ehkLcZ3549Oa7zwxYRTRkmCOJU42sMsB79q5/THW7vJHFsIEjGcunUj0Brq/D19PBeFWlKwPyyqgAJ+poA6nw/oumTQ7pZmnmiJMdvAh4Pu1WtX0sx2heaKKO4b+KQjao9wOT+dadjfRWlubn7WSSMBUUKpPue9VZhYXzx/boWfzDkMvLA+woA5a6ubm0JWxjLs4w9xsEaE+xPOK47U7KS0kYNdP50x3SuhOwZ7D1+teqeJXMcsFvFp7SRgDb55CZ/rXAeNLuOJSl1Ja7uixxAkZ9AaAOavnjRwlnEXkAxlBwT/WuaRZrae4WdXN7JyzbdqoO1bd1rBjg8pI1tto5lVgWPsB2ridT1YSXDTzSz4B+WMdaAKd1b3C3UryuUXrgtz+PoKoJFcXswSMbY05LE4H4VY+2i53iCNy5OTkZA/xNaGk2c003ks4DMee+KAMK4g/flEjDOvQuc/pX0L+xkJBeeNvNzu22P87ivNbvSY7RUito/Ou5OMgZIr2L9lnTJdK1vxjDcMTI8FhIc9stdDH6UAeM+N9YuNP8Z+JRG4KLq9+Qp9ftctcjrPibWZbjzJVjW3AAU7M5+rda6bxdbm48feLgSjKusX3yFsH/AI+ZOlctfTanp0qzeVHNaIcBlToPRq6MO/fV0n5Ml7EVvrURZX/1Vzjksch/of8AGuusJBd+VuYZYBgoUDnHSucsbuw1LdGthaQ3Cnf5kY2tjua6uL/j1C/YxIVAKypzuH1FKvy875I2XZjV7C6fe3S30iwLJCyj06gfXpXY6H441iyMMkt3cTBDhWV8TJ7c/eX2Ncfb3cjTnzYg8ZXH70hTj3NMa+07TbhEvlhDE5RWkztGeoPcVgVZn0HH/ZHxB0hjqlhHHdEYF2ihWJ/2gO9eKeLPCaeHNZMSBZwoLBYuGYe4711XhTVreZ2ju7pCgwStu2CV9Qa7HUPDNjqkSajo1+l0gXaUun2SD+hoEeE2wmF21vp8hAddxjeE8e2ahu9Fj8qR5ZWt7pfvRSLjf7+4rvryCztpJkuHaC7iztaNtw/lXP6jfi4smUwLK44Dtzn/AApMaONls7iLT5kgUldh2mM4OT/MViaPMsUW0H7vyke9eiW7wW0CG5b7AIyBm4YKqk9g3qa4TxPdW954jllsnV7YRqquihdxxyTgc89658TBSjqevk1eVGvor3Om0PxFPp+77LKyMw52nFdvb+JbXVdO8rVIYLkKNpDqNx9w3XNeK+aR90mnLdujghmH414rwTU/a0ZOEl1Ts/vR9ZXnh8RHkrwUl5o94Xwhpc2mxouqXAsyfMjti5ZUz3xnGeeuKB4M0G3QJcXE0pbpswu0e+a8eh127cqGuXXaMDBq+niy+gZSJTJt6bq76mecQ8vIsVp6RT++17vqeJHhTKm+eze/V/59D1XVvEul6XAsdnBD5tqvlwPL8xA9ee9eN+Ndeudald7iRnx6nNZGs6tPe3TzTKQScjB4osLdrqWD7XuCPghB3Hp6msqGFrVJqtiJucu7d7X1du1/IupVwOXUpUcPDlvpot/U9d+Gvhnw7rOg6Usj67MJWWCa5REMEEpyQhOMgYHXpXb6Z8P/AA3qelG9XVL+2tfMaIrJNGArBiOo456gehql8N9C1WC28OyaTostnaMym5v4bjEV3a/MGjmiP8fYYH41tweFtRsNBgtZvD1vqIt7q4DWauFWYOT5cw/3RheeeOK9lHykndkGp/BzwpqU0K315fNNDwqCdFYbugxj24q1YfB/whbDalvLcOjbs3EnmMp7e2PbFb2g+Hbq1nJ1GNZZo7SJIbgjOyQZ6dztyACfStLRLW+hBW9MrSKNrOVXEh9Rjn862hiKsIckZNLtchxT1ZDp/hjTNPsza2VsILctvcBAFc+uMYpX8O2Wc7iqkg4wpB9K1rkvMUjkjdo1BGCeCMfypijyrNFjt9xVQBEMHb/9asr9Sjn9a8LWOqpEbzUrpUT5lZXVcgf57VQPgDSGnaOTULmWZl3LG7IzKPUDrj3rfttPnlaA3djDHb73Z4S5crkce3PcVinQNSHilpItOTLXHnrqvmEMke3AhC9Tj8qQGXqXwx0K5jWOfWbuJImyw3xdR2ORxVTVfhV4cu4N8+v3lvAjeXvE0QAb+7uI6+1YWpw3+r3dxomlWkV1qcdldxzT2cnmCVyRhm7Ic8c4Oa6Dx94HvX0/RV0HS5ZrK2hZJ7G2WNnaVgP3uJflY8EFj8w7UAUT8FPDSXCWz6/qQu2XKxvJF5jDuQuMke9ed/FjwFo3hHSdPu9H1K61JbueSGXzJEZV2gHqnfJ6V6Nb+CNbTxXol0NOu5Yzp629/PeSxOVURsu1HA3JKMgZHy965vXfCd1pvhKzt9YsxaQRXrvbpKqLKyCMDMhThj6HrjrQB4VeRzLbnyUCq3dByfqa+jf2KVZX8YhgR8ll1/3rmvMJdAuNWRpI0aG1U7VwuN30r2v9lfTRpWreLbdf+fawY85533X+FAdD6DooooA8A/bW/wCSWaV/2Gov/RE9fFVfav7a3/JLNK/7DUX/AKInr4qoAKcvWm05etAHeeF2c6LbgoCgkfDHvz+ldD5D7Ha3IdCOVI5FYfgwSy6JEIERnjdyVJHzc+/Wt0JeQMtzHC8ZB++nT6MKACJVdAt40jEH5Cx5H0PWmzJbWzRzSPIOcbgeUPuPSr1xOt80bXNrhcfMUOOfUUT26ukkcUqywsOY5B8y/TNAETztLbFXmkT028hvw7VYtFgQQuzvbNjhpBnP1x2qraSOYkSZhsiO0ELkgds1fkZLq4jiBa4VRk+V1T8DQAlylpMkrblF3jiQDg1Ho1zPFeRstyoZeO+D+VT3UC+bvhmTygMEAYIPuOtZEkc0bFTdbYs/eQ/4UAemaJqMN3BcQ3sGJ0+YyRkt+JB7fSsbU7XS7jz5rVo3lXgxMxXPuo71W8N6nC21p1UleDiTDfUV11vp2meKDHHplzBBd9FMuFYn0oA5PQb2LT7po1t45ISOYy3zH6A9afquvqkTwhTBCh343cqfQCuh8UfDnxJpNqspge7Cg/NCQQB7HrXm+oyXb2M1vfqYphxiaDL/AJ/1oAx76e3vhcyRPIZpODlvvf4Vm2lswbagIccNxkY+tQXqPFZP+/XzERnCdCMAkGvpvR/gl4PvNe13R7XWfFaXOmGFbhne02P5qb12nySenXIHPrQB8/W1rJGg2gCLOWO7GfrVaaCaQuwRdmehavofwr8GfB3iSxvprTWfFlv9ivJrG4iuXtFdJYmw2cQkYxgg56EVhw/DzwNdaTpGoWWpeOLqfWZJU0+yh+xma4WNiDIAYwix4AO5mUYYZxmgDxCDzFPlrJhMZA4OD9KsfvZId2/y0U4YnGT+Fe3WPwk8JzXV7aJ/wncWv2sa3B0maTT1nkiZtvmRsV8l1B6kScYwecA1dJ+GPh3W9Zv9Ot9O+IwudPnSC8L3GkqsDOoYE4b5htYH5d358UAeR2UNvaTmQ3DvGy9I/l5rX024eTzJUR4pYvljLHcSPpWXqNrBpPjHWdOeW5eDT9QubaKWQrudY5XRSdoAzhecAc1NfSLdRr9ih3KvLyB9pNAHVJeXU9tJI8ZgbgdOorpdC1W3RhbpaXRG0f6Q+Ag/rXB6F5724MakMn8ABJI+p4FdlpMNrqKy/aLl7REwCC38jQB3vhlILm4a4ECT7ON5uDg/8B7VpXGvy2l9N5P2WBEGMqNzA1zfh+UWYWHRLOa72nLPL8w+uKh8ayTkgQxQJcSAFkRfmc+/pQBY1DxNFKPLuornULyTiM7tq/X/ACa878VTyQKQVJn7Dd8q/Qd/rWprV9O1vFEz+W6rjbHDzn6iuNvbKeWOR57qRgTycEAe2TQBg6ldTzON0CMFH3gepqmkMs7p5oVBnnJz+lXZ0WzcCTdgDhV43VStrU3U7TXZZFzlRGcUAdjofh+OZBNGNwUcIvGT6mltPD95d62kdtL5SqfnZei1oaVqNra2KWVmpMhGWJY7R9T/AEFdh4Tt4ZH86aTzJP4VUBI19+ep+tAHS+HvCVtYWuYsz3DDLzP1/wA+9b3wbaA+N/Fy2rh0Sy09CV6Z8y8zj1Fa+maIJdM3Xb7bTG5vmIDfU96h+G09nN8QPFSacIxBBp2nRAIMDIlvT/WgD4z+JE0tv8UfGEsDlJF1u9OQf+m71oWF6b0LNbu/lAANgY5HZs8GrHj7w3dah8Q/FU9v8ol1i+I3DIYi5kHHp0qp4Xt9X0m5ltriNTbOpzGT91uxHpXqV50K1CDi7TirepCumyxJoml3Uwlh3RyHJLRvtBb0NXtPuY4VWK0eTCHayE/Mp+vpVmCCAwsyF7Obdk91b8KilWW2vlmQR+ZIu1ioGGHrXmNt6MtIyfEVib2CR1upAkY8x2kHy4HY4rmra286MNGmB9K6vxU8p0JooHUL5gM4+6do/QjOKxtGXcyAH5MVxYuXKro+hyGkqjalsUIprmycNbTSQqCNxQ9vpXrfhnXGFhayNLFe2oIDHcwwff0ry/VNqzvsGFq/4AujBqNyW5hbaChPGfXFGGqOSFnOEhSfNFns2vHSZ0UT7oFkxtDDlc/7Q6iuTvra3s52MaRMUIKSLIShHrmur0zUdJaJYL0KpcFRk70/+tWtb/DXUdRtmu9Eu4JbQg4jjcbh7YrrPA2Z4z8UrmfUBpMn2UpZwRkPMhDRu7H1+g71xgYADb09q9R8U6fr3hmSUz6fdeWoIaNow6NjpxjAryq+uHv7nz2jhtCf+WcKbB+I9awrQvq2evluJcFyKN/Mm6jiopCR9aSIMvcn3NCtGLlGnRpYf40RsMfpXPGOtj2K1W1PmsIJGAt/LZ84Pmg9jnjH4U26uTjCMN3pW9dWFu+nEwxNDv5jZ0w/4ion0zNsin7O7IMZCgAf1rpdFN3PFWZShBwV/myrpctulwihvMmmUABugbvz2rQuIAsU7394FaI7hhQSPYUy3jSJkWSyVSBxKi9fxqlqkrrZTRL86E4G1gxx6k1qlZHmzlzzvd/M9v8ACuipc6X4XuoLicaZc6bcTXqvqZilZ037fLizuI+Ufd4rb1/ZpWjTSJHqOmWkVvbSW2o3N47x3ckiqTEoJ4PJOenymvFNL8aTwN4dkWwikl0eyms4l+bMok35J9CN56elWdT8aXl3LrNrqdnbJb6nb20DwBjL5DRKqrKo7NhTxn+I1mps7J4WmkrS37anqzXMelkXs/iA6tGWXFtpsrmQKRyRu4ruLhIJLu8jD3DxW8Ecwga5ZGO7HVu3Wvn6D4i3d0sNpr93fXFrG2EdVjRYxjAOxFBOB2zXr+n6xptxdnWoJWu11C1jiMEZIDooG3jqpyM1pGSaOWtQlSdmj0ISJY29vDDEm99oHm3Bxg9fmPp29ar6pdXEkURt7kBQJT5CkJJLtPRR6gCsxNQuZrN5NR0uBYUw8QlyOnTnqcVzMni3UAkrPZ23mIsnk3nllmVnOSVHp2/WqMTR8Q2V7cQxz6fM0MJSN2SO5bzgj4+cjsATzXHap4V8VLdTJa6zZOA0sMcf9oSAmZBu8oerFefQd8Vc8S+LJJJIodHSDY0Nuk115LCWQJgtEM9AWHXrjiubuvF15aakl59gt3kg1G51LYzsMNOmwp7ADkdzQB51b3+oRSSG1kuLcy8yNFMyFz7kHmtrRH1K4cK+q33mNwMXTnH61z90zSosFuWYfxOT/nFdF4XSy02c3E7SMYxnBOT+AoA6DVLbUrWyCxahfjPRvtL7mP5103gbwrdX0EUuv39xcBDvSGSQtz75PFZlnc/2ncxkyCCNumBufH8lr1bwlpqyvHHZDAHQE7mz6n3+tAGbrtpbaZbx+ZFy/wAsVvGPmc+gHp6mtT4Fwyw+MfF4uMCQ2ensUB4T57v5fwrW8R/2b4cia4uWV75hjcTucewrG+A14b7xj4ynKBAbWwCgc8b7vr70Ae00UUUAeAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVABTk65ptOXrQB3vhFpDoUYj2sBIxKj7y+4NevaR4JQaVost34wlS/1TSoNVNna+GLq+aOKRQcs0TkYByMkDp05rxfwtn+zEKuAxdsgDn619P8Agy61uz1XwpN4c0yz1O7X4f2RMFzeG2zhsgKRG4JJwMHaPcUAZ2nfBj+2dDi1Sw8d6bNproZFuE0hguBnJP8ApHBGDkHkYOapeFPg/F4u0qPVvD3xBtruz3tF5o0SSM7h1BV5gfTqO+a6A30UPwRXSdBluL7W/Eeoy2VzboqwzxXE0jPdR+W7AIUTzAAxA+6ScHNdJ8PriTQvibq+jPol9oemazax31jbXbwt++hVYpgnlSSDlPKbkg8HigD5r8PW8eqWEct8jjzY1kxHxyQDxz0rRgh2ZFo09vdRnhm+YMPrWNo8hOhabPBIEaOCNGOeDhR+taUU7xSb1d493SZRlfoR2oAt3szTpELiACbo8g4b60R6THFJvjeKRSMlXwpA+nekmvZXuojewLtAzuQDB96SW5FyMoIgXOBhNwI/xoAjhsrUzsFbqcq8K5Ct7+laMA1VYcy+XE6HiTu3oeP61t+H9IgDL+88t8ZEZTy2P0PQ10J0+3vMWyM0OPvbo8sD+dAGZpPinxHbOsMdwZZMcIuSp/A1satJLr1n5ur2kcEuzBlgUMW9iO1aOh2+p6SfNKxS2qnbuji2tj1710No8M1wYZLR5kmPzsE8sn2x/WgD5d8Vae9rbairxYVYpMOE5PynrX1Ro/ibQdA+K3xATXdb0vTHmawaNb27jhLgW/JAYjPXtXIeNPhodRW9UW1xbQzxlA0ZzgEY5zWRruv/ABP0eRfM8VXk8RGS8Wn2hC/U+TQB0Hj3U5NF8S6taeHJUng+IVnCmnXFsQ8YutywySKwO3HkyLJu77PxrptUtbLwH8QfDOpXI+zeGYdEfQ0uGH7uzkEkboZW6IrKhG44GRzivD7n4o/EONsJ4tuQc/dawtMqPf8Ac023+KXxFnm8r/hK50c/dL2dmAf/ACDQB71aXlt4u+Luk6t4dmjvNJ0fTbmG51GA7oJpJmj2wo4+VyuxmOCQMgHnip/ht/yUL4m/9hO2/wDSWOvn9/ih8RlnMf8Awl7nHULZWpY/gIadH8U/iDJ5gXxTeAx/eBsrPI/DyaAOO8dWrt468TzeaiJ/bV/1xk/6TJV3w5pMksqPIdihv74Ut9Kbp1ncahfXF9eq1xf3M8k8skqKC7yOXZsABRkseABXcWPhu4a1JSaeQ/8APJAOfoe1AFG5s7ue7WFsvbY+VNwTn6d6v6fpMj3ccR+4h4QHduP4CunsfCEMEcU01pIksi7SZmJYD29K2YtDmstNS2sL2SSQNuEhx8o9OKAJdFt54Y5QksNosY+dFjLMR6cVyOpXtraalNdzQzu3OwzDqf8AZGeK3Z4dV2PD5czQMPv48sMfXI5rzHxTcSx3Qtru5BUcbcnA/EUASal4lkVpLhWC7jhS33V9hWFd+JvtFuvn+UxU8bjxn19KyLmVDKSiExgYBYZA+mawb24Wafyk4Qd84oAv6hfRXs4MsokfpuHCj6U+Oe3CeTFEZmPPJ2rn371kDy9mS6q/pjJ/AV0nhjTG1EFNwiP8TEZKigCz4etZ7y+SNEj5IyFJx+fpX0B4Q8NafZQxXWpOJZ1wVgj+6P8APqa83sLPTNBhjFon2q567nkxz6/St1tcvHsHMsbBQO37uJPqTyaAOv8AHfiwyRfZY7iNZMYWGI7hGP6mof2dPMPibxeZVcMbWwPznJPz3fNeYxm5gSa6lSOBGJPnzHbn6Z5r0X9mWcXPiDxi4meb/R7AF2XGTuuug9KAPGPEjEeOfFY87ygNYv22sTh/9Jl/I1WGp+cciQSMvBUj5vz71q+Jhotx4s8Sw3k1xY3a6zqGZiN8L/6VKRkDleCBkVk6h4cubO2NxHtubTkpc2zbwv4j+tAkSNCSA6Sr5b8OFboPcHpVK7DWcLNLI720YLGRsHAqhaXzM5juwHT1zgg/X1q5/a1iEeyvpI1hYcrJ1IpPQtanNTarNeRyiGBIBK3JJL5T0IPGfernhyF7Y/PiSM8YIrJuRDY3TLBPHPA7Ex+Wc7R6GtHS7sxk5yV7V5mL55Jo+xyaGHSU4fEReIpoxNIYV+UV0+gaMtnocAumtzcSHzlwwJKnBxkd64vVD9qvI4IjzK4Ucepr1XQ7CKcgEKEjUKrx2+QMeoHSujCQ5YI8vPa3PV5U9hLaC5gaM6YhaJ+JI5VxtP4/0rY0zUdZ02SRra7SNf4lXIIPtXS2VlbWsCksZFYcOg3JmrNvodyJUn0+WJ5JOsbxZA+hrrR4LJNM8Ta7fwGC8torq0lXrNgN9QTXA/EPQonaOe2gDych0kiGFz2Fexw3Uxtlhv4CZYD/AKsQgq3uD2qfVvDqeItJZ4dOkNxnli3Qe1MR8my6DCqt5Pmq+eQeNv4VV0uwe31FnkDyOgymOB+Ne4+IPhteoZJbaWSPYufKlUb8+3rXnd7pE1icXAngmJ5aRcD6VPKtzX20+Xlu7GfNFdOYniCbZB/q9wZh/WqEenrbXryXClyTkjcRitFJbiKFkjUbSeqKA2PrT0tJIoRdI9uwk/56N/OqMhLjfNAkcO1YiOE4JNZ8enD7PIIxEhJxt960i7pAvnbXUnAZQQoPoCRUksE8jpbSK5iPLcdPxosBkaXpczzmNJRLhsZU8L+NX9T8BXa21xf6fKs8uQfsyDOfXDeveux0DQpJtojY2yLwDGAC31rr9L8HyXdy8d1DdTx44kLYQ/UClJKSszSlVlSlzR3PI/Cngy5uxPca3ZzRpGVEcbOFD+vHUivZfCuj/wBn2kIhiiVBgB2T5V9BWzpnhmGK4gnjlNr5GR5SYw//AH1UlxaapE7yQvJJk5iiC7iPfngUowUVZFVq860uabG+Lt4sUhuZp7pm5xAhVQPck1wuq65FHDHaWUZjVfvMg5Y+n/161vFn9oQW7XU0jQMy4csxYn8K8tv543UtuMszf3ScgfjVGJrXHiuVLgIHQoOO3H1PesDUtbjkV41eONDnIQcsazNQuUhhzsAccBcc1lJhiGcjJ5PtQBo20lqpErEkA5CgZz9asrIZZAYYEQE9WbLH/PpWbZoslygRg6FuWxgCvSNE8NWQcXWpTn5RlYQdv50Ab/w88NvfhWvHSCE8u5PzY9B6V7BHf2HhjSXi090gQj57iQ/O3so6/ia8q0zWXt3EWnWwhgBxlAZHJ9h0FVNbkvdUvUhhtJZmByY929vq2OFoAd4q1KfVbxpYi8qZwoz8o9ye9dp+zQGHiDxfvcO32awyQOPv3XSvOtZktrFVXV7/AAUH/HlYkPIfZm6KK7v9lnU49V1zxlNDZJZxpDYRqiyFyQGujuYnvz29KAufQlFFFAHgH7a3/JLNK/7DUX/oieviqvtX9tb/AJJZpX/Yai/9ET18VUAFOXHOf1ptKvWgDrfDRCWSM7fKXbjuPevXfD3xj8S6Fp+m21hYeGJXsLGLToruTT5TO0MYAVWYTA44zgcZ5xXhtjcsljGhQMoY9ua1rC/gJVWZ1x3IzigD2WL4x68dRbV4tD8FDVw243H9kyCckrtzv87Odvy9enFSz/HjxZPc295c6T4XkurTcYJm0yZnh3DDbGM+VyODjqK8oZ3HzqUkQj7yjBFQTXvksu+SQDHVRQBpWMudPghhZiIY1jdSuN2BjNa8awQGJllleOXj5Gzj2IrBju1lUGAEEj5sdT71atpoiFTa0r5+VkBDfSgDclslM6raK7P1xuI/z9K39O0ia+ZPtJtoxH0CHax+orC0O0uFka6s74rJn54JsqR9M8Vcv720iKvK0ryg/M0ZwV+tAHoeng2TRm8knkt1PTcrqP61qXviDw/GQWvJbecjC5h8xT+PUV5supw3NuJI5HAQd5BkVTh1mZ52R/JlwPlVsfN+IoA9J0rxzc2V00EVxBIvVVVCocfQ9K1rXxpJqFyLh57O3uE4KCPnFeL6jqweRDKxt3HSODLZ/Pmi21u5BaKKNmDdN7AMPxxQB9IT+NIJ1gDK0yEYMiKSPxHar2nC0vkbzLiFoyPlidSF/HFfOZ17VRZrFaB4yw+YKc59yBVjTdfvY0aISFrgj/WcgfQigD1LV/h5FqGqh7aWzRJDyIMsPxzVK6+B92WkW3vIzG4zw2DXnth4o1ayaXN1k5yGDhMVuwfEPVV0540v5YZj0JJJP0NAEZ+FWoaUZnum8uUHah3FuPU4rpPDfgSwg2yXmo2wYjLlxtDfnzXE6r8Rdcv7eK3h1rOOH3Akn8cVy2oeINQAYyXlxI/TDAgD6UAfQOk2fg/T3ldrlXkXkxABw30zWa/ijwvmb7NAI5FfkMSpB/CvC11mVFRlu5lkkHzKV5/Os+XUHSWQyPO8R6DHf1oA+lW8V6fqVqIDeKir13r8v0A6muc17xI9uI2tJo5bcHaVSPykA9T6mvFLbX5ooNkwAT1J+YfjT21wNA2BtT0di4oA9zbW7W7sT5EJkZl+aTeT+leb6xOXkbNq+3JAZsL+JriLDxjd20xaKZygOAi8Z9hWlLqT3KG5vN7yNyIN5Yn6gUAZ2rZid8XCsOyAgCsm0VpXKpHGz/7XOPpSanMJ5GKRmLH8Iaqlt5ULF55fsw9sktQBZubBotskjbHB6AjP04robVUtLWPe8sLNzx1+tYlnrNnBKJPLOAeMjk/hU0niGK5kby7XzGPADdqAOz0vWBBiKxTJ/jup8Mw+i1pLqSBzc30jXTp/qlkPyqf73pXmkV63UAL654Aqjf6uQSqzPJjkoD1oA7DxHrQlmErETOTwXPyr7Kteu/sh3P2vU/GkhbcfLsQT+NzXy+9/NcfNKG29gO9fSH7FDB5/GxAxxY/+3FAHlvjWRP8AhOfFSBtr/wBtX/fGf9JkrN0K/uNHumks7qW2Eh5wflz79v0qr8RLxIPiX4uD7hjWb3kHr/pD1Xtp45o8QSjfjOxxigDq5dV0y8uCda0pVmY/8flhhSfdk6H9Kxr/AMLrqF5Jc+HdRt9UP8Vq37qeMD/YbG78KznlcKckxkDkDvUdlf2zyEMC8gPUj5kPrmlJc2jNKVSVGSnHdCtYGCX7PqFrLBID0ddrD8DVmS3t7XhZtvuRWqnijUIbYrdSx38CjIgvI/NU/wC6eoP41ciXw9rTeXd2F9pZbG2aEmSHPfIPI/OvPq4Sd7xeh9Rhs9o2/eQs++6/zOS0Ii38TW8kktuVcmNGYEqGbgE46V7boujS2C7oLhw7HLGKUc/n1rk9C8LT6S7Wttf6Ze6ZLulUhhHLv7cN7cda0IVm0t3iuLG/gU8bmyYx+PIrtpRcY2Z89ja0atVyj+Z6LZappVtatFfmZX/jJUbh746GqF54qs7fbLo2oJKidVktyjr+PSvPrzUzafJbSqB1ZSwb9KJNYcW/MNuEYczAkE/h0FaHKeqr8Q7iW2SGZrYxSrgzugP610Wg+MFtYZInuYZwy/IkS4z+PevnSPVjECYJLiUqc5ZQFH6citWz12981ZRFwRwQ4wD7elAj6CtNbg1NwVZraUHBMic4/Gl8U+G7HV7BY43sDJjO+QsHJ/lXz+Nd1ZroTXkshjzwhHLfjVy98Qak7QyxThIweEPJ/HPSgD0VPg9JqFnvS7jWRTxkY/WsTXvgpqsbxSiRZUbiQ+ZworIsfHeqW9xGGupAg6gSbsfhVm7+Jmrw3bv/AGw6xOpCKQcA/SgCey+HwF4Ybu6RIIuAjKxP19K7BfDPhqwjt/7Qv7dyP4o25FeOX/ivWr0tNeapI+4nmIHOPSsZNbnnndZ55UjUfK/UH8KAPojWNX8H6XHbRBfPXORKFCj9OtV7DxlpFrPILSQRI3XYSc/n0r56vNVnuIlb7VM7rwNoAxVePV5YZ1MKybl++X4B/wAaAPoy91u1/eTW1/bmaUdfJLuPoe1YWj+J1kuJodQUu4PyrvwXHqfSvHD4hDyZZSZOvyPgD8BVK/8AET28w8l0V2P8I5/E0AeveLr7zZFaK1f5h91eRj6151rB8xMjFuR03YJP+FVIPFF5qEYtZJWEa/fmaQKoFVL+VroeRY2M92zHAdAWyfX3oAxr2TMo3YkUd93WpWsZZ1B2IseOMYH5nvVv/hDtWZfP1FbfTrYfN5t7cBDj2Xr+lSiTwtpg2XGqXesTjrHaR7EH/A27fQUCuipodptuWG53CfxdhXa6Nps7E3MyzpbJ90XTiGMn1yeT+FYI+INpZRGDRtNt7LHVsb5Afdj/AErH1DXZ9TnWW781m7MzFifpnpQGp6sNUtYlVHujOccx2o8qJf8AgX3m/Ss3W/Eqi0a0ssWltjLJb8NJ9TXmk+pNHEcyGPP8Knk1i3GrTu/lx72B6se9MLG7f6quyRFCRRk9E6k+5717h+xdL51142bGBixA597ivmS6m4LFfn9WPX6V9I/sOtubxsf+vL/24pDPqeiiigDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqAClXrSUo60AaViZBCuMbMmuh0WK1kuI1unij3cbu30NYFkji1BBOMnjGadtcOD09xQB6DqXh2CCDzrS7WLI6bt0b/Q9q5Wf5CRIGbHGajivmij2u52NwRu4NJEpz5kRaVM8qvORQA+0jWVyqO0Tj+90NdlpCpaWm+Zgsg5PGR+BrKigT7H51uiOcZMXRh+FZ8l9JECY1YIfvIxwRQB0tz4jl2MkkqPEehPP5HrWHcPBdZL3Dq3XHUVg3F1uJZBgHnB5xTbe8+UiQr7gdaAN2BlhGInLSH+IDrU89y3AE3luP4f/r1hQSlVL25yvdWHJqKTUi837yMUAbwv7hGQXUwYDkMME1J/aVzLcfulMkfYY5rnPtgjO6I7c9s1ZhvhJGCZgknvQB1sV35MA88mNmPTJB/GpbjWWl27A0igYwDmuU82SaIhm/4EvJqCNkXi3lkVs854zQB0ceoOZnLRSMg/gwMCtO38Q+TB5LxwrGemV5/WuVjunVihOCw+/wBadJcJGAJOo79c0AbN7LHJgp5io3LbBzWReXRhYm2MzNj+M5plzqJSJVW6BTHQDpWbcaoFQhHOT/EVxQBeiu3cAzuzyDt6U67vI12u3mM/dWfCisbzvOyVLKemaY6EJuMiyfWgC+b9Wl3NGAnpnJqvcXwZiY2IFZ0spJKgKPpUYBxyTQBbivCJg2SdvPPStWHV25eV3jB446n2rnS7DgUqN8w3UAdCt6sw2wxRoM/MxPJpk1woYK0sO36ZNVLYBhy6rTJrQCTcrA565oA191nFDujBdz145pILm6ZWit40hQ9W28ml0RrYSgXUqbAa2rrWdKsCDDBHKc8ktQBDY6Dc3MRIguJR/eJwtZWpwQWRKMyJjqfU+laWsfEG/wBRtvsdjEI4QNu1BiuNuI5pXMl0xJJ4JNADru88w+Xb7mA7mvpv9h9HjfxsHzkixPP/AG8V83abZXM8ix2UeXfgYTNfU37IekzaPf8AjCC5GJXhsJCCcnlrkc+h46UAeAfEPD/EzxeHCFBrV7kMP+nh6vaNoun6hYgrOu8DOFfDr+HcVk/E9WPxJ8X4AP8AxOb3/wBKHrBspXgYFWIA9+fwoA39VsWsZCi3QnToD0I9iKyHZDINyOO3FPmuBdsCZCJPc81oaREjuYrkbW6rI3AoAs6LaZmRzIHh68HJX8K6SfV2scJazBT3GOv4HrXN3pa3k2NFsP8ADIDwfesu8v2lIWYYkXoQ2aAN+/1ZL6T966qx6lOP0pmn6tfaXMGsNYu0jzkxlsqfwPFcl9rZJf4R6k1Y8+ORxl8P2IHFAHe2/iyWUs2q6dp98vZ3h2N+a0h1bQZgCLTULPP3zbXKumP9164e4v5YYvLdQQf4h3qv9sSQA7cMO9ArI7+NtElidbLxFLbv6XdoQD+K1dttDuGEcq6vo06HqyTlP0bFebw6gwkCu2Eq0lydw2SoynqD0oCx6amkavCJPIgWcMOPKuUfP4ZrMvdJ8QiMFtGv+vDiMNXAzLGsgkkkkVj0CngVbtdQvoVYxXlwR/CPNbH86B6nYQR6vZyI50e7Eq/xSQsc/kKnvDe3/wA0ml3SuOm23IAP5VzEeuakR5n9oXY4wVM7D+tOi8T6iNwTWruMj1kJoFqW5NLv2DYsNTLsegibH8qgj0XxNNOETStREeOP3J5/Gs6bxVqe4s2r3rt7O3zfrWZJ4i1G4kfff3hzwB5r8frQGp2UPhXxB88cmmXUKd2kdY8/iTVWfw1qEKlbq50ezzyGuNQU5+oGa4ybz7gt5t3Kx64eU4/WqcoET/MkZOc5Lc0BZncvpmi2yGO98U6eJFGT9jieY/QHABqg1x4Nt3DO+valIOAAkcC/nya48M7Ec9OwobKnnk0BY7iDxnp1ink6P4YtUXdkSXkjzt/MCpbn4gavKgiS7aJCciKBREif9881wG9mPUVatG+bGcDuTRcLI2prqSUme5lRpDz+8YsfzNJavbTMTcurHsqDiqkkCyRY8zJ9BimW0Qgf7ygZ60DNF7pVlH2aBXx0+XgVct7a9v5g02+Rz/BCK0LOfSYbRWmKO47Zxmi28fRaSsgsLSNZG4BAyRQBBqGifZIhLdQtGT0Ehyx/wrmry6hgJCsGkPZeg/GpdY1bU9blaa6YhTz14FZcFuA3A3npQBGyzXGWOQvXPavqD9h1Sp8a57ixPT/r4rwzQvC97qaiaVdlqv8AEw2oP8fpX0n+ylYR6dq3jCGIllMFg27GM/NdDP6UAfQ9FFFAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFOX9KbTlznigDptFG7S0yMKWbn8abc2bR7mVyy98f4Vu+E42bw1EZEBhMj8suQOal1HTJ4IjcW6iaAj70RzQBzUVuJMF9pUnAZR/Stuw8N3ybZ7VlUnld4IDVNoMNtdSeVdKBn3wwrvtPgOl2hWyvHuIWH/AB7zjcpoA4V7i8RjBfwxtIOhU4P1rDv5njmJO3B612niS3tpIzK1rJFz1+8B9K4i/iVgcDeOzDPHtQBUuCrITHjnrWeF+bOOvFWFVl4GMelNaMNyAQ3saAGSSmMdcVXZ2Y4J59aklVwRu5zUJGO1AE0Y3LktgirEKKRwAzexxVIOR9KduJXjIPrQBeju3hYq0ft0xxR5qb9yhlb1JzTNKtrzVtTstMsYvPvLyZLeCPcF3yOwVVySAMkjkkCvSP8AhQfxOJ58MsB7X9r/APHaAPPWuXcjLHA7k9Kle7k8sL98euK7xfgH8TlOR4ab8b+1/wDjtc3428EeJ/An2IeK9KNh9t3+R/pEUu/Zt3fcZsY3r1x1oA5uV3DfKMn6dKmFxvTE/T2qmZXLfL396SRWxliPXANAFoTxovytkDs1Ry3ZbgKmPYVTLZHBOKAB680AEhDHgAe4p4+7zmo6XccYoAB1OGxz3pykZOTk0zp260qIxPyrk57CgBzNt6OfzpRPLgKD0/WtGz0DULwgw2rvn0XJ/Kuq0f4aateDMkLKOpGOn1oA4q3WWdtsEZdu9XY9JuJHCuGb/ZQEn8hXtfhr4dWNnD5uqSO23qjP5aiunWPRrMLHpdk4RfvPbIAT/wADNAHjeh+CtRu0LGBrWID7zjDNWzYfD5ZLoNNllXq8jfyFdrqviC9tY3S2htbKI/8ALTG+U/ie9ctLrvnkoklyzfxSO/J+gFAHXW2maToOn4hEUczDBkPLn2Fd5+zSYz4i8Y+UGA+z2GSzbiTvuuTXhNw88oMkhMSdMs2Wb8e1ey/smLGuqeMfJYMDDYEkZxndc9z1oA8D+I1qJ/iB4sYPhhrN9x/28SVyRhcShMjI9Rj9a9J8Z2P23xp4pELRicazf4UnBb/SZPzrjZ0ktroJdRFcHHzdDQBXsdEe/YiAN5gPI6kD1rZW01bSYOfJlt89zn889K6LQtKs5Clzb3M1rcAfeib+dauqP9qQx3UIuCBgTxjazezdjQB55qErSRB1jVD32nINYxm8zIlxu7Vs6pDBDcSJGrJz9xxj8u1c5PCBJuA289DQBDcjk8Dr1pEOxSwzgelSMM4DqSDUckbBTs6ehoAhlnLfxH8aYjHP3sUMCPvL83em9KALSKA3UP7VOxaBdyJhe/eqAc55yaVZpEPy5x70AX2u1mQB42yOnNKtyY1wjH6VQMxLehpTyM7qANK3uWXJD4z29ajnneVjuBGPpVNJSo+Zt1Oe44GFoAminkRsrgA9eKcZId+5WYOeuaq5dx1FRMcHkc/WgC7Jd7QQqoTnqRmqs0wkPKrmosjOaGAHegAXk8cCnMMscHt3pmTQTnk0ALj3wfan5AHWo+h5zn0FWbeyuLlwIonJz6daAIRK6cq3PrS+c7N8zMx9K6TTvBOsXxAS1dQTySOBXbaF8LLmOWL7c0kaHkkLz+BoA8yisbqWPcE8tTyM1r6R4bvbqRfItJpmP8Ww4H417zZeHfDeix4kt457gcqHYyMD64p1zf8A2WMPZ6eXf+EXRCoo9kH9aAPMm8AXHlp9qdiT0RDgfjXVeGvA2nWOJNQjjcr82zPH4+tV9V8T3Ek2b6d3xwsVsAiCsuS+nuQfLWRmbsznav8AjQB0uvXFiJFChJI4+AgbEa16X+zRcm61/wAXOccW2nrgHgfNdV8/yJE06C5mDHrgAt+AH9TXvP7LjK2teL9ilVW2sAAccfNdelAH0DRRRQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAFOHekFOXknpn3oA9M8FtDJ4VhgKt5wlkO4H3rpdOtIHhcOksUg6soDKfwpvwm025uPClrK1nFdWjzSDBO1wQeoP/669P0vwjJq5MenSxpOOkc3yuPbPRqAPNZNCiKfaEtfMVTy8an9Qao3rvaRE26si98AlfxB6V7DL4R1nTVYSQSo3cjoa53W7T7DbldR02adG/5axEEr78daAPIry/nYZlAC/wB3ccH6ZrAvmhmJeJzGw6rnrXfSWSefJEytHbvyrTJkf/WrG1zwpcpGJIRBKvUSQmgDko44yMiTY/v0qvJvZz83I7gdauXGmXED4nQAjvTjBIyYIKAcZAxQBisrs+Cck96Y6unDLkVpi2eNyCev8Q6VXuIpEfhsigCgQCSAMUmCOrYq01tIwzkg+lV2RgdpPNAHS/Cof8XS8Hc5/wCJ1Zc/9t0r7n+EX+q8Y/8AYy3/AP6EtfB3gq/g0LxhoOr3SyyQafqFvdyJEAXZI5VZguSBnAOMkV9AWvxq8I6fdalLpGqfETT4r+8lvpYIbTS3RZZDltpkVmx04JNAHQ/FbxJptx431jWv7c0+C/8ABf2b+zrGa7SN7mXcJLoKpYFsx7YxgckEVz/7ad3DqFl4BvLRxJb3EV5NE46MrC3IP5Gtjwx8fvh9oWjz6db6V4ru47iaa4uJbqC2d53lcs5fEoB646dABXjvxg8Y6D4m8PeENF8Jxa2lroMdzFv1VYg5SQxlFBjYghQhHQcBevJoA8pAyeKdgng5NWobaTbyufcUv2CZ3GxCzH0oAqhU3AHI+lSR/Zh95WY+xrTttIupWZfkXHHPH86u2/huWQFS2XPp0oAwmSKT7o2k+9KLKU4I5Wutt/Bj7R5Eksk3XakJOPqa6Kx8I3sCK92VCdcAgn8qAPPbLSHkIZm3fhXZ+GvD1o8qi7maMDtGoLH866+y0azQAOkwb1YcD3Irc0rR9FguVmn1G4MnXbFCAv50AN0qbQ9M+W1sbq4KffZ32r+laV94ruZbcw6XZx2cRHzHOCf6motQ0XV9clEWj2U8dovRyMbqdN4ImsLTfrV7Hbk9EL8k/hzQBz1/rdptEL2u+Xu7MTzWNPqlw86ia4mjth0iQ4P5Vv3GiaTaZne4kkc/dBUrn8K56Sw8+dmWUQqT2+ZqAGzTS3jn7Nbqqn/lpLkn9aqrZyg7UnAPVn2hQPzrUaI2kOELNn+OVgB+QrOjdFmMrIsrj7pc/wBKAGXUEVuV86SW5kPQAcfnXt/7K6suseL920Zt7Dhe3zXXFeHXHlO5luzLcTnhYoVO1fxr2v8AZNL/ANq+MQ6BMQ2ACg5wN1zQB5d4igRvG3iRpYmkU61f9GwR/pUnSpJdJt7hwiq0m4cJKhDfnXZppcVzrevPLEYi+taiBMw3I/8Apk33h29M1uH4e6vEi3MCpcW5GQ0JDYoA8mbTUsSUFs8bjpuBB/AisW9v7lZGUA8euVYf417Ne6LqEZJnhklCD7jnk/nXAeJIYbiXdbafd21yn30IyD7igDzq+ukkBW5+8ekmf0NYzIm/55Sy9ie1eh3GgnUo98D2vm4+aJ12t+vWuP1Dw/e20rBowAOooAzJhsT5JAyn2qlOsm3CklfQ1pQ28iNgR5/DOKZc2jls5BP93ofyoAyvLkCbgM+1RE8/MmK1JYJDCSCRj1qp5TycEk+9AFTb3AIoO7HJ4qaSBkPOTUax7m5J49KAGxoWJwKVkZR86mrAQR/dJpskhPDEk0AQZHHy0jcnmpzAfvbT+dILeUsMgY9KAIRx1OKUKuetXHtHIA2cn3xT4tNuMZRCoPHPSgCmqwj7+7OexqU/ZSBtQg+pNbC6DO4QyMoU8/IRmr0HhIzcvM0cXrsLE/hQBzK2pkyY+akh06RiAxxn1Fd3pvgvUC/7kOIx0aVfLz+ddFY+Hkhwt0HZh1ZMfzoA4DTNC3SLvwAOpI/xr0rw/pOh2ESzXJurhzjAXAGfQVoQaLpsqbZbh7aPqf3W5j+ddDFbWltYCDQ0vL65bhdyAbaAFtfElnYpstNHImx8plfcR+fSsrUPEE8kr3GrIHGMLGjnC1csfAPiC4kae7zDG3JaRgAtVb/wxpqymGTUDKV+8Uy2PqaAOdutZYhpLCI2zNyWX/E1STUN0RR/Ou525O4krV7VrOyQCCwO9R1dzgZ/rVa307y23tcSSHssYwKAKUttNJh5jHGOyRrnNCWTlGaa6KoP+Wajn/P1qa/YyEI+0KOqK5yfq1RSPvgECNHbQY+YouSaAIrZElYrbqYwTje2Mk+1e7/sx2H9n634sjLbme10+RuehL3Qx+leASMI3B0+GVAOPOnOMn2Fe6/specdW8YNcuXkaCwOT2+a64oA+h6KKKAPAP21v+SWaV/2Gov/AERPXxVX2r+2t/ySzSv+w1F/6Inr4qoAKcvWm0+PGTmgD7Q/Zk0GDU/g7YysAZRd3GQ3Q/N29K9F1fwtMluZLOISSLztBw34GuL/AGUL2GD4OWKSsFP2u468A/Nnr+NeyDUbQqGEyFfUHOKAOG0nUdbsl8vUIzNZdCJ13Mv1NJqWm2l8WewMClxyqvkZ+h/pXdyLbXsZQlHUjsea5vUvB0Mi79OfypevzdDQB5J4o8MamjmOW2tp4G6FV5/GvPrvQdR0q4ZTaSi2PTAOK+h7jSLyPEVy7/Ugj8j0/Oqk0AtJBHLICTwDIm8GgD5zvdMnuFYnTzOh/wBggisNvDybWKpd25b+HGV/EGvpLU9JtPMWS01CKJ26oqEc1yniPwtLOCWeKT/acsjfpQB4o3hSZY9rRKxPIwdoNVF8MNOzRxwSrKOzMD+teuQaBLDEdyQzKOqrJk49s1LFo9s6nMs2eyGIFh7UAeKf8IlqXzBbWdlB6gcH8aqf8IvfTE7LfZjqrEcV9FWGmK8LbJ7qFh/AAAPyNMn8P2xiFy10GcdU8ng/XFAHzzF4Pvp0JSFyO5UZ/lT4vCN/B8rROx7DYa+j9H0ezYmSQx2qn/loilVNXLTSrW6ndG1ISY6HYR+poA+aR4ZmgG6VCjH+Ec1JH4duJjlVUAeuK+rbTwvpUihbiSHzOxcgg/jiln8GaXCuVXQoCTy29nY/gBQB85aJ4LkktyzBVf1OP5Vr2ug24fyFjQXA6uxwPzAr3S8t7G1RIE0mGdsYWeIfL9cECuU13TtbVmWF0ETdFRBgD3NAHnMvhpGO+5cEKegJIP51oQPpGhxCWYzJkYCrgA/1qxqmgarNbncVODyFbv8AhXNt4d1GTKyl9o65Q8fiaANmz1PTp97Ws1zGXPOelaMeihgLne+Ou9ycVzDaA/lA/M208bnArWsJNSgt9tqPPwOgGQp+tAHWRaRaTRpJcFvJHJd2CKfw5JqzaRWWmz/araGykZR8u5S4P4HrXKaXdXs0sg1SWedx0jL4VamUN9oVViK7jwFzn86AO1ufGOp7QbyZLSAj5RGMMfoo6VxviXVZbkbrW58t2PLyt8x/DrVvULowKIkgh80Dl5RuxXN3d4sjsWe1MnQbYyT/AIUAIySywrtQXEv8TzH5RVe5nmiTBmih2944h/M0n2aVoiXmjLHn5SSf8BS2VlpyhptX1F1Uf8s1HJoAw2kFxIxEsryf3n+Y/gKI9KvbmTZb5jJ6uwJNa11f6bayf6DFKgPQH/WP9PapIL69u2WNLZYkbsz/ADfjQBJp/ha8fak9wiwfxOz7RivaPgDaWNl4m8UwaaUMa2On7yhzlvMu8n8sV5JLoV0UBdxg8lmJ2j8K9S/Zys0svEXiyNJfN3WmnsWz333f+FAHTeC/DyX2malcEKGk1nVeeucX9wOR+FJJYa5o9+Rp8bwgnIKnMb/Udq2/hzfW8Wh3sUsyK/8AbOrcE8/8hC4rqlvbaQlRKhPQg0AcfLdQ6pa+Xq8MEV4v8WShz7GuV1/w3ezQtLYfZnwPuuA276EV6ZqegWOo/PKh3diDxXMy+GL2wd2gmLwnkbByPqKAPCNd8K6hKWuEsdtwh5MSmsKS0u2j8uS2fzh1DoTmvod9NkUNKXYHqQCfzwaqT2lnewt9ouII2UfLJ5RB/OgD5o1DQWklXztNmgPUPHkZqo3hl5nLRGSRV+8JVAZfxr6Bu9Cae3dY71JkHqpKn6+lcZN4WlhvCwa3BPX9838jQB5Pc+GjEQXt3KnoY26fUVWuvCN5lHt4pGVum3k/kK9kOkKrhJ1a3b+/EN6NVmHSreKZdr3G1usiR7cfjQB4Rc+GL+NgslnKM9CeKgPhK+Eiq0QyegB5r6Ql0OOd1imvJPLbo0qBj+Bqomh20c/kbY7nByGaIhv8KAPn4+C9QRtwhkXHUFDUo8LXbZ3QHZ3YjFfSs2m2kUUYj1IoT96PaTj8O1aNn4dsZNrtcJKhGTnA/SgD5bGgSj5FXcfU1e0/wnPNcoHUEEjpjivqg+DdHmUNGmlzKOpuJCu0/gKZBoOnac0jCLTbzHHlW4bI/EigDwL/AIRWOw/eXKLJF6DFW/8AhHxLEpiMaQt/ACc/lXreo2091Cz6PZx2JX+FlBJ+lcZe6XrU8hM0i5zxuwp/KgDmbLQbC0kIlDMw5LLgkfnVi71vRHlS2WS5LR8FhjP6VS1Lw9qiXB++M9wCQfwFVYvDtxHJ++L7j6ALQB0cUEWrELFPcOMYC98fhWnpukxxubdmZm/uIMt+JNchZafcafcnyXCMe27cT+Fadxe60jIpeS1g/iZPlLUAdX/Y2nRoFPkNNnJV3LN+grWtfEF5pcX2XSYLVEAyzogU/i1cdMQ0KMkLE4yXdiSffANWdPcpbSTyQl0HGG6H8KANfU/Ez3kbpcXbTSjqoOEH4muHae4uLp2mufMi/hjQ8Ve1C/ZgVYWccZ6KYz09/Wsc7rmQeTJAIl64G0UATMJ4CWMNtEp6Ajc31rH1K7bOyW6kKk/dQBQfrirslkZJwjXYijJ5IBx+vNWbgaBax4iklvLhR8zHhF/pQBzzWzygeWrsvYBTj/69XrDw7qUpEhlUE/dQACpotYYsRZ25lH99ztQfStSysr7UozI2VHTCsTn/AAoA0dE0HTdNzda7NbyyryI2fdivUPgJqUWqeLPFstvGkcMdnp8aKqbRgPdn+vWvIF0LBY3dxHEVHCFv1avTv2aDGfEPjARXAuAttYAsowAd11wKAPeqKKKAPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+KqAFFOT73I/CmjrSr16ZNAH1b+zhrNpaeALW0vA8Be5mKzZOxssOCOler3dw9uwlt1wP+ekY6j+Rr5r+EOtS2PhaGC5h8yxaWTDLwyknn616Jp7yRT/adI1qRI+pgccfTH+FAHp6a9dJJG8biVOpKJ/kiuntvFVuYB9oDxyY7rmvJrPXbW6uljuCguR1aByjfiO/0rp/tKrbHypftIAzsYbZB/SgDsbbxPFNIYpIPMT+/Flh+I60zUNItb9fN0yfbIeShfj8jXnS64UkDQi7jkXsy8j8etWG8R3bSCR2WYDqrLhhQB0a+HNQim/dzW0gP3o3YEj8DWdq+l30JCXSl0H3WhGdvsaqQ+J7xpB5scLRDow+Zvpg81qaf4whkudrzCOYdCy4B+ooAwriwdlDBHV19F/nUbvbmIpMhtrnoDG23d+ddxLrWlao/l3inzMfejJ2n8e1QlNFmBtyd7dNrTZ/U0AefXEr6cElyJQf+me4/mKs6fdB5fPkBQH+4px+NdpPoFosW2GfG7/lnu/rVBfCdhvY3F1NA7djKMfhigDEj1VI3eOaH7Qp6CMnI/Cmpf2CqYszISfuSLwD9a05fCAt1L2NxcrzncJFYGs6Xw9DNcKWv5C4+8JAM/mKANS0ax+zl5DKxHZRgH8asW/ibSUG0QeXt7svzD6etchrEWj6XOI5tSmhY/wARJwKr3Oo2dvbgw3bX3cHGaAO5u/FNmIGMCPO3YSx7R+ZrGl8T3L25B0dUU9/MBX9K5U+JQ6hHOxSPulef5VDZXcFxctFJJN5Z7spUUAbdtq9zdzNbppz7W/iiA/nTv+EQv7tyVubdIe63EhP8qoxXkIfyobea4C+twUH6VuW6PLbhkZYVA5SFmcj/ABoAjfw1p8cflXGoaX5vZYgS2av2uh2lhZsWDOT0WBc5+pxVS3uUtZxIkcruDy8kPP5mtK48Tauyf6NIqr2ZVyf5UAYV3osJhaae0gVTyqSbtwrk72GC0fPnq0rcCOH5AB7mup1DVElBl1BrqaUfxSPwPwFchqFxZ3jM8DTkjtH8ufx9KAM6/lkjBUo8ynkhASPzNc/e3DBvktVyOQp5NdBG19O2z7FLIg+6h3Ypl9pl1Io+0WsFsncs4Gfb1oA5qykmvC/zDdnlEXp+JrXj0VioeWAQe7uAT+J6Co57mK0Qxo4XAwPKQDP41z6zzRXDTNcJJI3RWJYLQB1dvY2YlKxxLM3fy/l/Njyfwov9Vs9Jx5dvD53QBDkL9W6muPF+3mE+e7E/e8sY/X0qtcXzxuXhgVpMcb+i/hQB1d9q738YaSSQIOcv8q/gO/416j+y9Mk+ueMWj34FvYAlhjJ3XX6V85XOp3Rybi5yx7IBx7Adq91/Y3n8+98atuZsJYjLNk9bmgDt/C80Mlnq8aNHLLHrWqB4+CVJvpyPfoavx6tcxEx+bsYdEdf5E/1rymae0uNY162N3NZXcWtajiReAc3kx6jnvW3baxcafAItSvoL2A9HlBB/OgD1HQ/E0sJK3iSle5C4rTufFdupVoNsnPKtlSfoelcBot7ayxB4LmSEdg7eYn59RS6nqYt5SJIZ8H/lpDhlNAHohutO1mEC5WS3k6gsdpz9aw77wxdMzGK6QR/wsz4/lXJw+IrlIzFFNIidvMTj9afH4lvYl2xRxB++4kK39KAOhl0TVYrcuDbFlGCUx89YBsXEjGSCQE9Q6nj6cYq3F4sMCD7QqID94KnH4EcV0Fn4rtGtQJJElgYfdHDCgDi1h+yMRNAZYO5cEFfoRUM8cc0ha1nJQDIVyGx+Fd08miNidWkVT13Slf0700aRpV45ntyI/wDaV85/KgDzuPUWlP2UxqCpwf3ZX8ua1TerDCmxs7fvBwQfwroLvw1b3LkvLI0QP+sjkAI+uagl8HafMFMF3NM69Asoz+vFAGPLqdnKySy29xCw/jQZz/jVixuLK5m3BztPXanP5Ut14eaJGiu764RD93IUiqUmg2NpZNNc3shC8gpmgDdbVNK0yUB4ZXLD77rkfiKsp4n0wDCGSM/3I48g1wNteaQzMbfWHO3jyiTz+BqB/EKW8rCEMF/vlev6UAdleeKX+0YtdLjuFH8QcI35Vi6l4iuGl3nTED/3M7jXO3etRzr5nmP5g4PlRk5q6lxaRxJOGlaRh90Ng0AajWF5rkSypFJaPjH7xti1LbeD2tcyajf6Sue8hJNQabN5rgC1WAn/AJaTXJdj9BV64TyuJ5J5QeiiIsp/HNABa+GLCS6EsFzazKOrRjj8BUuo6XDcS+VbW8r46yTKQv4cVasteuLSHyrNFQ/3WUL/AEqnf67qVwCl/PcCI/wQ4QH8etAHNazpVrExVWtbZR95lUkn6ZNc9O6lD5DsUXgEsWLH2UVuaxqNh/qSroT/AHjk/rXNXLywSYsY7iQnq5JOPoAOKAMy+uGwxe2bf/efjNYk13KHVQkUKE/fKn9PWuvW0vpoyU03I/vyHr+dZ01qtk7S3BtxKew+cr/SgCpbabNc9bd5l/vHCge+KtHS7aBf9IaIkdF++R9FHA/GsXV7l7khIblkQdS7bQfoBVCa+cRpGZkVE6fKck/1oA7VYrO1g82W2iROu+VgxP0UcVQTxOJGeG2R4kHAEeNx/HoK5WW9Z4cuZZOOr8D6DNUJtUuwgSPZbQD0Ay31NAHRXt7FGG80tIWOdikkn6mvWv2Ubn7TrHjJvKjiCw2ChE5wN1z1PrzXzVqGolsb5pGz6HANfQP7F83nXPjRgMAJYjH43FAH05RRRQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUALSr19aSlXr1oA9H8E7D4fjAmkRxI5+RunPpXV22vLaKIpvKfsTIMA/Q9jXlmhamtrbeW/K5JxXQWstteEKl00ef4ZBkfrQB6ZZwPqDpPbypKvXCuDIn0zya7LS7yYKsJ1aF5BwIrldp/A141aWU1jiaNiY88vCdw/Eda17m+e6iULNFc498Ov9aAPZftk1scahEHjPQk7l/Bhz+dVLuy0+/cSxXZikHRXlzXl9prskcHkXNzNsA4XutNfxAqJt86G5Xt5qbWFAHoOp293FFm3u4329CpB5+tRaRrM8hMGobJCP4goLCvMo9bhkn3QTyWr+gbKf1rprC5SZQ0cwSYfxwuD+lAHpematHA4SONS/Z3yv6Gu00oW+oId4gkkI5ETKDXht1eajFGNt7JKBzyQCfwNQWviZIplGoWs6Ff8AlomMH8jQB7rc6Xq1s2LSKae2zkq+G2/SsnWodyKsit545wcjaa4m38Z2haNob26Rh/dLc/kavXHiD+1FP766ZscYcEH9M0AXvtlyHEc91NE4+6djkfyxVCfV7u1mZWkFzn+JRtP51Qkv7jyinlSlx90tN8v865rWLm/Uh4ynmD+4d1AGvreqSzH97bqU/wBt1fFYkmqKPltlQg9o5SCKyLvWZZD5d/A+8fx5AqhFewxSFlK5PqaAOrS+hQZuJplY9w+4irdrremwyhUmMznrvya5iPU4Qu24u40U/wAMac1Y/teyIAheNCn8W3k0Ad3bTJJ++tdPa4b+9vwB+ddV4bWRnV7m6FjntHHux+PSvHo9dWSQfNPNGv8ABGc5rej8WXe0R6fC0MYHImBH6mgD3Sa20u6tMXeseYoH3guDXPyaNpl3diG11W4MXoxAU15aniq8Q75ooZFzgopLE/lW9p3iB7tQ8dhYxMeokDMfyFAHoF34W0VIv9O1WOVV/wCWKY2n8uapN/Z2kpm3g0+CHsTGMn8K468vLqY72MUSD+LYFx+JrivFGsW6/edbgj3zQB6Vq2qRSoTaW0Usp6GWYKv5DmvOfENuLiYy3ksLyf8APG3bp9Sa5WXXkNq2Y1I7IM8/lWLc69EEKujIP7kY/nQB0N/f2ltFtkEUR7KW3H9K5+7u2lzskIQ9guKwbrVklkLkKoHQMc1nyak8sn72d2T+4mB+tAHQSzhBsWUs5/gB6flVK4zsw8roOpVT1qu+rxx2xSGNYc9So+Y/iaxpb45JRSAexOc0AaElxGq7EgLerMa+jf2KW3XHjYhQvFjwP+3ivmAXEzjIAUerV9N/sRHMnjY7t3Fjz/4EUAcX4gu2svGfiaTzGZP7av8AMbDIH+lSdKltNXj1M+UstvDL/eDYDezDtXKeOr6BPiH4rhkaSNl1q++Zfe4kqvaacLoB4LmOZuuCdrf/AF6APVtEjn00hmvWs1bqV+eM/lXW2s95LF5sE9vdIO9uwBP1U8GvGtNvprRDDLcGF+m2YcH+hqS2v7iyufNidoc9fKOVP4UAexy3VjeIY7jMEh4Yq5T81P8ASqP9mJbKRZ38TBuil815xNry79/20rIeSsiblP49qoX+vwOu2aJEY/xwkg/WgDu5L3UtNu+Z0aDupAxXQWmpQkJM0fJ+8gT5T+Iry7SNTSXasl0twh4AlOGFdHbzXCITaXssa9kJG38DQB6xo+qR3WI3FtHF2V2B/nXQXOkyTRLNpokjkxwYnG1vwr58l1u9tHP2iOS6TvypI+hrZ0bxfYxIU33MDt1U5B/nQB6zJb38aOdTgeIY6hT835VzNw01q7tamRIGPOzcc/lmsu18ZKYfKjvLuVfdyCPzqCe+kEvmw/aZUbrmTBoA0Lq+uBAJIr7KjrHJGc/qKzrrXbmS3YeUSen+sCj8iKzNSu7uRW2Kqx/7cu5vyzXKzapqNsHDo0kHcYA/+vQBpz6jGshM0cEcx5GWwf0qNL9pjuk3ovtNwfwrmrm+gnIcoY/9lmFT2+pKNoSSGML3ZcmgDpRqmnId011OoH8JJxWvY6nZXyhI4jJn7qrkE/jXHQ6vYLlnnWaQ/wB9OB+VSf23FAMRTgFv7vGKAPSdPNw8yRx2SWsY6ux3H8hXoWirbrCFn1sgkY8sx4FeD6X4jFrGdlvdPOekjAkZ/Or58U6o2DILfJ6Etj9KAPYdX0/RELsmqyic/wDPMAVFp/hexkg82TVwm7q74L/rXmFh4qkdzFLYwSN/z0fIX862zqdzJBhILMZ/54xMR+OaAOtk0PQrOUtai3vbhessy5/HPaql5q9mqmEi2dh/DAVQfiTXB6nffZoHFzcRhj/yzUgfoK8+n1uJLtxHGinPLUAej+Ibia6jdFSxtbY/xvLuc1wcyW1m7FULjvK8gAP0FYF/rqecWEQz/wA9Dk/zrDv9cifIjD7j95mPFAG9e6lBK7LbOue5Vc/rWQ8uWLyzFR6ng/nWBNqpC7IZFX1I5NFnqEKNukj89h3kOQPwoA1JJGmO4MQo6M3P5Vm3Doj7pDLM3ueKq6jqnnOSSWx0GcKPoBVAXkjYKrvNAFu6nDciFYx+Zr6Q/YhbdJ42PtY/+3FfMUsjEDzXH0Hevpz9h8gv4229MWP/ALcUAfU1FFFAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFKKSigBysV6EirltfyQMCcOPQ1RpQcZoA6OLXdq5ikkhY+/FI2smQ5diD6g9a50H1oJ96AOi/tq5BwZ2K/7XNTxaky5PX2DcH8DXMB24APNSedx059c0AdVDqsAbMtkc/34zitKDUoFIe2u2hf0fiuHhuSh6nHvzVpbpG4LigDvY/FEqLtuJUkHZlOKbP4iWZCiztn0YAiuEe5UdDkUzzlByHI9hQB3+m6rdxEhQGRuxUHP41oT6wVgOHmibPRWxj8a8+tNTuoQBDPhfTFasWrXE2A6QsPUrQB3dpr0/wBk2sJpP+B7s/nTBdzyMHFsIge6MRn8K5SJtxD5CjqdrEVrWOsQ+asbpNKRwD5nIoA07qzluiAY7nLdsdatWHg3U7hgbe3YIf7xAph1WW1dZdsu3tun6VZs9cuLyUBUuHY8BTNkGgC/N8OtTbb5jpaxHrJKyjH61G/w7ntsu/iCxkjXkjG4/pUkt/eQTgXFq8WO0ku5as2+rXMkwUpvj/uRBVFAFC0hgtJTHGTMw6yRpjFU9Ul0xWLFL+a4PGC4wPyrR1y5uokyLZUhI5G4A/pXH3OoKC32a3WBj1cnk/nQBIuq3dmSwMkcf90nFXbDxpqakpazrEPZOtcbqGplGJlcO2f72azV1k5IC4HsaAPQb7xRfnLXl87D0VAa5i+1uGeQs32lz6yN/Sufe7klOEDDPcnNWbGxt5X3XtzJjusYoAL6/wB6cGRR6s1Y7PubKsQSe7HmuuZ/DVnCWayuLiQf35to/IVi3+u2+Sthp1rbJ2Kjc350AZcluoG6SbBPaq5IH3STTZpzK7M5zntUW44xxQBMXOPmOTR5u0cAVBmkoAmednABNfUv7DJyfG3/AG4/+3FfKlfVX7DH/M7f9uP/ALcUAeC/FOZ4vip4xKnprV7x/wBt3rLs9ZCACVWX/aQ1f+LH/JU/GX/YZvf/AEe9cqDigDpH16Rht80yp6N2pq6vKpzBK6+waudzShiOhIoA6OPVZH/1rbu/oasDVEGA8AnHoTz+dcukpAwckU5ZyCCOPegDsrbVLJgFKyWxPbOQK04NentcCG8jkj/unriuFivBwGIP1FSmdcZDjmgDvf8AhKlI5kZG77SD/OqcurSyzB4X3n1K4/SuKecNw1Pt7pkOYpMfWgD0yDWJmCtcJggfeUY/SnWmtypeHy5p2TP3fNI/KuJtdavFXazpJ7Moq9BdPOMOkSse68UAdrc6rNcOQLQyn1k6j8RTVaaaJkKTkdwpzj8a5u1v0sclmkOf4VciugsdRWa3ZraKdD3xLgGgBsXh+5vJP3EErse7/wCNb1n4A1eaE5gbI9CMVlp4jljUQgTjBx8k/wD9atWC8vntvMjtLiSPu/n4IoAQfDa8ZS0utWdtMP8AlmzCoJ/DceisBdahb3T55SKPk1ai1e4SLCLGreuAz/nV8XV1PbbltmaUD77svNAGbO1obULeC8SLGdsTAVzl9cokn/EshuEUfxyHJ/wqXVr4+aftlossi9DvyB+ArA1HUZdvzskaD+BWoA1l8V3drIo37pR0L8n8q0ZfF+szwjdfgDHQJivN5tYCSHywOffrUcmptKv3Wz7NQB1uqeJDIpSee6lPcIAoP49awZtTjZSEWUD/AHsfrWWqyXBHmTGJM9eprZsrLRIAGvDczn0UhKAOfurkyuQXIPoWNQrGZBkyFc+veuhvtV0O23LY6PCT/fnk3n/vmudvtTe7JGxIox/CgxQBDKiIxAfcajVmxxUW7r/WkLE0ATBgvb86DcMo+XA+lQZNJQA9nJOa+qP2GTn/AITb/tx/9uK+VK+qv2GP+Z2/7cf/AG4oA+qqKKKAPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+KqACiiigAooooAKKKKACiiigApc85pKKAHBiM4PWl3t65plFAEomYdMVIt04xz0qtRQBpxaiy8MHx7VZttZEDhlDfkM1iZNLkg5oA7ZfFkDwbZE+b/bXOKbZeJLa2diCvzf7JGK4rJFGTQB3reJdPdg0ssr+zhjV+Px1ZQReXbrImeN6jGK8zyaMnFAHe3njOCXfHIbuf0Y4x+Ga5m+1GOaQtEZz/AL7VkZ7UE0ATPMZGy9IJsfwjFQ0tAFj7XJjAOKYZ5uMyP+dQ0UAOJJOe/Wkz3ApKWgApKKKACiiigAr6q/YY/wCZ2/7cf/bivlavqn9hj/mdv+3H/wBuKAPAPix/yVPxl/2Gb3/0e9cpXW/FVGf4p+M9ilsazek4GcDz35rkzQAlFKaSgApaKSgBc0ZoooAUMQeDTvMYjtUdLigCZbhwBj9KmjvmU5+b8DVOkoA2E1MDB/eZ9Dg1rad4oW34kV9vsOlclS5IoA7K48R2s0ocBEI/6ZnJq0PFdrIgSSWVAOgj3AH64rgj704owUMVIU9Djg0Aeg2fivTLZ96ozuP9k5P51NceO4ZVLrLcouf9WhrzYk0ZOKAOq1fxDb3oOEuUY9eQP61gS3RfhN2Pc1V54pOSaAJVlx1GT7mnC4dRlQAKg60UATtczE53kduKiaV24ZmI9zTKKAHZz2pCfaiigAzSUtJQAUUUUAFfVX7DH/M7f9uP/txXyrX1V+wx/wAzt/24/wDtxQB9VUUUUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX1V+wx/wAzt/24/wDtxXyrX1X+wz/zO3/bj/7cUAYlnFDpPjnxTqM8UTS614wn0gF0DZtzM5lGD6nb+VeA+I7NdP1/UrKPPl29zLEueuFYgfyr034geJ5P+FqLpsKiK20vxJeTSf8ATSV72Qlz9E2L+BrlfiLo93L8TfEVnYWs1zILyR9kMZc4JznA7c1o9Y6HLBOFVuXW/wCDOL60Yrt7L4X+KriJZrjT00+3Iz519MsK49eTmrY8CaNZf8h3xppEDD/lnaBrhh+QAqeSRbxNJaJ39NfyPPaK9B+y/DWz4k1HxFqTD+KGCOFT7YbJpv8AwlPg60O3T/BCSqP4r29d2P5AAU+Tuxe3b+GDf4fmcBSV6ENV8Da4fs97oVxoM0nC3lncGVI27Fo2/h7nHPpWRrvgTXdLkV4rRtRsZeYL2wBmhmX1Ur0+hwaXL21KjWW01yvzOV70c5rstJ+G/iW/gFzLYrp1n/z8ahILdP8Ax7k/gKvnwx4M0oZ1rxcbyZPv2+k2xfJ9BI2F4o5GDxFNOyd35a/kefUlehG++GtsNkej+IL0f35blIz+S8UDxB8P4TmLwZeyY6GXU25+oC0+XzJ9u+kH+H+Z59RivQRq/wAOp2zL4Y1e2LdfKv8AeF+mQKXyfhldABLrxNYuf4pI4pEX8uaOXzD276wf9ejPPkUswUdScCve/iJBHJ4E1Tw5HEoPhWGxlQkcoZFxJz7lgTXE2lp8Nre6hmOs65L5DiQo1ou2bBzsHPGema0/D+ty+LG+Jt3OnlvfaaboRA7ggjkXaM+wwKqKto+pjWl7S07NKOuunVfpc8mNKATgVs6N4W13XDH/AGTpF7dLJkK8cR2nHX5un610sXww1K3USa/qejaLEeCbq7VmB9CqZOahRbOmdanB2k9TgMc4FLgjmvQm8MeBrIZ1Dxq9ww6x2Niz5+jEgVleIz4KTSSnhwa3JqBdfnvNgjVRnJAXqTx9KHGwo11J2Sf3P9TkRRWp4bsrDUNYhttW1FdMsmDGS6MRk2YBI+UcnJ4/GuuVPhnZkq0niPUmH8YWOFG+gzkUKNxzq8jtZv0R55RXoP8AbPw7Rvl8KatIB3bUcZ/IULrfw8k4k8I6nD7x6mW/mKfKu5PtpfyP8P8AM8/ox6V6Ct58NLrKTaX4h08DkSQ3CTE/UMBSGx+Gr7gmseIYm2kgvaowJxwOD60cnmHt+ji/uPP6SlNJUG4UUUUAFfVX7DH/ADO3/bj/AO3FfKtfVX7DH/M7f9uP/txQB9VUUUUAeAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAtfVP7DH/M7f9uP/ALcV8q19VfsMf8zt/wBuP/txQB4H8VSR8VPGJUkMNavMY/67vV/UPibrcthFHYLFpl86ot7qFrlbi9KKFUu3UcDkDqeazviucfFPxl/2Gb3/ANHvXKE5pptbETpxn8SuWr7ULy/kaS9up7h2OS0shYn86q5pKUGkUklohQeaQmiigYua19E8T63oSsuj6reWSNyywylQfw6VjUueMUJ22FKKkrNXL2q6vqOrzmfVL65vJSc7p5S5/WqINJRQCSirIXNGaO1JQMXNAJFJS0AGa2vCfiC58O6wt5bqJY2UxT27khLiI/ejf/ZNYlLQJpSVmdTrnjjXdSDQx3s1jpv3YrC0cxwQoOiqo/n3rl2YsxZiSTySe9ITRTbb3FGEYaRQA0uaTPOaAcHikUAOKCaKSgBc0UE5pKAFzRmg80lACnmkpe1JQAUUUUAFfVX7DH/M7f8Abj/7cV8q19VfsMf8zt/24/8AtxQB9VUUUUAeYftC/D/VfiP4LstI0O4sYLmHUEu2a8d0QoscikAqrHOXHb1r56/4ZU8cf9BXw3/4ET//ABmvtSigD4r/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa+1KKAPiv8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZr7UooA+K/wDhlXxxj/kK+Gv/AAIn/wDjNH/DKvjj/oK+Gv8AwIn/APjNfalFAHxX/wAMqeOP+gr4b/8AAif/AOM0f8MqeOP+gr4b/wDAif8A+M19qUUAfFf/AAyr44/6Cvhr/wACJ/8A4zQf2VfHH/QV8Nf+BE//AMZr7UooA+K/+GVPHH/QV8N/+BE//wAZo/4ZU8cf9BXw3/4ET/8AxmvtSigD4r/4ZU8cf9BXw3/4ET//ABmj/hlTxx/0FfDf/gRP/wDGa+1KKAPiv/hlTxx/0FfDf/gRP/8AGaP+GVfHH/QV8Nf+BE//AMZr7UooA+K/+GVfHH/QV8Nf+BE//wAZo/4ZU8cf9BXw3/4ET/8AxmvtSigD4r/4ZU8cf9BXw3/4ET//ABmj/hlTxx/0FfDf/gRP/wDGa+1KKAPiv/hlTxx/0FfDf/gRP/8AGaP+GVPHH/QV8N/+BE//AMZr7UooA+Kx+yr44H/MV8Nf+BE//wAZo/4ZV8cf9BXw1/4ET/8AxmvtSigD4r/4ZV8cf9BXw1/4ET//ABmj/hlXxx/0FfDX/gRP/wDGa+1KKAPisfsq+OB/zFfDX/gRP/8AGaP+GVfHH/QV8Nf+BE//AMZr7UooA+K/+GVPHH/QV8N/+BE//wAZo/4ZU8cf9BXw3/4ET/8AxmvtSigD4r/4ZV8cZ/5Cvhr/AMCJ/wD4zR/wyr44/wCgr4a/8CJ//jNfalFAHxX/AMMqeOP+gr4b/wDAif8A+M17V+zf8Ktc+GX/AAkX9vXWm3H9o/Z/K+xSO+3y/N3btyLj74xjPevaqKAPkXxv+zV4x17xpr+r2epeH0ttQ1C4u4llnmDhJJGYBgIiM4IzgmsX/hlTxx/0FfDf/gRP/wDGa+1KKAPiv/hlXxx/0FfDX/gRP/8AGaP+GVfHH/QV8Nf+BE//AMZr7UooA+K/+GVfHH/QV8Nf+BE//wAZo/4ZU8cf9BXw3/4ET/8AxmvtSigD4r/4ZV8cf9BXw1/4ET//ABmg/sq+OCP+Qr4a/wDAif8A+M19qUUAfFY/ZV8cD/mK+G//AAIn/wDjNH/DKvjj/oK+Gv8AwIn/APjNfalFAHxX/wAMq+OP+gr4a/8AAif/AOM0f8MqeOP+gr4b/wDAif8A+M19qUUAfFf/AAyp44/6Cvhv/wACJ/8A4zR/wyp44/6Cvhv/AMCJ/wD4zX2pRQB8V/8ADKnjj/oK+G//AAIn/wDjNH/DKnjj/oK+G/8AwIn/APjNfalFAHxX/wAMqeOP+gr4b/8AAif/AOM0f8MqeOP+gr4b/wDAif8A+M19qUUAfFf/AAyp44/6Cvhv/wACJ/8A4zR/wyr44/6Cvhr/AMCJ/wD4zX2pRQB8V/8ADKvjj/oK+Gv/AAIn/wDjNH/DKvjj/oK+G/8AwIn/APjNfalFAHxX/wAMq+OP+gr4a/8AAif/AOM0f8MqeOP+gr4b/wDAif8A+M19qUUAfFf/AAyp44/6Cvhv/wACJ/8A4zQf2VfHB/5ivhv/AMCJ/wD4zX2pRQB8V/8ADKvjjGP7V8Nf+BE//wAZo/4ZV8cf9BXw1/4ET/8AxmvtSigD4r/4ZU8cf9BXw3/4ET//ABmj/hlTxx/0FfDf/gRP/wDGa+1KKAPiv/hlTxx/0FfDf/gRP/8AGa9q/Zv+FWufDL/hIv7eutNuP7R+z+V9ikd9vl+bu3bkXH+sGMZ717VRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The proximity of the defect to the pulmonary valve and the relationship to the tricuspid valve can be seen from this short axis window. As the imaging plane changes, the aortic valve leaflets come into view over the LVOT.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; TV: tricuspid valve; LVOT: left ventricular outflow tract; PV: pulmonary valve; RA: right atrium; LA: left atrium; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37414=[""].join("\n");
var outline_f36_34_37414=null;
var title_f36_34_37415="Busulfan-induced pulmonary injury";
var content_f36_34_37415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Busulfan-induced pulmonary injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Erich W Russi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37415/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/34/37415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     Busulfan",
"    </a>",
"    is an alkylating agent that was previously used for treatment of chronic myelogenous leukemia, but is now used exclusively as a component of a preparative regimen prior to hematopoietic stem cell transplantation (HCT). &nbsp;Busulfan was the first cytotoxic drug reportedly associated with pulmonary toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/1\">",
"     1",
"    </a>",
"    ]. The reported patterns of pulmonary toxicity include acute lung injury, chronic interstitial fibrosis, and alveolar hemorrhage. Busulfan is often used in combination with other drugs, many of which cause pulmonary toxicity, which can make it difficult to ascertain which drug is the culprit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H7#H7\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Chemotherapy without radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical characteristics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -induced pulmonary injury will be reviewed here. Pulmonary toxicity caused by other chemotherapeutic agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17050?source=see_link\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=see_link\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147763\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic pulmonary injury is thought to occur in fewer than 8 percent of patients who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ; the incidence of pulmonary toxicity appears to be similar in children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/2-16\">",
"     2-16",
"    </a>",
"    ]. However, the true incidence is unknown; most of the early data in patients treated with busulfan alone for chronic myelogenous leukemia (CML) consisted of single case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/3-7,9,10\">",
"     3-7,9,10",
"    </a>",
"    ]. Such treatment is no longer considered a standard approach since the introduction of oral tyrosine kinase inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present the utility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    is limited to preparative regimens prior to hematopoietic cell transplantation (HCT). Modern data examining the risk of pulmonary toxicity in such patients are derived from series in which patients received busulfan in addition to other myelosuppressive chemotherapy agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy prior to HCT. The incidence has been variable, and interpretation complicated by competing causes of pulmonary toxicity, particularly cytomegalovirus (CMV) pneumonitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 4 of 53 patients (7.5 percent) treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      in the setting of autologous HCT developed pulmonary toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, two of 78 patients (2.5 percent) who received a conditioning regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      prior to autologous HCT developed pulmonary fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 84 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      prior to autologous or allogenic bone marrow transplantation, seven patients had severe lung toxicity (8.3 percent), five of whom had also received irradiation to the lung fields [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/16\">",
"       16",
"      </a>",
"      ]. Five deaths were attributed to alveolar hemorrhage and one to pulmonary embolism.",
"     </li>",
"     <li>",
"      In a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      <span class=\"nowrap\">",
"       (Bu/Cy)",
"      </span>",
"      versus total body irradiation (TBI) as a preparative regimen prior to allogeneic transplantation in 167 patients with leukemia, bronchiolitis obliterans was significantly more frequent after",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      than after TBI (26 versus 5 percent, respectively) after a median of 7 years followup [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/17\">",
"       17",
"      </a>",
"      ]. The number of patients with grade 5 (fatal) interstitial pneumonitis was similar (6 versus 5 percent with",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      and TBI, respectively). The higher rate of pulmonary toxicity in this study compared with others could reflect graft-versus-host disease rather than busulfan toxicity. &nbsp;",
"     </li>",
"     <li>",
"      In an early trial of allogeneic transplantation for acute leukemia using a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      -containing conditioning regimen, 15 of 51 patients developed interstitial pneumonitis at a median of 47 days post transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/18\">",
"       18",
"      </a>",
"      ]. Fourteen of the 15 had CMV detected on biopsy or at autopsy, and 14 of the 15 died (including 13 with presumed CMV pneumonitis). Thus, the contribution of busulfan is unclear. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These reports reflect symptomatic pulmonary toxicity. Subclinical lung damage, however, may develop in a considerably higher number of those exposed to this agent.",
"   </p>",
"   <p>",
"    The factors that contribute to the development of lung toxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    are not well-established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/15\">",
"     15",
"    </a>",
"    ]. In the older literature in which long-term busulfan was administered as monotherapy for CML, most (but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/7\">",
"     7",
"    </a>",
"    ]) cases were described in patients treated for longer than eight months, and the threshold dose beyond which the risk of pulmonary toxicity increased was thought to be approximately 500 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among patients receiving a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -containing conditioning regimen prior to HCT, concurrent or subsequent administration of other potentially toxic modalities, such as other chemotherapeutic agents (eg, additional alkylating agents) or lung irradiation, such as may occur with total body irradiation, may enhance pulmonary toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/16\">",
"     16",
"    </a>",
"    ]. On the other hand, the risk of busulfan-related toxicity (including pulmonary toxicity) may be reduced by the use of pharmacokinetically-based rather than traditional weight-based dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -induced lung injury are unknown, since adequate animal models do not exist. Direct toxicity of busulfan to epithelial lining cells is suggested, but cytologic and histologic findings are nonspecific. Lung biopsy specimens reveal pneumocyte dysplasia (degeneration of type I cells, atypical hyperplastic type II cells), atypical bronchial lining cells, mononuclear cell infiltration, and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/11,22\">",
"     11,22",
"    </a>",
"    ]. Occasionally, severe desquamation of injured epithelial cells into alveolar spaces leads to diffuse alveolar damage in a pattern suggestive of alveolar proteinosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/23\">",
"     23",
"    </a>",
"    ]. Organizing pneumonia and diffuse alveolar damage have been described in patients who received busulfan among other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/24\">",
"     24",
"    </a>",
"    ]. In a single case report, pulmonary alveolar hemorrhage developed after hematopoietic cell transplantation in a patient who received busulfan in combination with other agents as part of a conditioning regimen, although it is not known whether busulfan was causative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -induced pulmonary injury commonly complain of cough and progressive dyspnea on exertion. Fever and weight loss may also be present. Pulmonary examination may be unrevealing or may demonstrate basilar crackles.",
"   </p>",
"   <p>",
"    In patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    monotherapy, the interval between initiation of therapy and onset of pulmonary symptoms was usually greater than four years. However, symptoms may occur insidiously after only six weeks or as long as 10 years following onset of busulfan exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/2,14,23,24\">",
"     2,14,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time frame for pulmonary toxicity among patients receiving high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    (most often 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for four days) as a component of the conditioning regimen for autologous or allogeneic stem cell transplantation is less well established, given that these patient often have competing causes of interstitial pneumonitis, including graft-versus-host disease and interstitial pneumonia syndrome, and lung infection due to cytomegalovirus (CMV). However, in most cases, pulmonary toxicity is manifest between 30 days and one year posttransplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28639968\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients who develop dyspnea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cough following HCT is designed to evaluate the severity of respiratory impairment and the various potential causes of these symptoms.",
"   </p>",
"   <p>",
"    The differential diagnosis includes infection (eg, cytomegalovirus and other lung infections), idiopathic pneumonia syndrome, organizing pneumonia, pulmonary alveolar hemorrhage, volume",
"    <span class=\"nowrap\">",
"     overload/heart",
"    </span>",
"    failure, and pulmonary alveolar proteinosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=see_link&amp;anchor=H88599909#H88599909\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Post hematopoietic cell engraftment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5626886\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests, such as complete blood counts, coagulation tests, liver function tests, B-type natriuretic peptide (BNP), and blood cultures are nonspecific and function to exclude other processes rather than to identify evidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    toxicity. Other studies such as serologic tests for viral or fungal infection may be indicated based on specific features of the patient presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chest imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs may be normal or may reveal bibasilar reticular opacities. High resolution computed tomography is often obtained as it is more sensitive than conventional chest radiographs and it allows better clarification of the pattern of radiographic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. Patterns associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    toxicity include ground glass opacities, asymmetric peripheral and peribronchial consolidation, centrilobular nodules, reticulation, and dependent consolidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/24\">",
"     24",
"    </a>",
"    ]. However, in virtually all cases, busulfan was combined with other agents, so it is difficult to know whether any particular agent was uniquely responsible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with lung toxicity following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    therapy, pulmonary function tests (PFTs) show a reduction in the diffusing capacity for carbon monoxide (DLCO) and eventually a restrictive ventilatory defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. One prospective study, for example, evaluated changes in PFTs among 43 patients before and after a conditioning regimen of busulfan plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    prior to HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/28\">",
"     28",
"    </a>",
"    ]. DLCO was decreased by 20 and 15 percent upon follow-up examination 3 and 12 months after transplant, respectively. In addition, the ratio of the forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) to the forced vital capacity (FVC) increased, reflecting the development of a restrictive pattern. After five years, baseline values were restored for all variables, except in four patients who developed obliterative bronchiolitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link&amp;anchor=H14#H14\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\", section on 'Bronchiolitis obliterans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=see_link&amp;anchor=H464750157#H464750157\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Airflow obstruction and bronchiolitis obliterans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28640048\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy and bronchoalveolar lavage (BAL) are performed in most patients with suspicion of drug-induced pulmonary toxicity, largely to exclude other processes such as infection (eg, cytomegalovirus), lymphangitic spread of tumor, and diffuse alveolar hemorrhage. Both lymphocytosis and neutrophilia have been reported in BAL from patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -induced pulmonary toxicity, in addition to atypia in type I pneumocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/22,31\">",
"     22,31",
"    </a>",
"    ]. Diffuse alveolar hemorrhage has been associated with busulfan in a case report, but is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/25\">",
"     25",
"    </a>",
"    ]. However, it is not uncommon for the BAL findings to be normal. The technique of BAL and the evaluation of diffuse alveolar hemorrhage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=see_link&amp;anchor=H12#H12\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cellular atypia may be seen on BAL in patients who have been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    (or other alkylating agents). While the presence of cellular atypia establishes that the patient has had significant exposure to busulfan, it does not confirm that the patient&rsquo;s symptoms and radiographic abnormalities are due to the drug. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis and pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients with chronic myelogenous leukemia who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    for several years, several case reports described a clinical presentation of pulmonary alveolar proteinosis (PAP) with periodic acid-Schiff (PAS)-positive lipoproteinaceous granular material and foamy macrophages on BAL or transbronchial biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, PAP has also developed in patients with CML who were not treated with busulfan and may actually be a feature of the underlying disease related to macrophage dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Furthermore, this complication has not been seen in patients receiving busulfan as a component of the conditioning regimen for HCT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8168?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -induced pulmonary toxicity is usually established clinically based upon a history of drug exposure and a compatible clinical picture, but it is a diagnosis of exclusion. The differential diagnosis includes infection, radiation-induced lung injury, pulmonary edema, lung involvement by an underlying malignancy, pulmonary alveolar proteinosis, pulmonary thromboembolism, graft-versus-host disease (in patients who have undergone hematopoietic stem cell transplantation), and pulmonary hemorrhage.",
"   </p>",
"   <p>",
"    Laboratory testing (eg, complete cell counts, coagulation tests, B-type natriuretic peptide (BNP), blood cultures, sputum cultures, viral culture and viral serology) is used to determine whether other disease processes are contributing to the patient's respiratory compromise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=see_link&amp;anchor=H194946070#H194946070\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Pulmonary infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchoalveolar lavage is used to exclude infection, pulmonary alveolar proteinosis, and pulmonary hemorrhage, while lung biopsy may be used to exclude lung involvement by malignancy and infection not identified by less invasive tests. As observed with other cytotoxic drug-induced lung disease, cytologic and histomorphologic findings due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    -induced pulmonary toxicity are nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis and pathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8168?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H13#H13\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Bronchoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    associated lung toxicity is not known. Given that most patients with busulfan-induced pulmonary toxicity received the drug weeks to months before the diagnosis of lung toxicity, therapy is mainly supportive and includes supplemental oxygen as needed, vaccinations against influenza and pneumococcal infection, and pulmonary rehabilitation. Some spontaneous improvement may occur. As an example, in a series of 43 patients who received conditioning with busulfan and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    prior to allogeneic HCT, a 10 percent decrease in lung volumes and a 20 percent decrease in diffusing capacity were found at three months after HCT, but subsequently normal lung volumes and a partial improvement in DLCO were noted at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/28\">",
"     28",
"    </a>",
"    ]. In a followup study, lung volumes and gas transfer were decreased in 43 patients at one year after busulfan, but normalized by five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Anecdotal reports, almost all of which involve patients who were receiving long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    for CML, describe responses to systemic glucocorticoids, but no controlled studies are available and some patients had only a transient response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37415/abstract/1,23,24,36,37\">",
"     1,23,24,36,37",
"    </a>",
"    ]. For patients who are believed to have busulfan toxicity following HCT, the decision to initiate glucocorticoid therapy usually depends on the severity and rapidity of worsening of pulmonary impairment and on the pulmonary histopathology, if known. As an example, if the patient has a known histopathology that is usually responsive to glucocorticoids (eg, organizing pneumonia, nonspecific interstitial pneumonitis), it is reasonable to use glucocorticoid therapy as would be done for that disease in other clinical settings. In addition, for patients with rapid deterioration in lung function and no evidence of infection, we initiate a trial of oral glucocorticoids with the equivalent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. If no response is seen within four to six weeks, the glucocorticoids are tapered and stopped. The approach to glucocorticoid therapy for pulmonary toxicity associated with antineoplastic therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent tapering of glucocorticoid therapy is based on the clinical response, as assessed by symptoms, pulse oxygen saturation, pulmonary function tests, and radiographic imaging. The potential adverse effects of glucocorticoid therapy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The issue of rechallenge with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    in patients with prior lung toxicity has not been directly assessed, but it is generally not clinically relevant as administration of busulfan is a one-time event in patients undergoing HCT. (See",
"    <a class=\"local\" href=\"#H1147763\">",
"     'Epidemiology and risk factors'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147771\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic pulmonary injury is thought to occur in fewer than 8 percent of patients who receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ; however, the true incidence is unknown. Modern data examining the risk of pulmonary toxicity are derived from patients receiving busulfan in addition to other myelosuppressive chemotherapy agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy prior to hematopoietic cell transplantation, where the incidence has been variable, and interpretation complicated by competing causes of pulmonary toxicity, particularly cytomegalovirus (CMV) pneumonitis. (See",
"      <a class=\"local\" href=\"#H1147763\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cytologic and histologic findings in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      -induced pulmonary toxicity are nonspecific. Lung biopsy specimens reveal pneumocyte dysplasia (degeneration of type I cells, atypical hyperplastic type II cells), atypical bronchial lining cells, mononuclear cell infiltration, and fibrosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis and pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      -induced pulmonary injury typically include cough and progressive dyspnea on exertion. Fever and weight loss may be present. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On high resolution computed tomography (HRCT), radiographic patterns associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      lung toxicity include ground glass opacities, asymmetric peripheral and peribronchial consolidation, centrilobular nodules, and increased reticular markings. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chest imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      -induced pulmonary toxicity is usually established clinically and is a diagnosis of exclusion. The differential diagnosis includes infection (particularly with CMV), radiation-induced lung injury, pulmonary edema, lung involvement by an underlying malignancy, pulmonary alveolar proteinosis, and pulmonary hemorrhage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected lung toxicity due to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , the main purpose of bronchoalveolar lavage (BAL) is to exclude other processes such as infection, pulmonary alveolar proteinosis, diffuse alveolar hemorrhage, and metastatic spread of the underlying cancer. A lung biopsy is indicated when the patient has progressive or severe disease and the cause of the pneumonitis is uncertain. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H11#H11\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      -induced pulmonary toxicity, the main therapeutic intervention is supportive care. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate to severe",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      -induced pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than 4 percent decrease from baseline, or worsening clinical status) and no evidence of infection, we suggest administering systemic glucocorticoid therapy, rather than observation and supportive care alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The initial dose is the equivalent of oral&nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily; intravenous glucocorticoids may be used initially. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H18#H18\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/1\">",
"      OLINER H, SCHWARTZ R, RUBIO F, DAMESHEK W. Interstitial pulmonary fibrosis following busulfan therapy. Am J Med 1961; 31:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/2\">",
"      Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986; 133:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/3\">",
"      Smalley RV, Wall RL. Two cases of busulfan toxicity. Ann Intern Med 1966; 64:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/4\">",
"      Heard BE, Cooke RA. Busulphan lung. Thorax 1968; 23:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/5\">",
"      Burns WA, McFarland W, Matthews MJ. Busulfan-induced pulmonary disease. Report of a case and review of the literature. Am Rev Respir Dis 1970; 101:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/6\">",
"      Podoll LN, Winkler SS. Busulfan lung. Report of two cases and review of the literature. Am J Roentgenol Radium Ther Nucl Med 1974; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/7\">",
"      Hankins DG, Sanders S, MacDonald FM, Drage CW. Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard. Chest 1978; 73:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/8\">",
"      Schallier D, Impens N, Warson F, et al. Additive pulmonary toxicity with melphalan and busulfan therapy. Chest 1983; 84:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/9\">",
"      Pearl M. Busulfan lung. Am J Dis Child 1977; 131:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/10\">",
"      Oakhill A, Green ID, Knowlson GT, et al. Busulphan lung in childhood. J Clin Pathol 1981; 34:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/11\">",
"      Jochelson M, Tarbell NJ, Freedman AS, et al. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 1990; 6:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/12\">",
"      Fernandez HF, Tran HT, Albrecht F, et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/13\">",
"      H&auml;nel M, Kr&ouml;ger N, Sonnenberg S, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002; 81:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/14\">",
"      Ulrickson M, Aldridge J, Kim HT, et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant 2009; 15:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/15\">",
"      Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000; 25:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/16\">",
"      Crilley P, Topolsky D, Styler MJ, et al. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplant 1995; 15:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/17\">",
"      Ringd&eacute;n O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/18\">",
"      Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/19\">",
"      Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982; 9:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/20\">",
"      Sostman HD, Matthay RA, Putman CE. Cytotoxic drug-induced lung disease. Am J Med 1977; 62:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/21\">",
"      Perkins JB, Kim J, Anasetti C, et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/22\">",
"      Vergnon JM, Boucheron S, Riffat J, et al. [Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases]. Rev Med Interne 1988; 9:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/23\">",
"      Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/24\">",
"      Cleverley JR, Screaton NJ, Hiorns MP, et al. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/25\">",
"      Worth L, Tran H, Petropoulos D, et al. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone Marrow Transplant 1999; 24:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/26\">",
"      Lund MB, Brinch L, Kongerud J, Boe J. Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide. Eur Respir J 2004; 23:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/27\">",
"      Padley SP, Adler B, Hansell DM, M&uuml;ller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol 1992; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/28\">",
"      Lund MB, Kongerud J, Brinch L, et al. Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide. Eur Respir J 1995; 8:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/29\">",
"      Bruno B, Souillet G, Bertrand Y, et al. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004; 34:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/30\">",
"      Lund MB, Brinch L, Kongerud J, Boe J. Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide. Eur Respir J 2004; 23:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/31\">",
"      Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/32\">",
"      Ito K, Iwabe K, Okai T, et al. Rapidly progressive pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Intern Med 1994; 33:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/33\">",
"      Aymard JP, Gyger M, Lavallee R, et al. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung? Cancer 1984; 53:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/34\">",
"      Tsushima K, Koyama S, Saitou H, et al. Pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Respiration 1999; 66:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/35\">",
"      Ohmachi K, Ogiya D, Morita F, et al. Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase. Tokai J Exp Clin Med 2008; 33:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/36\">",
"      Kobayashi S, Ishikawa M, Wakabayashi Y, et al. [Busulfan lung exacerbated during steroid therapy: a review of Japanese literature]. Rinsho Ketsueki 1990; 31:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37415/abstract/37\">",
"      Korbitz, BC, Reiquam, CW. Busulfan in chronic granulocytic leukemia, a spectrum of clinical considerations. Clin Med 1969; 76:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4348 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6AB2C9D7C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37415=[""].join("\n");
var outline_f36_34_37415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1147771\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147763\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28639968\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5626886\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chest imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28640048\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147771\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17050?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_34_37416="Cirrhotic bile stained liver in a 52-year-old";
var content_f36_34_37416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cirrhotic bile stained liver in a 52 year-old woman with rapidly progressive fatal non A non B hepatitis (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This specimen was obtained at autopsy. The sinusoids are dilated and filled with bile-stained macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37416=[""].join("\n");
var outline_f36_34_37416=null;
var title_f36_34_37417="Bipolar disorder in adults: Treating major depression with antidepressants";
var content_f36_34_37417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults: Treating major depression with antidepressants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37417/contributors\">",
"     William V Bobo, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37417/contributors\">",
"     Richard C. Shelton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37417/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37417/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/34/37417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20879315\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antidepressants for acute and maintenance treatment of bipolar depression is controversial because of concerns that these drugs are not effective and may harm patients by causing switches from depression to mania as well as rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Nevertheless, antidepressants (",
"    <a class=\"graphic graphic_table graphicRef53818 \" href=\"mobipreview.htm?24/43/25278\">",
"     table 1",
"    </a>",
"    ) are the most commonly prescribed drugs for bipolar depression. Studies of bipolar patients in the United States (N = 7760) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/4\">",
"     4",
"    </a>",
"    ] and Europe (N = 2231) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/5\">",
"     5",
"    </a>",
"    ] found that an antidepressant had been prescribed for 50 and 81 percent; this may be due in part to the limited efficacy and tolerability of other treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the efficacy of antidepressants for patients with bipolar major depression and the risk of these drugs causing a switch in polarity; the risk of rapid cycling is discussed separately. Choosing a medication regimen to treat bipolar major depression, mania, hypomania, and mixed episodes is also discussed separately, as is maintenance treatment of bipolar disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link&amp;anchor=H190200740#H190200740\">",
"       \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\", section on 'Antidepressants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1837258\">",
"    <span class=\"h1\">",
"     DEFINITION OF BIPOLAR DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 2",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 3",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 4",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/7\">",
"     7",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879322\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879330\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of antidepressants collectively (as a drug class) for short term (eg, 4 to 26 weeks) treatment of bipolar I or II major depression is not clear, due to mixed results from meta-analyses of heterogeneous randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, individual trials indicate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/10\">",
"     10",
"    </a>",
"    ], whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    generally is not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two meta-analyses of randomized trials that compared antidepressants with placebo for bipolar I or II depression came to different conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four heterogeneous, randomized trials (662 patients with bipolar depression; 69 percent were treated in a single trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/10\">",
"       10",
"      </a>",
"      ]) found that response occurred in more patients who received an antidepressant (deprenyl,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32215?source=see_link\">",
"       tranylcypromine",
"      </a>",
"      ) than placebo (58 versus 34 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A subsequent meta-analysis of five heterogeneous randomized trials (906 patients with bipolar depression; 84 percent were treated in two trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]) found that response (improvement from baseline on the depression rating scale &ge;50 percent) was comparable for patients who received antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ) or placebo (42 versus 38 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The large heterogeneity in each meta-analysis (perhaps due in part to the different drugs that were studied in the trials) suggests that the results may not be meaningful (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39609?source=see_link&amp;anchor=H78553636#H78553636\">",
"     \"Systematic review and meta-analysis\", section on 'Heterogeneity'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thus, it is more informative to examine the largest, most rigorous randomized trials individually:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An eight-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (25 or 50 mg per day) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      to placebo plus olanzapine in 437 patients with bipolar depression; response occurred in more patients who received fluoxetine than placebo (56 versus 30 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/10\">",
"       10",
"      </a>",
"      ]. A second randomized trial (N = 410) found that improvement of depressive symptoms was greater with fluoxetine plus olanzapine than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 26-week randomized trial assigned 366 patients with bipolar depression to an antidepressant (either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      10 to 40 mg per day or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      sustained release 150 to 375 mg per day) or placebo; all patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a second-generation antipsychotic (most patients also received a psychosocial intervention). Response was comparable for patients who received antidepressants and patients who received placebo (32 and 38 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An eight-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      monotherapy (20 mg per day) with placebo in 248 patients with bipolar depression; response was comparable for paroxetine and placebo (55 and 53 percent of patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most antidepressants have not been adequately studied in patients with bipolar depression, and it is not known whether antidepressants vary in their efficacy (only a few head to head comparisons have been conducted).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H672545\">",
"    <span class=\"h3\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon a randomized trial, depressed bipolar patients with comorbid anxiety are less likely to respond to treatment than patients without anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/15\">",
"     15",
"    </a>",
"    ]. Prospective observational studies suggest that in patients with bipolar major depression, a positive response to antidepressants plus an antimanic drug (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ) may be more likely in patients with a prior positive response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/16\">",
"     16",
"    </a>",
"    ], whereas a poor response may be more likely in patients with concurrent manic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/17\">",
"     17",
"    </a>",
"    ] and a prior history of multiple hypomanic episodes (eg, five or more) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H672688\">",
"    <span class=\"h3\">",
"     Bipolar II depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon randomized trials, the benefits of antidepressants for acute bipolar II depression and bipolar I depression do not differ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. As an example, a randomized trial found that response to antidepressants plus antimanic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) was comparable in patients with bipolar II depression (N = 54) and patients with bipolar I depression (N = 118) (20 and 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879337\">",
"    <span class=\"h2\">",
"     Maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with bipolar depression who are treated with an antidepressant and then recover, maintenance treatment with antidepressants generally does not appear to reduce the risk of depressive relapses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five randomized trials (246 patients with bipolar I or II disorder) compared antidepressants plus antimanic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ) with antimanic drugs alone; treatment lasted for at least six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/19\">",
"       19",
"      </a>",
"      ]. Depressive relapses were comparable for the two groups (RR 0.8, 95% CI 0.6-1.3); heterogeneity across studies was not reported.",
"     </li>",
"     <li>",
"      Patients with bipolar major depression (N = 70) who recovered during treatment with antidepressants plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , divalproex,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or second-generation antipsychotics were randomly assigned to open-label continuation or discontinuation of the antidepressant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/18\">",
"       18",
"      </a>",
"      ]. At one year follow-up, the mean number of depressive relapses was comparable for antidepressant continuation and discontinuation (0.6 and 0.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One randomized trial compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    monotherapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    monotherapy, and placebo in 81 bipolar II patients who recovered from an episode of major depression with open label fluoxetine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/20\">",
"     20",
"    </a>",
"    ]. Although the mean time to relapse was longer with fluoxetine than lithium, the time to relapse with fluoxetine and placebo were comparable; thus, it is not clear that fluoxetine was beneficial. In addition, antidepressant monotherapy is generally avoided in bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879358\">",
"    <span class=\"h1\">",
"     RISK OF SWITCHING TO MANIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bipolar major depression with antidepressants remains controversial because of concerns that these drugs cause patients to switch polarity directly from depression to",
"    <span class=\"nowrap\">",
"     mania/hypomania,",
"    </span>",
"    or within a short time after the depressive episode has remitted (eg, two to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/23\">",
"     23",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, switching is a basic phenomenon in bipolar disorder that often occurs in the absence of antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/2,24\">",
"     2,24",
"    </a>",
"    ], and the evidence indicates that antidepressants may not increase switching during acute or maintenance treatment. As an example, a meta-analysis of randomized trials and observational studies (7915 bipolar patients) found that the risk of",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    was comparable for patients who were exposed to antidepressants and patients who were not (15 and 14 percent); heterogeneity was not reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the evidence suggests that antidepressants collectively (as a drug class) do not induce switching polarity, the risk of treatment emergent mania may nevertheless exist for specific antidepressants; patients who are treated with antidepressant monotherapy; and patient subgroups, including certain genotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If manic, hypomanic or mixed symptoms emerge during antidepressant treatment, antidepressants should be abruptly stopped and antimanic treatments should be optimized (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237966\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with bipolar major depression, acute (eg, 4 to 26 weeks) treatment with antidepressants in randomized trials does not appear to increase the risk of switching to",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of six homogeneous randomized trials (1026 patients) found that switch rates were comparable for patients who received antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ) or placebo (8 and 7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/8\">",
"       8",
"      </a>",
"      ]. Most patients received concomitant treatment with another drug such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , or a second-generation antipsychotic.",
"     </li>",
"     <li>",
"      A meta-analysis of five homogeneous randomized trials (779 patients) found that switch rates were comparable for patients who received antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ) or placebo (4 and 5 percent); 76 percent received concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, randomized trials typically exclude sicker bipolar patients, including those with rapid cycling, psychiatric comorbidity (eg, substance use disorder), comorbid general medical disorders, and suicidality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, these trials may not generalize to many patients; as an example, comorbidity in bipolar disorder appears to be the rule rather than the exception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, randomized trials may provide closer monitoring than occurs in routine clinical care, permitting study investigators to discontinue antidepressants prior to onset of full blown",
"    <span class=\"nowrap\">",
"     manic/hypomanic",
"    </span>",
"    episodes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237973\">",
"    <span class=\"h2\">",
"     Maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term treatment (eg, &ge;6 months) with antidepressants plus antimanic drugs in bipolar patients does not appear to cause treatment emergent mania:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five randomized trials (246 patients with bipolar disorder) compared antidepressants plus antimanic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ) with maintenance treatments alone; patients were treated for at least six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/19\">",
"       19",
"      </a>",
"      ]. Treatment emergent mania was comparable for the two groups (RR 1.4, 95% CI 0.8-2.3); heterogeneity was not reported.",
"     </li>",
"     <li>",
"      Patients with bipolar major depression (N = 70) who recovered during treatment with antidepressants plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , divalproex,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or second-generation antipsychotics were randomly assigned to open-label continuation or discontinuation of the antidepressant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/18\">",
"       18",
"      </a>",
"      ]. At one year follow-up, the mean number of",
"      <span class=\"nowrap\">",
"       manic/hypomanic",
"      </span>",
"      relapses was comparable for antidepressant continuation and discontinuation (0.3 and 0.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171998108\">",
"    <span class=\"h2\">",
"     Pharmacologic risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of switching in patients with bipolar depression who are treated with antidepressants may vary according to the antidepressant class or specific drug that is used. In addition, prescribing antidepressants in conjunction with antimanic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , or second-generation antipsychotics) may mitigate the risk of switching to",
"    <span class=\"nowrap\">",
"     mania/hypomania.",
"    </span>",
"   </p>",
"   <p>",
"    Case reports describe",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    following abrupt withdrawal of antidepressants, tapered discontinuation, or a decrease in dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879365\">",
"    <span class=\"h3\">",
"     Antidepressant class and specific drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not established whether the risk of treatment emergent",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    varies among specific antidepressants because most drugs have not been compared in head to head trials. However, switching polarity during treatment of bipolar depression appears to occur more often with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    or tricyclics, compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , selective serotonin reuptake inhibitors (SSRIs), and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials found that among patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      plus antimanic drugs (combined N = 95), switching occurred in 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A meta-analysis of six homogeneous randomized trials (370 patients) found that switching occurred in more patients who received tricyclics (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      ) than other antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/5/18518?source=see_link\">",
"       moclobemide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32215?source=see_link\">",
"       tranylcypromine",
"      </a>",
"      ) (10 versus 3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A pooled analysis (415 patients, number of trials not reported) found that switching occurred in more patients who received tricyclics than SSRIs or placebo (11 versus 4 and 4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A meta-analysis of two homogeneous randomized trials (240 patients) found that switching occurred in fewer patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      than other antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ) (5 versus 13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171998695\">",
"    <span class=\"h3\">",
"     Using antimanic drugs to prevent switching",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with bipolar depression who are treated with an antidepressant, we recommend that clinicians concurrently prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , or a second-generation antipsychotic. A review of randomized trials found that switching to mania occurred less often when these concurrent drugs were used with an antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, avoiding antidepressant monotherapy is consistent with North American practice guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/21,35\">",
"     21,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171998864\">",
"    <span class=\"h4\">",
"     Lithium, valproate, or carbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    can be used in conjunction with antidepressants to prevent switching from depression to mania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/21,35\">",
"     21,35",
"    </a>",
"    ]. Evidence for the efficacy of this approach includes the following studies: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pooled analysis of 15 randomized trials (2,691 patients with bipolar or unipolar depression) found that switching polarity during treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      monotherapy occurred in 51 percent, with imipramine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      in 28 percent, and with lithium monotherapy in 21 percent; differences were not analyzed statistically [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/36\">",
"       36",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A 26-week randomized trial compared an antidepressant (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ) with placebo in 366 patients with bipolar depression; the large majority of patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      (the remaining patients received a second-generation antipsychotic). Switching to mania was comparable for antidepressants and placebo (10 and 11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 158 patients found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      prevented switching in bipolar depressed patients treated with tricyclic antidepressants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171998243\">",
"    <span class=\"h4\">",
"     Second-generation antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with bipolar major depression who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    may reduce the risk of switching to",
"    <span class=\"nowrap\">",
"     mania/hypomania:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An",
"      eight-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      with placebo in 423 patients with bipolar I depression, and found that treatment emergent mania was comparable for patients who received the combination and patients who received placebo (7 and 6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 12-week, open-label, randomized continuation trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      with olanzapine monotherapy in 114 patients with bipolar I depression who initially responded to 7 weeks of acute phase therapy with olanzapine plus fluoxetine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/38\">",
"       38",
"      </a>",
"      ]. Treatment emergent mania was comparable for patients who received the combination or olanzapine monotherapy (2 and 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, rates of metabolic side effects and weight gain were higher with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/13/30937?source=see_link\">",
"     olanzapine-fluoxetine",
"    </a>",
"    combination.",
"   </p>",
"   <p>",
"    It is not known if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    reduces the risk of switching from other antidepressants, or if other second-generation antipsychotics reduce the risk of antidepressant-induced switching.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171999377\">",
"    <span class=\"h2\">",
"     Clinical risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Switching from bipolar major depression to",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    during treatment with an antidepressant may be more likely to occur in patients with bipolar I disorder than bipolar II disorder. In a meta-analysis of seven randomized trials and six prospective observational studies that reported treatment emergent mood elevation separately for bipolar I disorder (N = 462) and bipolar II disorder (N = 315), switching occurred in more patients with bipolar I disorder than bipolar II disorder (22 versus 13 percent); there was little to no heterogeneity across studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/39\">",
"     39",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In addition, switching has been associated with early age of onset of bipolar disorder, female sex, history of suicide attempts, symptoms of",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    concurrent with depression, and comorbid substance abuse and anxiety disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/17,24,40-43\">",
"     17,24,40-43",
"    </a>",
"    ]. However, these factors are generally not consistently associated with switching across multiple studies, and are likely to have little predictive power for any specific patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879407\">",
"    <span class=\"h1\">",
"     RISK OF RAPID CYCLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible risks of using antidepressants in bipolar depressed patients include increased mood cycle frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the development of rapid cycling, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link&amp;anchor=H190200740#H190200740\">",
"     \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\", section on 'Antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2771094\">",
"    <span class=\"h1\">",
"     RISK OF SUICIDAL IDEATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants are not associated with new onset suicidal ideation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/45\">",
"     45",
"    </a>",
"    ]. A prospective observational study identified 425 bipolar patients with new onset of major depression that initially did not include suicidal ideation, and followed them for 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/46\">",
"     46",
"    </a>",
"    ]. Suicidal ideation (and two suicide attempts) subsequently developed in 6 percent, but there was no association with initiation of antidepressants or dose increases. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879421\">",
"    <span class=\"h1\">",
"     ROLE OF ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy and safety of antidepressants for bipolar depression remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], we think that there is a limited role for these drugs as adjuncts to antimanic treatments for treating patients with acute episodes of bipolar major depression. This position is consistent with multiple authorities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/3,28,49-52\">",
"     3,28,49-52",
"    </a>",
"    ] and practice guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/21,22,27,35,53\">",
"     21,22,27,35,53",
"    </a>",
"    ]. The choice of a specific medication regimen for acute treatment of bipolar major depression is discussed separately, as is maintenance treatment of bipolar disorder (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879428\">",
"    <span class=\"h2\">",
"     Acute bipolar depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants appear to be effective for some patients with acute bipolar depression, particularly those who have responded favorably to antidepressants in the past without treatment-emergent affective switching or mood cycle acceleration. By contrast, we suggest that clinicians avoid using antidepressants in patients with bipolar major depression who have previously experienced poor outcomes with antidepressant treatment, including patients with a history of treatment-emergent suicidality, switching to",
"    <span class=\"nowrap\">",
"     mania/hypomania,",
"    </span>",
"    or rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/17,24,40-44\">",
"     17,24,40-44",
"    </a>",
"    ]. In addition, we generally avoid antidepressants in patients with concurrent manic symptoms, substance use disorders, early age of onset of bipolar disorder, and a recent history of mania or hypomania (eg, within the last two to three months).",
"   </p>",
"   <p>",
"    Patients with bipolar depression who are treated with an antidepressant should be educated about the signs of treatment-emergent affective switching and the risk of mood cycle acceleration, and should be monitored for these potential complications. This recommendation is especially important for patients who have never received antidepressants, but also applies to patients who were successfully treated with antidepressants in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879435\">",
"    <span class=\"h3\">",
"     Avoiding antidepressant monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that clinicians avoid antidepressant monotherapy in patients with bipolar I or bipolar II major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/54\">",
"     54",
"    </a>",
"    ]. Although a few randomized trials suggest that antidepressant monotherapy may be effective and safe for some patients with bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/55-58\">",
"     55-58",
"    </a>",
"    ], most were small and lacked a placebo control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The largest randomized trial (N = 248 patients with bipolar depression) found that response was comparable for patients who received either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    monotherapy or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, combining an antimanic drug with the antidepressant appears to decrease the rate of switching polarity (see",
"    <a class=\"local\" href=\"#H171998695\">",
"     'Using antimanic drugs to prevent switching'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879443\">",
"    <span class=\"h2\">",
"     Maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For bipolar major depression that remits with an antidepressant plus an antimanic drug, it is unclear how long antidepressants should be continued. Generally, we continue antidepressants for approximately two to six months after remission of the depressive syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/21,22,59\">",
"     21,22,59",
"    </a>",
"    ]. However, we attempt to avoid maintenance treatment with antidepressants in patients with a history of antidepressant-associated switch from depression to",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    or increases in mood cycle frequency; a current course of rapid cycling; and a history of frequent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe manic episodes, including episodes complicated by psychotic features. However, bipolar patients who repeatedly suffer depressive symptoms in the absence of antidepressants may benefit from longer treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674333\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;If long-term adjunctive antidepressants are used, mood symptoms should be assessed for increases in mood cycling, including more frequent depressive episodes or depressive symptoms. Self-report mood symptom rating scales may help in monitoring patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mood Disorder Questionnaire &ndash; This 15-item instrument is the most widely used measure that screens for episodes of mania and hypomania, and has good psychometric properties (",
"      <a class=\"graphic graphic_table graphicRef53409 \" href=\"mobipreview.htm?19/63/20477\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/60-63\">",
"       60-63",
"      </a>",
"      ]. The Mood Disorder Questionnaire does not generate a diagnosis of mania or hypomania; thus, patients who screen positive require a clinical interview to make the diagnosis.",
"     </li>",
"     <li>",
"      Patient Health Questionnaire - 9 Item (PHQ-9). This 9-item instrument screens for episodes of major depression, provides a diagnosis, and has good psychometric properties (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/64\">",
"       64",
"      </a>",
"      ]. The PHQ-9 is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=see_link&amp;anchor=H100014092#H100014092\">",
"       \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Patient Health Questionnaire - Nine Item'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is not known whether screening instruments improve outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20879457\">",
"    <span class=\"h2\">",
"     Tapering and discontinuing antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants should generally be tapered slowly (eg, over two to four weeks) to avoid discontinuation syndrome symptoms and limit the risk of depressive relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37417/abstract/65\">",
"     65",
"    </a>",
"    ]. However, if treatment emergent",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    occurs during antidepressant treatment, the antidepressant should be abruptly stopped and antimanic treatments should be optimized. The discontinuation syndrome and antimanic drugs are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85352872\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antidepressants (",
"      <a class=\"graphic graphic_table graphicRef53818 \" href=\"mobipreview.htm?24/43/25278\">",
"       table 1",
"      </a>",
"      ) are the most commonly prescribed drugs for bipolar patients. The use of antidepressants for acute and maintenance treatment of bipolar depression is controversial because of concerns that these drugs are not effective, and may harm patients by causing switches from depression to mania as well as rapid cycling. (See",
"      <a class=\"local\" href=\"#H20879315\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medication regimens for bipolar patients are selected according to the phase of the illness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The efficacy of antidepressants collectively (as a drug class) for short term (eg, 4 to 26 weeks) treatment of bipolar I or II major depression is not clear, due to mixed results from meta-analyses of heterogeneous randomized trials. However, individual trials indicate that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      is effective, whereas",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      generally is not. (See",
"      <a class=\"local\" href=\"#H20879330\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bipolar depression who are treated with an antidepressant and then recover, maintenance treatment with antidepressants generally does not appear to reduce the risk of depressive relapses. (See",
"      <a class=\"local\" href=\"#H20879337\">",
"       'Maintenance treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Switching polarity is a basic phenomenon in bipolar disorder that often occurs in the absence of antidepressant treatment, and the evidence indicates that antidepressants collectively may not increase switching from bipolar major depression to",
"      <span class=\"nowrap\">",
"       mania/hypomania",
"      </span>",
"      during acute or maintenance treatment. However, the risk of treatment emergent mania may nevertheless exist for specific antidepressants, patients who are treated with antidepressant monotherapy, and patient subgroups. (See",
"      <a class=\"local\" href=\"#H20879358\">",
"       'Risk of switching to mania'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not established whether the risk of switching varies according to specific antidepressants. However, across different studies, the switch rate for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      was 13 to 15 percent, for tricyclics was 10 to 11 percent, and for selective serotonin reuptake inhibitors (SSRIs),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , or placebo was 3 to 5 percent. (See",
"      <a class=\"local\" href=\"#H20879365\">",
"       'Antidepressant class and specific drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antidepressant monotherapy should be avoided. Prescribing an antidepressant in conjunction with an antimanic drug such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , or a second-generation antipsychotic appears to decrease the probability of switching from bipolar major depression to",
"      <span class=\"nowrap\">",
"       mania/hypomania.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H20879435\">",
"       'Avoiding antidepressant monotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H171998695\">",
"       'Using antimanic drugs to prevent switching'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Switching from bipolar major depression to",
"      <span class=\"nowrap\">",
"       mania/hypomania",
"      </span>",
"      during treatment with an antidepressant may be more likely to occur in patients with bipolar I disorder than bipolar II disorder. (See",
"      <a class=\"local\" href=\"#H171999377\">",
"       'Clinical risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If manic, hypomanic or mixed symptoms emerge during antidepressant treatment, antidepressants should be abruptly stopped and antimanic treatments should be optimized. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The possible risks of using antidepressants in bipolar depressed patients include increased mood cycle frequency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the development of rapid cycling. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link&amp;anchor=H190200740#H190200740\">",
"       \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\", section on 'Antidepressants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antidepressants are not associated with new onset suicidal ideation. (See",
"      <a class=\"local\" href=\"#H2771094\">",
"       'Risk of suicidal ideation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a limited role for antidepressants as adjuncts to antimanic drugs for treating patients with bipolar major depression. (See",
"      <a class=\"local\" href=\"#H20879421\">",
"       'Role of antidepressants'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/1\">",
"      Fountoulakis KN. An update of evidence-based treatment of bipolar depression: where do we stand? Curr Opin Psychiatry 2010; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/2\">",
"      Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 2008; 118:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/3\">",
"      Salvi V, Fagiolini A, Swartz HA, et al. The use of antidepressants in bipolar disorder. J Clin Psychiatry 2008; 69:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/4\">",
"      Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007; 58:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/5\">",
"      Greil W, H&auml;berle A, Haueis P, et al. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 2012; 136:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/6\">",
"      Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: an update. J Affect Disord 2008; 109:21.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/8\">",
"      Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/9\">",
"      Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/10\">",
"      Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/11\">",
"      Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/12\">",
"      Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/13\">",
"      McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/14\">",
"      Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/15\">",
"      Tohen M, Calabrese J, Vieta E, et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord 2007; 104:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/16\">",
"      Pacchiarotti I, Valent&iacute; M, Bonnin CM, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol 2011; 21:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/17\">",
"      Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007; 164:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/18\">",
"      Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010; 71:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/19\">",
"      Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008; 118:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/20\">",
"      Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010; 167:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/21\">",
"      Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/22\">",
"      Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/23\">",
"      Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/24\">",
"      Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 2010; 35:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/25\">",
"      Tondo L, V&aacute;zquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010; 121:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/26\">",
"      Daray FM, Thommi SB, Ghaemi SN. The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord 2010; 12:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/27\">",
"      Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     Wang PW, Ketter TA. Management of acute major depressive episodes in bipolar disorders. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA.  (Ed), American Psychiatric Publishing, Inc., Washington, DC 2010. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/29\">",
"      McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/30\">",
"      Thompson WK, Kupfer DJ, Fagiolini A, et al. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry 2006; 67:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/31\">",
"      Andrade C. Antidepressant-withdrawal mania:a critical review and synthesis of the literature. J Clin Psychiatry 2004; 65:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/32\">",
"      Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/33\">",
"      Vieta E, Martinez-Ar&aacute;n A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/34\">",
"      Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/35\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     Rouillon F, LeJoyeux M, Filteau MJ. Unwanted effects of long-term treatment. In: Long-Term Treatment of Depression, Montgomery SA, Rouillon F.  (Eds), John Wiley &amp; Sons, Chichester 1992. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/37\">",
"      Bottlender R, Rudolf D, Strauss A, M&ouml;ller HJ. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/38\">",
"      Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009; 29:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/39\">",
"      Bond DJ, Noronha MM, Kauer-Sant'Anna M, et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008; 69:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/40\">",
"      Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003; 5:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/41\">",
"      Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009; 166:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/42\">",
"      Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord 2003; 5:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/43\">",
"      Valent&iacute; M, Pacchiarotti I, Bonn&iacute;n CM, et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry 2012; 73:e271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/44\">",
"      Sachs GS, Dupuy JM, Wittmann CW. The pharmacologic treatment of bipolar disorder. J Clin Psychiatry 2011; 72:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/45\">",
"      Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/46\">",
"      Bauer MS, Wisniewski SR, Marangell LB, et al. Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2006; 67:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/47\">",
"      Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry 2008; 165:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/48\">",
"      Yerevanian BI, Koek RJ, Mintz J, Akiskal HS. Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants. J Affect Disord 2007; 103:13.",
"     </a>",
"    </li>",
"    <li>",
"     Goodwin FK, Jamison KR. Medical treatment of depression. In: Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007. p.747.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/50\">",
"      Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/51\">",
"      Frye MA, Ha K, Kanba S, et al. International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry 2011; 72:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/52\">",
"      International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression. J Clin Psychiatry 2008; 69:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/53\">",
"      Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004; 38:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/54\">",
"      Malhi GS, Adams D, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009; :27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/55\">",
"      Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. J Affect Disord 2005; 87:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/56\">",
"      Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/57\">",
"      Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008; 28:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/58\">",
"      Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/59\">",
"      Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000; Spec No:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/60\">",
"      Chessick CA, Dimidjian S. Screening for bipolar disorder during pregnancy and the postpartum period. Arch Womens Ment Health 2010; 13:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/61\">",
"      Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/62\">",
"      Hirschfeld RM. The mood disorder questionnaire: its impact on the field [corrected]. Depress Anxiety 2010; 27:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/63\">",
"      Hirschfeld RM, Cass AR, Holt DC, Carlson CA. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 2005; 18:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/64\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37417/abstract/65\">",
"      Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167:934.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14655 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37417=[""].join("\n");
var outline_f36_34_37417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H85352872\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20879315\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1837258\">",
"      DEFINITION OF BIPOLAR DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20879322\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20879330\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H672545\">",
"      - Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H672688\">",
"      - Bipolar II depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20879337\">",
"      Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20879358\">",
"      RISK OF SWITCHING TO MANIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H237966\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H237973\">",
"      Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H171998108\">",
"      Pharmacologic risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20879365\">",
"      - Antidepressant class and specific drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H171998695\">",
"      - Using antimanic drugs to prevent switching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H171998864\">",
"      Lithium, valproate, or carbamazepine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H171998243\">",
"      Second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H171999377\">",
"      Clinical risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20879407\">",
"      RISK OF RAPID CYCLING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2771094\">",
"      RISK OF SUICIDAL IDEATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20879421\">",
"      ROLE OF ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20879428\">",
"      Acute bipolar depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20879435\">",
"      - Avoiding antidepressant monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20879443\">",
"      Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H674333\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20879457\">",
"      Tapering and discontinuing antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85352872\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14655\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14655|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/43/25278\" title=\"table 1\">",
"      Pharmacology antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 4\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/63/20477\" title=\"table 5\">",
"      Mood disorder questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/12/14541\" title=\"table 6\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=related_link\">",
"      Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39609?source=related_link\">",
"      Systematic review and meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_34_37418="Nonresponse and resistance to clopidogrel";
var content_f36_34_37418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonresponse and resistance to clopidogrel",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     Charles H Hennekens, MD, DrPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     James L Zehnder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/34/37418/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/34/37418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    resistance\" has been used to describe the occurrence of occlusive cardiovascular disease (CVD) events despite regular intake of this agent at recommended doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Such circumstances are best termed treatment failures, which resemble those with other drugs of life-saving benefit in the treatment of occlusive CVD events, including statins, beta blockers, as well as angiotensin converting enzyme inhibitors and angiotensin receptor blockers.",
"   </p>",
"   <p>",
"    When used for secondary prevention, antiplatelet therapies reduce non-fatal CVD by approximately one-fourth and fatal events by approximately one-sixth. Accordingly, three-fourths of non-fatal and five-sixths of fatal events are not prevented by these drugs. Thus, for any drug of lifesaving benefit that has less than 100 percent efficacy, treatment failure does not necessarily imply \"resistance.\" For CVD events, treatment failures may be due to numerous reasons, only one of which is inability of the antiplatelet agent to specifically block its platelet target [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to nonresponse, treatment failure, and \"resistance\" after the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/10\">",
"     10",
"    </a>",
"    ]. The various uses of this agent in the treatment of patients with CVD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Clopidogrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to nonresponse, treatment failure, and \"resistance\" after the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19401?source=see_link\">",
"     \"Nonresponse and resistance to aspirin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is useful to describe how the terms resistance, nonresponse, and failure, as applied to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , have been utilized in the literature:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clopidogrel treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is a",
"    <strong>",
"     clinical",
"    </strong>",
"    observation, defined as the failure of clopidogrel to prevent occlusive CVD events. Treatment failure could result from noncompliance, events independent of clopidogrel's specific actions on platelet function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate",
"    <span class=\"nowrap\">",
"     response/resistance",
"    </span>",
"    to the antiplatelet action of clopidogrel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clopidogrel resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    resistance has been defined as incomplete blockade of the platelet membrane P2Y12 receptor, as measured by various",
"    <strong>",
"     laboratory",
"    </strong>",
"    tests specific to clopidogrel's mechanism of platelet inhibition, in a patient compliant with clopidogrel therapy. This could result from several circumstances, including variations in the absorption or metabolism of clopidogrel, drug-drug interaction, or in the combination of clopidogrel with its specific platelet receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clopidogrel nonresponse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;nonresponse&rdquo; is nonspecific, as it might imply either the clinical observation of treatment failure or the laboratory demonstration of drug resistance. For this reason, the term &ldquo;nonresponse&rdquo; will not be used further in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLOPIDOGREL RESISTANCE TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Available assays and test correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple laboratory methods available for detecting in vitro &ldquo;resistance&rdquo; to therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . These methods all have different definitions for &ldquo;high on-treatment platelet reactivity&rdquo; in the setting of percutaneous coronary intervention (PCI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/13\">",
"     13",
"    </a>",
"    ], and are known to correlate poorly with one another, as illustrated by the following two reports:",
"   </p>",
"   <p>",
"    In a study of four different platelet function tests performed in 116 patients with stable coronary artery disease who were receiving one to seven days of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    prior to diagnostic angiography, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although all four assays (light transmission aggregometry with ADP, whole blood aggregometry with ADP, PFA-100 using the collagen-ADP cartridge, VerifyNow P2Y12) were sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ingestion, none could distinguish reliably between patients who had, or had not, ingested clopidogrel.",
"     </li>",
"     <li>",
"      Agreement between assays to identify patients with insufficient inhibition of platelet aggregation by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further data useful to formulate but not test hypotheses are derived from the Swedish Coronary Angiography and Angioplasty Registry. Patients were identified who had angiographically confirmed stent thrombosis (n = 48) or myocardial infarction (n = 30) while receiving dual antiplatelet therapy within six months of PCI. Results included the following observations, which question the clinical use of platelet function testing to identify patients at high risk for stent thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a substantial overlap in on-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      platelet reactivity, as measured by the VerifyNow assay, between patients with and without on-treatment stent thrombosis.",
"     </li>",
"     <li>",
"      Results with the VASP phosphorylation assay were not related to the occurrence of stent thrombosis or myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16062031\">",
"    <span class=\"h2\">",
"     Normal variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of platelet inhibition seen following use of the second-generation thienopyridine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    varies from patient to patient in a normal or bell-shaped distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The variability in response is such that, when laboratory measurements of platelet aggregation are performed, and depending upon the various definitions that have been employed, 4 to 68 percent of patients treated with clopidogrel do not have an adequate antiplatelet response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/6,18-25\">",
"     6,18-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar observations have been made concerning the degree of platelet inhibition seen after use of the first-generation thienopyridine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . In one study, 143 patients undergoing PCI were evaluated for ADP-induced platelet aggregation at three different times: before treatment with any thienopyridine, after steady state",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    use, and after steady state ticlopidine use. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Responsiveness to either agent followed a normal distribution, with a percentage of nonresponders of 21 for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and 19 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Nonresponders to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      were generally responsive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      and vice versa. Only five patients (4 percent) were poor responders to both agents, suggesting that poor response was drug-specific and not related to the overall class of thienopyridines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ability to predict clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their poor correlation with one another, the available platelet function tests have only modest ability to predict clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This was most clearly shown in the prospective, observational POPULAR study, which measured on-treatment platelet reactivity by six different laboratory methods in 1069 consecutive patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and undergoing elective coronary stent implantation. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one year follow-up, the primary end point (composite of all-cause death, nonfatal acute MI, stent thrombosis, ischemic stroke) occurred significantly more frequently in patients with high versus normal on-treatment platelet reactivity (HTPR) as assessed by the following three tests: light transmission aggregometry (11.7 versus 6.0 percent), VerifyNow (13.3 versus 5.7 percent), and Plateletworks (12.6 versus 6.1 percent). These three tests had only modest ability to discriminate between those having or not having a primary event, with sensitivities of 55 to 63 percent and specificities of 59 to 64 percent. A subsequent study of 2849 patients who received drug-eluting stents failed to identify that HTPR, as measured by VerifyNow, was significantly associated with long-term atherothrombotic risks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The IMPACT-R, Dade PFA",
"      <span class=\"nowrap\">",
"       collagen/ADP,",
"      </span>",
"      and Innovance PFA P2Y were unable to discriminate between patients with or without a primary end point at one year.",
"     </li>",
"     <li>",
"      None of the tests identified patients at risk for bleeding, although a later, noncomparative study using the VerifyNow P2Y12 assay in 310 patients indicated a significantly higher incidence of post-procedural bleeding in those with the strongest in vitro response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Platelet reactivity assessed by multiple electrode aggregometry (MEA) may be more predictive for stent thrombosis following treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a comparative study, sensitivities and specificities for predicting stent thrombosis were 100 and 87, respectively, for MEA and 100 and 37 percent, respectively, for the VASP phosphorylation assay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, the 323",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      low responders (defined in this study as those in the upper quintile according to MEA measurements), as compared with the 1285 normal responders (the remaining subjects), had a significantly higher cumulative incidence of stent thrombosis within six months of the procedure (2.5 versus 0.4 percent, OR 6.5; 95% CI 2.4-17) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/31\">",
"       31",
"      </a>",
"      ]. There also was a significant inverse correlation between MEA values and the time of definite or probable stent thrombosis (in days), with events occurring earlier in the low-responder group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EXPLANATIONS FOR CLOPIDOGREL TREATMENT FAILURE AND RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Noncompliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncompliance with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy is common and offers a plausible explanation for the lack of clinical benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/32\">",
"     32",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a study of stroke patients, the rate of noncompliance with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was 38 percent at one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large cohort of patients with coronary heart disease and stroke, the rate of noncompliance with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was 22 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Variable platelet response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested that variability in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    may be a reflection of baseline individual variability in platelet responses to ADP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/8,35,36\">",
"     8,35,36",
"    </a>",
"    ]. In one study undertaken in 25 consecutive normal non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -treated subjects, platelet responses to 20 micromol ADP prior to administration of clopidogrel predicted the post-clopidogrel ADP response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/35\">",
"     35",
"    </a>",
"    ]. Results in the normal subjects and in 613 consecutive aspirin and clopidogrel-treated patients suggested that \"clopidogrel resistance\" was accounted for by a pre-existing variability in platelet response to ADP, and that this variability was not increased by clopidogrel administration. (See",
"    <a class=\"local\" href=\"#H16062031\">",
"     'Normal variation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A diurnal variation in the degree of platelet inhibition by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    has been described, with inhibition being less strong in the midmorning hours (10:00 AM) when compared with 6:00 AM, 2:00 PM, or 7:00 PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Genetic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in the hepatic enzymes involved in the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (eg, CYP 1A2, CYP3A4, CYP2C19, PON1), within the platelet P2Y12 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/21,25,38,39\">",
"     21,25,38,39",
"    </a>",
"    ], or in those affecting drug transport (eg, ABCB1, also known as MDR1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/40-42\">",
"     40-42",
"    </a>",
"    ], have the potential to affect platelet responses. Clopidogrel is a prodrug that requires oxidation by cytochrome P450 isoenzymes, followed by conversion to the active thiol metabolite by the paraoxonase enzymes PON1 and PON3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/43\">",
"     43",
"    </a>",
"    ], before it can inhibit platelet function. Accordingly, individual variation in enzyme activity (eg, polymorphisms)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    receptor occupancy would be expected to influence the in vitro effect of clopidogrel on platelet aggregation, its clinical effectiveness, as well as the risk of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. In a genome-wide association analysis, it was estimated that 83 percent of individual variance in response to clopidogrel was attributable to genetic effects, but the gene variants investigated up to that time explained only a minor proportion of the response variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3359454\">",
"    <span class=\"h3\">",
"     Cytochrome P450 isoenzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse in vitro and in vivo effects of reduced function CYP2C19 alleles have been demonstrated in a number of studies, although three meta-analyses have differed in their conclusions on this point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. Some of these studies are discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the EXCELSIOR study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/57\">",
"       57",
"      </a>",
"      ], patients carrying the loss-of-function CYP2C19*2 (681G&gt;A) polymorphism had significantly higher residual platelet aggregation (RPA) following a 600 mg loading dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      than wild-type homozygotes (23 versus 11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/58\">",
"       58",
"      </a>",
"      ]. The proportion of patients with a RPA &gt;14 percent was significantly higher in the *2 carriers, both after the clopidogrel loading dose (62 versus 43 percent) as well as prior to hospital discharge (41 versus 22 percent). This degree of RPA prior to discharge incurred a threefold (95% CI 1.4-6.8) increase in the one-year incidence of death and myocardial infarction.",
"     </li>",
"     <li>",
"      Among",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      -treated subjects in the TRITON-TIMI 38 trial, carriers of a reduced-function CYP2C19 allele had a significant increase in the composite primary efficacy outcome of the risk of death from cardiovascular causes, myocardial infarction, or stroke as well as a significant increase in the risk of stent thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 5059 patients with acute coronary syndromes (ACS) and 1156 patients with atrial fibrillation demonstrated a benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      over placebo regardless of the presence of loss of function alleles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/60\">",
"       60",
"      </a>",
"      ]. For the ACS patients, there was evidence that gain of function mutations improved the efficacy of clopidogrel. In the atrial fibrillation patients, there was no evidence of effect of gain of function or loss of function alleles on either efficacy or bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of interest, carriers of the CYP2C19*17",
"    <strong>",
"     gain",
"    </strong>",
"    -of-function allele have greater therapeutic responsiveness to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    than noncarriers, but also have an increased risk for developing bleeding with such treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/56,61\">",
"     56,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3359461\">",
"    <span class=\"h3\">",
"     Paraoxonase polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;With discovery of the need for activation by paraoxonase before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    can inhibit platelet function, it was estimated in one study that 72.5 percent of the variability in ADP-stimulated platelet aggregation after clopidogrel administration could be explained by the PON1 Q192R polymorphism and only 12 percent by the CYP2C19*2 loss-of-function allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/43\">",
"     43",
"    </a>",
"    ]. PON1 QQ192 homozygous individuals showed a significantly higher risk than PON1 RR192 homozygous individuals for stent thrombosis, along with lower platelet inhibition. These results have not been confirmed in other studies and a meta-analysis, calling into question the clinical significance of genetic alterations in this pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/42,62-67\">",
"     42,62-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16062884\">",
"    <span class=\"h3\">",
"     FDA statement 2010",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Boxed Warning has been added to prescribing information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    concerning how genetic differences in the metabolism of this agent can affect its effectiveness, ways to test for these genetic differences, and advice concerning alternative dosing strategies or use of other medications in poor metabolizers of clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Interaction with other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    -treated patients, stimulation of CYP3A4 activity by other drugs enhances platelet inhibition by clopidogrel and agents competing with clopidogrel for CYP3A4 attenuate platelet inhibition by clopidogrel. Some of these interactions are discussed below. However, there is no consistent evidence to date that these interactions have clinical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some statins are predominantly metabolized and eliminated by the same cytochrome P450 isoenzyme (CYP3A4) that activates",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (see above), leading to the formulation of the hypothesis of a potential negative interaction with concomitant administration of clopidogrel and CYP3A4-metabolized statins (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ). Results to date have been conflicting in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/71\">",
"     71",
"    </a>",
"    ]; most, but not all, of the studies do not support this hypothesis.",
"   </p>",
"   <p>",
"    A post-hoc subgroup analysis, useful to formulate but not test this hypothesis, was performed in the CHARISMA trial, which compared long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    versus placebo in over 12,000 patients with cardiovascular disease and approximately 3000 primary prevention patients with multiple risk factors. There was no clinical interaction apparent among patients receiving concomitant clopidogrel and a CYP3A4-metabolized statin on a composite endpoint of myocardial infarction, stroke, or cardiovascular death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the totality of evidence suggests that clinicians need not choose one statin in preference to another on the basis of CYP3A4 metabolism when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    coadministration is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H24#H24\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the small to moderate effect sizes in available non-randomized studies of the interaction between proton pump inhibitors (PPIs) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , it will only be possible to conclude whether these associations are valid via the use of randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. The following two studies and a systematic review are of interest in this regard:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only large scale randomized trial of the PPI",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      versus placebo in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      users (the COGENT trial) showed no significant difference in cardiovascular (CV) events when the two were combined (HR 0.99; 95% CI 0.68-1.44) although there was a significant reduction in GI events (HR 0.34; 95% CI 0.18-0.63) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prespecified, nonrandomized subgroup analysis of the PLATO trial (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      in subjects hospitalized for acute coronary syndrome), the use of a PPI, compared with those not taking a PPI, was associated with a higher rate of cardiovascular (CV) events in those taking either clopidogrel or ticagrelor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/78\">",
"       78",
"      </a>",
"      ]. In addition, there was a similar association between the use of non-PPI gastrointestinal drugs and increased CV events. Although chance is a plausible explanation for these nonrandomized subgroup findings, the authors concluded that the association between PPI use and adverse CV events may be due to uncontrolled confounding, with PPI use more of a marker for, than a cause of, higher rates of cardiovascular events.",
"     </li>",
"     <li>",
"      A systematic review of available articles, which included 10 laboratory studies involving healthy volunteers and 33 clinical studies, concluded that an adverse effect of PPI use on clinical outcome in patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      cannot be substantiated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, the current totality of evidence does not justify a conclusion that PPIs are associated with clinical CV events among",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    users, let alone support a judgment of causality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]. However, in its 2009 Information notice, the United States FDA concluded that patients taking clopidogrel should consult with their clinician if they are taking or considering taking a PPI, including over-the-counter PPI preparations (eg, Prilosec OTC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers (CCBs) inhibit CYP3A4 and, in observational studies, CCBs reduced the in vitro effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/86\">",
"     86",
"    </a>",
"    ]. Their use was also associated with decreased clinical effectiveness of clopidogrel in a prospective observational study in 200 patients with coronary heart disease undergoing PCI. Observations from this study included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/87\">",
"     87",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vitro platelet reactivity, as measured by the VASP assay, was significantly higher (implying less",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      effect on platelets) in those taking clopidogrel plus CCBs (primarily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ) than in those taking clopidogrel alone (61 versus 48 percent, respectively).",
"     </li>",
"     <li>",
"      The primary clinical endpoint, a composite of death from cardiovascular causes, nonfatal myocardial infarction, stent thrombosis, and revascularization, occurred significantly more often in those taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus CCBs (25 percent) than in those taking clopidogrel alone (8 percent), giving a significant hazard ratio of 3.9 (95% CI 1.7-8.5).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two case series, useful to formulate but not test hypotheses, provide additional data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In the larger of the two, 56,800 patients surviving 30 days after a myocardial infarction (MI) in Denmark during the period from 2000 to 2006 were evaluated for the composite risk of cardiovascular death, MI, or stroke according to their treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a calcium-channel blocker (CCB) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/88\">",
"     88",
"    </a>",
"    ]. The results of both multivariate (HR ratio 1.08; 95% CI 0.99-1.18) and propensity score analyses (HR ratio 1.00; 95% CI 0.90-1.10) showed no significant association between the use of CCBs and the clinical effectiveness of clopidogrel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Interference from other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs, herbal preparations, foods, and smoking have been shown to alter the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    on platelets.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      St. John&rsquo;s wort &mdash; Stimulation of CYP3A4 activity by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      or St. John's wort has been shown to enhance platelet inhibition by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , whereas administration of agents competing with clopidogrel for CYP3A4 (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , troleandomycin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ) attenuate platelet inhibition by clopidogrel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/23,90,91\">",
"       23,90,91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polyunsaturated omega-3 fatty acids &mdash; In a randomized trial of patients undergoing PCI and receiving treatment with both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , the addition of 1 gram of polyunsaturated omega-3 fatty acids significantly potentiated the platelet response to clopidogrel after the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5358998\">",
"    <span class=\"h4\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stimulation of CYP1A2 associated with smoking has been shown to enhance platelet inhibition by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]; smoking cessation reverses this effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/95\">",
"     95",
"    </a>",
"    ]. Smoking has also significantly enhanced the clinical benefits of clopidogrel in patients with ST-segment elevation myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/96\">",
"     96",
"    </a>",
"    ] as well as in those with established cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Presence of diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes mellitus (DM) have increased activation of platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/98-101\">",
"     98-101",
"    </a>",
"    ] and a higher percent of circulating immature platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/102\">",
"     102",
"    </a>",
"    ]. These characteristics could, at least in theory, counteract the inhibitory effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    on platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/4,94,100,103,104\">",
"     4,94,100,103,104",
"    </a>",
"    ]. The available data are, however, not consistent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the poor responsiveness to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in DM patients was attributed to insufficient generation of the active metabolite of clopidogrel, rather than to alterations in P2Y12 receptor function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two reports, reduced responsiveness to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was not related to glycemic control, but appeared to be affected by a systemic inflammatory response, as reflected by increased levels of fibrinogen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/106\">",
"       106",
"      </a>",
"      ] or increased white blood cell count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a fourth study, impaired renal function was associated with reduced in vitro responsiveness to dual antiplatelet therapy in DM patients with coronary artery disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case series of 285 consecutive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      -treated patients undergoing elective PCI, the subgroup with DM had significantly higher platelet reactivity at the time of PCI despite adequate clopidogrel treatment, and had a significantly higher incidence of postprocedural myocardial infarction (11 versus 4 percent in those without DM) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These descriptive data contribute to the formulation of the hypothesis that patients with diabetes mellitus may require increased doses of one or both of these agents in order to show a therapeutic effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/110\">",
"     110",
"    </a>",
"    ], or may be candidates for a more potent platelet inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/111,112\">",
"     111,112",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    (AZD6140) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/53,113-115\">",
"     53,113-115",
"    </a>",
"    ]). This could, at least in theory, explain why some patients with poor responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    also exhibit poor responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/116-119\">",
"     116-119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link&amp;anchor=H23#H23\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Platelet activation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link&amp;anchor=H12#H12\">",
"     \"Platelet biology\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link&amp;anchor=H13#H13\">",
"     \"Platelet biology\", section on 'Other P2Y12 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15342101\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a case series, 440 unselected patients with or without chronic kidney disease (CKD), as defined by estimated GFR less than or greater than 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    , respectively, undergoing urgent or planned PCI had vasodilator-stimulated phosphoprotein flow cytometry testing (VASP-FCT) to assess response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/120\">",
"     120",
"    </a>",
"    ]. Of these 440 patients, the rate of nonresponse to clopidogrel was 41 percent, a weighted average of 42 percent among the subgroup with CKD and 40 percent among those without CKD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In subgroup analyses of those with CKD, the low-responding group (platelet reactivity index (PRI) &ge;61 percent by VASP-FCT) had significantly higher rates of all-cause mortality, cardiac death, and all stent thrombosis than responders (PRI &lt;61 percent).",
"     </li>",
"     <li>",
"      In subgroup analyses of patients without CKD, low-response status did not affect outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Why low responders with CKD had a worse outcome is unclear, although these differences may be due to chance, confounding, or bias.",
"   </p>",
"   <p>",
"    In another case series, 126 consecutive patients receiving a maintenance dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for at least eight days) were evaluated to determine whether there was an association between response to clopidogrel and decreased glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/121\">",
"     121",
"    </a>",
"    ]. Those with low response to clopidogrel had decreased GFR, PRI, PRU, and percentage of platelet inhibition. This finding was independent of the presence of diabetes mellitus, and was stronger in the subgroup of patients with a GFR &lt;15",
"    <span class=\"nowrap\">",
"     mL/min/1.73m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (GFR Stage 5). In multivariate analysis GFR Stage 5 and obesity were the sole predictors of residual platelet reactivity.",
"   </p>",
"   <p>",
"    In a third case series of 59 patients, 36 of whom had chronic renal failure, those with chronic renal failure who were prescribed increases in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    dose had no improvements in responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Other adverse influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a case series of 377 patients with stable coronary disease on maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy, the following clinical features were found to be independent predictors of high or low residual platelet reactivity, as assessed by the VerifyNow P2Y12 assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High residual reactivity &mdash; female gender, non-Caucasian ethnicity, and use of proton-pump inhibitors",
"     </li>",
"     <li>",
"      Low residual reactivity &mdash; active smoking (see",
"      <a class=\"local\" href=\"#H5358998\">",
"       'Smoking'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High residual platelet reactivity in this study was associated with significantly increased six-month mortality rates (3.0 versus zero percent).",
"   </p>",
"   <p>",
"    In 255 consecutive patients tested &ge;12 hours after PCI using light transmission aggregometry in response to ADP as well as the VerifyNow P2Y12 assay, anemia was the only variable (eg, gender, diabetes mellitus, hypertension, use of a PPI, statin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , chronic kidney disease) independently associated with high platelet reactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/123\">",
"     123",
"    </a>",
"    ]. While this observation is not new [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/26,94,124\">",
"     26,94,124",
"    </a>",
"    ], the mechanism through which anemia affects high platelet reactivity is not known, although an artifactual effect of anemia on platelet function tests cannot be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     CLINICAL RELEVANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369974572\">",
"    <span class=\"h2\">",
"     Relationship between clopidogrel resistance and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothesis of whether or not in vitro \"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    resistance\" has clinical significance has not been tested in analytic studies designed a priori to do so. Descriptive data contributing to the formulation of this hypothesis are available from two case series of patients with both acute coronary syndromes (ACS) and stable angina undergoing PCI and a number of meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/125-130\">",
"     125-130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 60 patients with an STEMI referred for primary PCI were stratified into quartiles based upon in vitro ADP-induced platelet aggregation six days after initiation of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/131\">",
"       131",
"      </a>",
"      ]. Over the subsequent six months, 6 of 15 patients in the most resistant quartile had a cardiovascular event compared with 1 of 45 in the remaining three quartiles.",
"     </li>",
"     <li>",
"      In 100 patients receiving chronic antiplatelet therapy with 325",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (all patients were aspirin responsive) and 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , two parameters of platelet aggregation were measured prior to nonemergent stent placement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/132\">",
"       132",
"      </a>",
"      ]. After one year, 23 experienced death, MI, stent thrombosis, stroke or ischemia requiring hospital stay. The mean pre-stent platelet aggregation for these 23 subjects was significantly greater than among the 77 who did not experience a clinical event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional case series, useful to formulate but not test hypotheses, have been reported concerning adverse clinical consequences (eg, cardiac death, stent thrombosis) of \"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    resistance\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/57,133-137\">",
"     57,133-137",
"    </a>",
"    ]. Two of these are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 802 consecutive patients undergoing elective PCI received a loading dose of 600 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      followed by 75 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/57\">",
"       57",
"      </a>",
"      ]. Platelet aggregation was assessed immediately before PCI by optical aggregometry following 5 microM ADP. Multivariate analysis confirmed in vitro platelet aggregation above the median level as a significant independent predictor of the 30-day composite of death, myocardial infarction, and target lesion revascularization (relative risk 6.7, 95% CI 1.5-29).",
"     </li>",
"     <li>",
"      In the second series, 683 patients with ACS treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and undergoing PCI with a bare metal or drug-eluting stent were tested for residual platelet reactivity (RPR) utilizing the VerifyNow P2Y12 point-of-care assay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/135\">",
"       135",
"      </a>",
"      ]. In a multivariate model, an RPR &ge;240 PRU (P12Y12 reaction units) was a significant and independent predictor of cardiovascular death and nonfatal myocardial infarction at 12 months (HR 2.5; 95% CI 1.3-5.1). No significant association was found between a high RPR and target vessel revascularization. A subsequent meta-analysis, which included this study, concluded that an RPR &ge;230 PRU was associated with a significantly higher rate of the composite endpoint of death, myocardial infarction, and stent thrombosis (HR 2.10; 95% CI 1.62-2.73) as well as a significantly higher rate for each of the individual endpoints of death, myocardial infarction, and stent thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/129\">",
"       129",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of interest, those patients noted in the second series who had an RPR &ge;240 PRU were significantly older, more likely to be female, more likely to be diabetic, and more likely to have a left ventricular ejection fraction &lt;40 percent when compared with those having an RPR &lt;240 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/135\">",
"     135",
"    </a>",
"    ]. This finding is consistent with other observations that some patients with cardiovascular disease (eg, older patients, those with diabetes mellitus) may have increased activation of platelets or increased platelet turnover that could override the inhibitory effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/138,139\">",
"     138,139",
"    </a>",
"    ]. Thus, patients with high residual platelet reactivity following clopidogrel might include those more likely to have extensive coronary atherosclerosis and a higher risk of periprocedural myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/140\">",
"     140",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Problem overview and conclusions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H35\">",
"     'Presence of diabetes mellitus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369974579\">",
"    <span class=\"h2\">",
"     Value of routine platelet monitoring prior to PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown whether individualized antiplatelet testing before and after percutaneous coronary intervention (PCI) with stenting improves clinical outcomes. The potential benefit of assessing platelet-function prior to PCI in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was evaluated in the ARCTIC trial, which randomly assigned 2440 patients scheduled for coronary stenting to either a strategy of platelet-function monitoring or no monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/141\">",
"     141",
"    </a>",
"    ]. All patients received dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus either clopidogrel or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the monitoring group, platelet-function testing was performed for both P2Y12 receptor blockers (and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) using the VerifyNow assay both before PCI and at 14 to 30 days. If high platelet reactivity on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy started at least six hours before stent implantation was found, the protocol called for the administration of a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor and an additional loading dose of clopidogrel (at a dose &ge;600 mg) or a loading dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    (at a dose of 60 mg) before the procedure, followed by a daily maintenance dose of 150 gm of clopidogrel or 10 mg of prasugrel. In the monitoring group, patients with high platelet reactivity during treatment with clopidogrel were switched to prasugrel 10 mg daily or received a 75 mg increase in the maintenance dose. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the monitoring group, high platelet reactivity on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (which was used in approximately 90 percent of patients) occurred in 34.5 percent of patients.",
"     </li>",
"     <li>",
"      There was no significant difference in the rate of the primary composite end point (death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization at one year) or the main secondary endpoint of stent thrombosis between the monitoring and no monitoring groups (34.6 versus 31.1 percent, and 4.9 versus 4.6 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ARCTIC trial does not support the routine use of platelet-function testing in patients undergoing stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     THERAPEUTIC ALTERNATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic alternatives for patients demonstrating reduced in vitro responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    have yet to be defined, but have included adjustment of clopidogrel dosing as well as the use of alternative antiplatelet agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16062367\">",
"    <span class=\"h2\">",
"     Adjusting the loading dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of increasing the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    loading dose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increasing the maintenance dose based upon laboratory evidence for clopidogrel resistance have been shown in a number of trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/142-149\">",
"     142-149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial patients were assigned to either a 600 or a 300 mg loading dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . Both in vitro clopidogrel resistance (8 versus 28 percent) and high post-treatment platelet aggregation (6 versus 24 percent) were less frequent after the 600 mg loading dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/142\">",
"       142",
"      </a>",
"      ]. Such effects may have contributed to the better outcomes with the 600 mg loading dose in an ARMYDA-2 trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/143\">",
"       143",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H6#H6\">",
"       \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Efficacy and safety'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"       \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a second study, carriers of the CYP2C19 loss-of-function *2 and *4 alleles showed reduced platelet inhibition after a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      600 mg loading dose, but responded to higher loading (1200 mg) and maintenance dose (150 versus 75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/147\">",
"       147",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical benefit of increasing the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    loading dose on reducing the incidence of subsequent adverse cardiac events was shown in a prospective randomized trial of 162 patients scheduled to undergo PCI. In this trial, clopidogrel resistance was defined as an in vitro vasodilator-stimulated phosphoprotein phosphorylation analysis (VASP index) &gt;50 percent after a 600 mg loading dose of clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/144\">",
"     144",
"    </a>",
"    ]. All patients with a VASP index &gt;50 percent were randomly assigned to a control group or VASP-guided group.",
"   </p>",
"   <p>",
"    In the comparison group, PCI was carried out without an additional bolus of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , whereas in the VASP-guided group, up to three additional boluses of 600 mg of clopidogrel were given in 24-hour increments. The VASP index was then assessed 12 hours after administration until an index &lt;50 percent was achieved, following which PCI was performed. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/144\">",
"     144",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the VASP-guided group, 38 patients required two doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      to achieve a VASP index &lt;50 percent, 14 required three doses, and 15 required four doses.",
"     </li>",
"     <li>",
"      Despite a total",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      dose of 2400 mg, 11 patients (14 percent) remained \"resistant\" and received PCI. There were no major adverse cardiac events in this subgroup.",
"     </li>",
"     <li>",
"      The overall rate of bleeding was similar in the two groups (5 versus 4 percent).",
"     </li>",
"     <li>",
"      The number of serious adverse cardiac events (two cardiovascular deaths, four acute or subacute stent thromboses, two recurrent acute coronary syndromes) during the one-month follow-up was significantly less in the VASP-guided group (zero versus eight events).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a case series useful for hypothesis formulation, 215 consecutive patients undergoing PCI with a drug-eluting stent for unprotected left main coronary disease received a loading dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/133\">",
"     133",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High residual platelet reactivity (HRPR, ie, platelet aggregation by ADP &ge;70 percent of control) after a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      loading dose of 600 mg was present in 18.6 percent of the patients.",
"     </li>",
"     <li>",
"      In post-hoc subgroup analyses, the 40 patients with HRPR had significantly higher three-year coronary mortality (28.3 versus 8.0 percent) and stent thrombosis (16.0 versus 4.2 percent) than the 175 with low residual platelet reactivity. Further, in stepwise regression analysis, HRPR after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      loading was the only independent predictor of coronary death (HR 3.82; 95% CI 1.38-10.5) and stent thrombosis (HR 3.69; 95% CI 1.12-12.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These descriptive data are compatible with the hypothesis that some patients demonstrate in vitro",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    resistance along with adverse clinical results, despite the use of increased loading doses of clopidogrel. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Therapeutic alternatives'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    GRAVITAS was a trial in which 2214 subjects with high platelet reactivity on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (as measured by the VerifyNow P2Y12 test) following PCI with a drug-eluting stent, were assigned at random to treatment with either standard dose (no loading dose, 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or high dose (600 mg loading dose, 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    thereafter) clopidogrel for 60 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary study end point (six-month incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis) was virtually identical in those receiving either standard or high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (2.3 percent in each group; hazard ratio 1.01; 95% CI 0.58-1.76). Severe or moderate bleeding was not increased in those receiving the high dose regimen (1.4 versus 2.3 percent; 95% CI 0.31-1.11).",
"     </li>",
"     <li>",
"      In subjects with high platelet reactivity identified by platelet function testing, the CYP2C19 genotype provided limited incremental information regarding the risk of persistently high reactivity with a treatment strategy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      maintenance dosing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8268853\">",
"    <span class=\"h2\">",
"     Use of alternative antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other options include the use of a &ldquo;third generation&rdquo; P2Y12 inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , cangrelor, elinogrel) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/151-153\">",
"     151-153",
"    </a>",
"    ], or addition of an alternative platelet aggregation inhibitor such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/154-159\">",
"     154-159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     Prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    are of active interest in this regard, since the common cytochrome alleles that reduce the effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    do not appear to interfere with the activity of these agents, although the risk of bleeding may be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/53,114,160-165\">",
"     53,114,160-165",
"    </a>",
"    ]. In an analysis of data from the",
"    <span class=\"nowrap\">",
"     ONSET/OFFSET",
"    </span>",
"    and RESPOND studies, the prevalence of high on-treatment platelet reactivity, using a number of different laboratory assays, was significantly lower for those treated with ticagrelor (zero to 8 percent) than for those treated with clopidogrel (21 to 81 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/166\">",
"     166",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link&amp;anchor=H12#H12\">",
"     \"Platelet biology\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the RAPID GENE study, 200 patients undergoing PCI were randomly assigned to either rapid point-of-care genotyping for the CYP2C19*2 allele or standard treatment. Carriers were given 10 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    daily, while non-carriers and those in the standard treatment group were given 75 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/167\">",
"     167",
"    </a>",
"    ]. The primary endpoint was high on-treatment platelet reactivity after one week of antiplatelet therapy, which occurred in none of the 23 carriers in the genotyping group treated with prasugrel compared with 7 of the 23 carriers (30 percent) in the standard treatment group who were treated with clopidogrel. Whether these findings have clinical relevance awaits direct randomized comparisons on clinical cardiovascular disease events.",
"   </p>",
"   <p>",
"    Some, but not all, trials have shown that either modifying treatment (eg, adding a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor to those with a poor response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) or increasing the clopidogrel loading dose based on in vitro testing significantly improved clinical outcomes without increasing the risk of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/137,143,144,168,169\">",
"     137,143,144,168,169",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     PROBLEM OVERVIEW AND CONCLUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the above-noted findings and FDA statements concerning poor clinical and laboratory responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    are of high priority for further research, additional evidence from studies designed a priori to test these hypotheses is necessary before it will be possible to recommend routine assessment of percutaneous coronary intervention (PCI) candidates for \"clopidogrel resistance\". Persistent, unresolved issues include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients undergoing PCI (eg, those with hypertension, smoking, diabetes, high body weight, low",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      dose, high C-reactive protein levels) may have increased activation of platelets",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coagulation, or increased platelet turnover that could override the inhibitory effect of aspirin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . This could explain why some patients with poor clinical and laboratory responses to aspirin also exhibit poor responses to clopidogrel (9 of 19 in a series of patients undergoing elective percutaneous coronary intervention). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Presence of diabetes mellitus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal method(s) for assessing and defining",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      resistance have not been defined. This includes the choice among a variety of point-of-care instruments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/13,14,99,170\">",
"       13,14,99,170",
"      </a>",
"      ], as well as the anticoagulant used for obtaining the blood sample [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accounting for concomitant treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Correlating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      -induced platelet inhibition with its cardiovascular benefits",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3795990\">",
"    <span class=\"h2\">",
"     Routine in vitro or genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accordingly, and until further data are forthcoming, we and others do not recommend routine testing of patients for \"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    resistance\" whether by in vitro tests of platelet function or by genetic testing for CYP2C19 poor metabolizers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/55,171\">",
"     55,171",
"    </a>",
"    ]. Further, we do not recommend the use of alternative antiplatelet strategies in patients with clopidogrel resistance based solely upon the results of such assays.",
"   </p>",
"   <p>",
"    Similar conclusions were reached by the 2008 American College of Chest Physicians Clinical Practice Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/172\">",
"     172",
"    </a>",
"    ], a 2010 report from the American College of Cardiology Foundation and the American Heart Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/173\">",
"     173",
"    </a>",
"    ], a 2010 report endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/157\">",
"     157",
"    </a>",
"    ], and a 2010 &ldquo;white paper&rdquo; from the Journal of the American College of Cardiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3795997\">",
"    <span class=\"h2\">",
"     Selected testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association Task Force on Practice Guidelines has suggested, for selected patients only, individual testing for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    resistance. The selected patients are restricted to those with recurrent acute coronary events despite ongoing therapy with clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/174\">",
"     174",
"    </a>",
"    ], although this patient group is still being defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/175\">",
"     175",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These guidelines also noted that the available evidence is not sufficient to recommend switching to an alternative agent, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      . In such cases, the clinician is advised to discuss with the patient the uncertain value of such testing as well as the potential benefits and risks (eg, increased bleeding) of switching to an alternative agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/176\">",
"       176",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Therapeutic alternatives'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H15#H15\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Platelet P2Y12 receptor blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Clinical Pharmacogenetics Implementation Consortium has published its guidelines for CYP2C19 genotype-directed antiplatelet therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/34/37418/abstract/177\">",
"       177",
"      </a>",
"      ]. These guidelines are to be periodically updated by the Consortium",
"      <a class=\"external\" href=\"file://www.pharmgkb.org/\">",
"       Consortium Guidelines",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of pharmacogenomics\", section on 'CYP isoenzymes and drug metabolism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Definition of terms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    exists when this agent fails to prevent occlusive CVD events. This could result from numerous factors, including noncompliance, events independent of clopidogrel&rsquo;s specific actions on platelet function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate",
"    <span class=\"nowrap\">",
"     response/resistance",
"    </span>",
"    to the antiplatelet action of clopidogrel. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Causes of treatment failure and resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various causes of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    treatment failure and resistance are presented above. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Explanations for clopidogrel treatment failure and resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Tests used to document",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    resistance (eg, in vitro tests of platelet function, genetic testing) are presented above. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Clopidogrel resistance testing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25\">",
"     'Genetic variability'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Specific recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Until further data are available, we suggest against routine testing of patients for \"",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      resistance\", whether by in vitro testing of platelet function or by genetic testing for CYP2C19 poor metabolizers (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We further suggest against the use of alternative antiplatelet strategies in patients with clopidogrel nonresponse based upon the results of these assays alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Therapeutic alternatives'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Problem overview and conclusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advice on the management of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      -treated patients who develop coronary stent thrombosis is presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9623?source=see_link&amp;anchor=H1128708641#H1128708641\">",
"       \"Coronary artery stent thrombosis: Clinical presentation and management\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Guidance concerning the",
"      <span class=\"nowrap\">",
"       use/nonuse",
"      </span>",
"      of proton pump inhibitors (PPIs) and the selection of one PPI over another in conjunction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      is presented separately. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Proton pump inhibitors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link&amp;anchor=H108005888#H108005888\">",
"       \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Proton pump inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/1\">",
"      Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/2\">",
"      Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/3\">",
"      Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/4\">",
"      Michos ED, Ardehali R, Blumenthal RS, et al. Aspirin and clopidogrel resistance. Mayo Clin Proc 2006; 81:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/5\">",
"      Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103:27A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/6\">",
"      Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009; 6:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/7\">",
"      Hjemdahl P. Should we monitor platelet function during antiplatelet therapy? Heart 2008; 94:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/8\">",
"      Jennings LK. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance. Crit Pathw Cardiol 2009; 8:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/9\">",
"      Beigel R, Hod H, Fefer P, et al. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 2011; 107:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/10\">",
"      Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 2009; 104:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/11\">",
"      Gurbel PA, Mahla E, Antonino MJ, Tantry US. Response variability and the role of platelet function testing. J Invasive Cardiol 2009; 21:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/12\">",
"      Cairns JA, Eikelboom J. Clopidogrel resistance: more grist for the mill. J Am Coll Cardiol 2008; 51:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/13\">",
"      Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/14\">",
"      Lordkipanidz&eacute; M, Pharand C, Nguyen TA, et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/15\">",
"      Varenhorst C, Koul S, Erlinge D, et al. Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. Am Heart J 2011; 162:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/16\">",
"      Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/17\">",
"      Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008; 52:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/18\">",
"      Bellemain-Appaix A, Montalescot G, Silvain J, et al. Slow response to clopidogrel predicts low response. J Am Coll Cardiol 2010; 55:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/19\">",
"      Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/20\">",
"      Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/21\">",
"      Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/22\">",
"      M&uuml;ller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/23\">",
"      Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/24\">",
"      Campo G, Valgimigli M, Gemmati D, et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 2007; 50:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/25\">",
"      Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/26\">",
"      Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/27\">",
"      Moerenhout CM, Claeys MJ, Haine S, et al. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP. Am Heart J 2010; 159:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/28\">",
"      Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol 2011; 58:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/29\">",
"      Patti G, Pasceri V, Vizzi V, et al. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011; 107:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/30\">",
"      Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/31\">",
"      Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/32\">",
"      Kolandaivelu K, Bhatt DL. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol 2010; 7:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/33\">",
"      Hamann GF, Weimar C, Glahn J, et al. Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/34\">",
"      Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of \"resistance\". Am Heart J 2009; 158:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/35\">",
"      Michelson AD, Linden MD, Furman MI, et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost 2007; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/36\">",
"      Gurbel P, Bliden KP, Tantry U. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance': a rebuttal. J Thromb Haemost 2007; 5:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/37\">",
"      Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011; 22:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/38\">",
"      Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008; 6:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/39\">",
"      Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010; 160:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/40\">",
"      Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/41\">",
"      Luo M, Li J, Xu X, et al. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Thromb Res 2012; 129:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/42\">",
"      Price MJ, Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012; 59:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/43\">",
"      Bouman HJ, Sch&ouml;mig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/44\">",
"      Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/45\">",
"      Bal Dit Sollier C, Berge N, Boval B, et al. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 2009; 101:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/46\">",
"      Roden DM, Stein CM. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 2009; 119:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/47\">",
"      Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/48\">",
"      Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/49\">",
"      Kwak YL, Kim JC, Choi YS, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/50\">",
"      Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/51\">",
"      Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/52\">",
"      Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/53\">",
"      Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/54\">",
"      Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/55\">",
"      Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343:d4588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/56\">",
"      Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/57\">",
"      Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/58\">",
"      Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G&gt;A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/59\">",
"      Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/60\">",
"      Par&eacute; G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/61\">",
"      Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/62\">",
"      Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/63\">",
"      Fontana P, James R, Barazer I, et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 2011; 9:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/64\">",
"      Cuisset T, Morange PE, Quilici J, et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011; 17:1039; author reply 1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/65\">",
"      Hulot JS, Collet JP, Cayla G, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011; 4:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/66\">",
"      Par&eacute; G, Ross S, Mehta SR, et al. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. Circ Cardiovasc Genet 2012; 5:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/67\">",
"      Reny JL, Combescure C, Daali Y, et al. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2012; 10:1242.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm204256.htm (Accessed on March 24, 2010).",
"    </li>",
"    <li>",
"     Available on the manufacturer's website at: file://products.sanofi-aventis.us/PLAVIX/PLAVIX.html (Accessed on March 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/70\">",
"      Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/71\">",
"      Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/72\">",
"      Angiolillo DJ, Alfonso F. Clopidogrel-statin interaction: myth or reality? J Am Coll Cardiol 2007; 50:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/73\">",
"      Trenk D, Hochholzer W, Frundi D, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/74\">",
"      Schmidt M, Johansen MB, Maeng M, et al. Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. Br J Clin Pharmacol 2012; 74:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/75\">",
"      Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA 2009; 302:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/76\">",
"      Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010; 56:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/77\">",
"      Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/78\">",
"      Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012; 125:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/79\">",
"      Focks JJ, Brouwer MA, van Oijen MG, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart 2013; 99:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/80\">",
"      Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/81\">",
"      Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 2011; 107:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/82\">",
"      Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf 2012; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/83\">",
"      Aihara H, Sato A, Takeyasu N, et al. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry. Catheter Cardiovasc Interv 2012; 80:556.",
"     </a>",
"    </li>",
"    <li>",
"     Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available on the FDA website (Search on \"Clopidogrel and omeprazole\"): www.fda.gov/Drugs/DrugSafety (Accessed on November 18, 2009).",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2009/safety09.htm#plavix (Accessed on January 26, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/86\">",
"      Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010; 96:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/87\">",
"      Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/88\">",
"      Olesen JB, Gislason GH, Charlot MG, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol 2011; 57:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/89\">",
"      Sarafoff N, Neumann L, Morath T, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011; 161:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/90\">",
"      Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost 2010; 8:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/91\">",
"      Lau WC, Welch TD, Shields T, et al. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 2011; 57:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/92\">",
"      Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 2010; 55:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/93\">",
"      Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008; 52:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/94\">",
"      Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 103:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/95\">",
"      Park KW, Kang SH, Kang J, et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. Heart 2012; 98:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/96\">",
"      Desai NR, Mega JL, Jiang S, et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009; 53:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/97\">",
"      Berger JS, Bhatt DL, Steinhubl SR, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009; 120:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/98\">",
"      Bouman HJ, van Werkum JW, Hackeng CM, et al. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008; 6:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/99\">",
"      Gachet C, Aleil B, Testing antiplatelet therapy. Eur Heart J 2008; 10(Suppl A):A28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/100\">",
"      Duzenli MA, Ozdemir K, Aygul N, et al. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. Am J Cardiol 2008; 102:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/101\">",
"      Angiolillo DJ, Bernardo E, Zanoni M, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011; 58:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/102\">",
"      Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/103\">",
"      Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 99:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/104\">",
"      Labarthe B, Th&eacute;roux P, Angio&iuml; M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/105\">",
"      Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/106\">",
"      Gaborit B, Fr&egrave;re C, Cuisset T, et al. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J Thromb Haemost 2009; 7:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/107\">",
"      Morel O, El Ghannudi S, Hess S, et al. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thromb Haemost 2012; 108:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/108\">",
"      Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/109\">",
"      Mangiacapra F, Patti G, Peace A, et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010; 106:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/110\">",
"      Frelinger AL 3rd, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol 2005; 46:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/111\">",
"      Siller-Matula J, Schr&ouml;r K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/112\">",
"      Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/113\">",
"      Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/114\">",
"      James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/115\">",
"      Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/116\">",
"      Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/117\">",
"      Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/118\">",
"      van Giezen. Optimizing platelet inhibition. Eur Heart J 2008; 10(Suppl D):D23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/119\">",
"      Storey RF. New developments in antiplatelet therapy. Eur Heart J 2008; 10(Suppl D):D30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/120\">",
"      Morel O, El Ghannudi S, Jesel L, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/121\">",
"      Muller C, Caillard S, Jesel L, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 2012; 59:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/122\">",
"      Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/123\">",
"      Toma C, Zahr F, Moguilanski D, et al. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. Am J Cardiol 2012; 109:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/124\">",
"      Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009; 102:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/125\">",
"      Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/126\">",
"      Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/127\">",
"      Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010; 8:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/128\">",
"      Aradi D, Kom&oacute;csi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010; 160:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/129\">",
"      Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/130\">",
"      Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/131\">",
"      Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/132\">",
"      Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/133\">",
"      Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009; 120:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/134\">",
"      Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/135\">",
"      Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/136\">",
"      Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/137\">",
"      Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/138\">",
"      Gremmel T, Steiner S, Seidinger D, et al. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 2010; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/139\">",
"      Cuisset T, Quilici J, Grosdidier C, et al. Comparison of platelet reactivity and clopidogrel response in patients &le; 75 Years Versus &gt; 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Am J Cardiol 2011; 108:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/140\">",
"      Mangiacapra F, De Bruyne B, Muller O, et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/141\">",
"      Collet JP, Cuisset T, Rang&eacute; G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/142\">",
"      Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/143\">",
"      Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/144\">",
"      Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/145\">",
"      L'Allier PL, Ducrocq G, Pranno N, et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol 2008; 51:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/146\">",
"      Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/147\">",
"      Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/148\">",
"      Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008; 1:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/149\">",
"      Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010; 56:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/150\">",
"      Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/151\">",
"      Bellemain-Appaix A, Brieger D, Beygui F, et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol 2010; 56:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/152\">",
"      Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 2012; 163:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/153\">",
"      Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012; 60:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/154\">",
"      Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/155\">",
"      Singh I, Shafiq N, Pandhi P, et al. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol 2009; 68:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/156\">",
"      Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010; 121:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/157\">",
"      Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Writing Committee Members, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA \"boxed warning\": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/158\">",
"      Angiolillo DJ, Capranzano P, Ferreiro JL, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011; 106:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/159\">",
"      Woo JS, Kim W, Lee SR, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J 2011; 162:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/160\">",
"      Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/161\">",
"      Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/162\">",
"      Sorich MJ, Vitry A, Ward MB, et al. Prasugrel vs. clopidogrel for cytochrome&nbsp;P450 2C19-genotyped subgroups: integration of the TRITON-TIMI&nbsp;38 trial data. J Thromb Haemost 2010; 8:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/163\">",
"      Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/164\">",
"      Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010; 3:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/165\">",
"      Alexopoulos D, Xanthopoulou I, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011; 162:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/166\">",
"      Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011; 162:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/167\">",
"      Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/168\">",
"      Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008; 1:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/169\">",
"      Sibbing D, Bernlochner I, Schulz S, et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol 2012; 60:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/170\">",
"      Dickinson KJ, Troxler M, Homer-Vanniasinkam S. The surgical application of point-of-care haemostasis and platelet function testing. Br J Surg 2008; 95:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/171\">",
"      Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 2011; 306:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/172\">",
"      Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/173\">",
"      Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA \"boxed warning\": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010; 56:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/174\">",
"      Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/175\">",
"      Reed GW, Cannon CP. Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein. J Am Coll Cardiol 2011; 58:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/176\">",
"      Cannon CP. Clopidogrel: to test or not to test? That is the question--still. Clin Chem 2011; 57:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/34/37418/abstract/177\">",
"      Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6684 Version 66.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37418=[""].join("\n");
var outline_f36_34_37418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clopidogrel treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clopidogrel resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clopidogrel nonresponse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLOPIDOGREL RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Available assays and test correlations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16062031\">",
"      Normal variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ability to predict clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EXPLANATIONS FOR CLOPIDOGREL TREATMENT FAILURE AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Noncompliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Variable platelet response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Genetic variability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3359454\">",
"      - Cytochrome P450 isoenzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3359461\">",
"      - Paraoxonase polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16062884\">",
"      - FDA statement 2010",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Interaction with other drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Interference from other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5358998\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Presence of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15342101\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Other adverse influences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      CLINICAL RELEVANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369974572\">",
"      Relationship between clopidogrel resistance and outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369974579\">",
"      Value of routine platelet monitoring prior to PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      THERAPEUTIC ALTERNATIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16062367\">",
"      Adjusting the loading dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8268853\">",
"      Use of alternative antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      PROBLEM OVERVIEW AND CONCLUSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3795990\">",
"      Routine in vitro or genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3795997\">",
"      Selected testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Definition of terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Causes of treatment failure and resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Specific recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9623?source=related_link\">",
"      Coronary artery stent thrombosis: Clinical presentation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19401?source=related_link\">",
"      Nonresponse and resistance to aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_34_37419="Weaning clinical criteria";
var content_f36_34_37419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical criteria used to determine readiness for trials of spontaneous breathing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Required criteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. The cause of the respiratory failure has improved",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       &ge;150* or SpO",
"       <sub>",
"        2",
"       </sub>",
"       &ge;90 percent on FiO",
"       <sub>",
"        2",
"       </sub>",
"       &le;40 percent and positive end-expiratory pressure (PEEP) &le;5 cmH",
"       <sub>",
"        2",
"       </sub>",
"       O",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. pH &gt;7.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Hemodynamic stability (no or low dose vasopressor medications)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Able to initiate an inspiratory effort",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Additional criteria (optional criteria)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Hemoglobin &ge;8 to 10 mg/dL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Core temperature &le;38 to 38.5 degrees Centigrade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Mental status awake and alert or easily arousable",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A threshold of PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"     &ge;120 can be used for patients with chronic hypoxemia. Some patients require higher levels of PEEP to avoid atelectasis during mechanical ventilation.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: MacIntyre, NR, Cook, DJ, Ely, EW, Jr., et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians, the American Association for Respiratory Care, and the American College of Critical Care Medicine. Chest 2001; 120:375S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37419=[""].join("\n");
var outline_f36_34_37419=null;
var title_f36_34_37420="24 hour fluid diary PI";
var content_f36_34_37420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    24 hour voiding and fluid diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 556px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    You can use this diary to record how much your child drinks and/or urinates for a 24 hour period.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37420=[""].join("\n");
var outline_f36_34_37420=null;
var title_f36_34_37421="B OHB in prolonged fast";
var content_f36_34_37421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma beta-hydroxybutyrate concentrations after a prolonged fast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 297px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma glucose and beta-hydroxybutyrate concentrations in normal subjects and patients with an insulinoma after a prolonged fast. In patients who become hypoglycemic, a plasma beta-hydroxybutyrate concentration below 2.7 mmol/L is suggestive of an insulinoma. To convert plasma glucose values to mmol/L multiply by 0.056.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Service, FJ, N Engl J Med 1995; 332:1144.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37421=[""].join("\n");
var outline_f36_34_37421=null;
var title_f36_34_37422="Dedifferent parosteal osteosarc";
var content_f36_34_37422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dedifferentiated parosteal osteosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image from a CT-guided needle biopsy procedure. The non-ossified anteromedial portions of the tumor into which the needle is guided are more likely to contain high grade tumor than the posterolaterally located densely ossifed portions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37422=[""].join("\n");
var outline_f36_34_37422=null;
var title_f36_34_37423="PIE in RDS";
var content_f36_34_37423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary interstitial emphysema in an infant with respiratory distress syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerardo Cabrera-Meza, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_34_37423=[""].join("\n");
var outline_f36_34_37423=null;
